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Part I
Introduction
Tension
The moment you are in tension,
you’ll loose your attention
Then you’re in total confusion,
and you’ll feel irritation
Then you’ll spoil personal relation,
ultimately you’ll not get cooperation
Then you’ll make things complication
Then your blood pressure may also rise caution,
and you’ll have to take medication
In stead, understand the situation,
and try to think about the solution
Many problems will be solved with discussion,
which will work out better in your profession
Don't think it is my free suggestion,
it’s only for your prevention
If you understand my intention,
you'll never come again to tension...
(Author unknown)
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Chapter 1
Current pharmacological aspects of a -adrenoceptors
Historical perspective
The endogenous catecholamines noradrenaline (norepinephrine) and adrenaline
(epinephrine), which are released upon activation of the sympathetic nervous system,
play essential roles in the regulation of a host of physiological responses.
Cardiovascular function is tightly regulated by the autonomic nervous system, i.e. by
the sympathetic and parasympathetic nervous system.  Sensory nerves monitor the
volume and pressure status of the heart and blood vessels, as well as the metabolic
state of cardiac and systemic tissues.  This information is processed by the nervous
system, and impulses sent via the autonomic motor nerves modulate cardiac rate and
contractility, as well as coronary and systemic vascular resistance.  In addition to
these direct controls over the cardiovascular system, the sympathetic nervous system
innervation of the kidney influences fluid and electrolyte balance[1].
Noradrenaline is the major neurotransmitter in the sympathetic nervous system,
whereas adrenaline is the primary hormone secreted by the adrenal medulla.  Several
decades ago, adrenoceptors (adrenergic receptors) were introduced to explain the
difference in actions of noradrenaline and adrenaline[1]  The introduction of the
concept receptor, however, has its origin at the beginning of the 20th century with the
pioneering work of Langley[2], Dale[3] and Ehrlich[4].  Studying the effects of
denervation of sympathetic nerves, it was Langley[2] who first introduced the term
receptive substance, which was later[4] constituted into the well-used appellation
receptor.  In today’s discipline of pharmacology, it is considered that receptors play
key functions in the generation of many biological responses.  Strikingly, even before
the term receptor was introduced, Dale[3] showed the first evidence for multiple types
of receptors, demonstrating that ergot alkaloids not only blocked the pressor actions of
adrenaline, but also revealed a vasodilator component, a phenomenon now known as
epinephrine reversal.  It was the revolutionary work of Ahlquist[5] that convincingly
established the coexistence of adrenoceptors mediating different physiological
responses.  He showed that the order of potencies of a series of adrenergic agonists in
inducing vasoconstriction was opposite to their rank order for producing
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vasodilatation and alterations in myocardial contractility.  It was stated that the
adrenoceptor mediating vasoconstriction should be termed the a-adrenotropic and the
receptor mediating vasodilatation and myocardial contraction should be termed the
b-adrenotropic receptor[5].  Several important advances in the field of receptor
research were achieved based on the work of Gaddum[6], Clark[7] and Michaelis &
Menten[8], leading for example to the occupancy theory; stating that the response of a
drug is linearly related to the number of receptors occupied.  In the following
decades, the existing theories were improved and together with others (such as spare
receptors[9] and relative efficacy[10]), the concepts of receptor, receptor theory and
drug action were refined to its present state[see 11, 12-14].  These theories have
subsequently been supported and challenged by the introduction of specific agonists
(sympathomimetics, which stimulate adrenoceptors) and antagonists (sympatholytics,
which prevent agonist-induced effects by adrenoceptor-blockade) at a-adrenoceptors
(e.g. phenylephrine and phentolamine, respectively) and b-adrenoceptors (e.g.
isoproterenol and propranolol, respectively).  Despite the fact that the range of
physiological functions mediated by the sympathetic nervous system is so diverse as
mentioned above, many of the actions produced by compounds that act at a- and/or
b-adrenoceptors are understandable in terms of known physiological effects of the
catecholamines.
After the initial division of adrenoceptors into a- and b-adrenoceptors, proposed by
Ahlquist[5], it took several decades to demonstrate that these adrenoceptors could be
subdivided into several subtypes (a1, a2 and b).  In the following sections of this
chapter, an attempt has been made to summarise several pharmacological aspects of
a1- and a2-adrenoceptors, whereas those of b-adrenoceptors (subdivided into b1-, b2-,
b3- and, probably, b4-subtypes; see Figure 1.1) have been described extensively
elsewhere[see 15, 16-20].
As reviewed by Hoyer & Humphrey[21], it is important to note that the
nomenclature for the classification of transmitter receptors is based on three criteria:
structural (gene structure/amino acid sequence), operational (pharmacological/
ligand-defined/recognitory) and transductional information (receptor-effector
coupling).  Thus, none of these criteria has priority and that as much information as
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feasible on these three aspects should be collected before the name of a receptor can
be regarded upon.
Figure 1.1. Current classification of adrenoceptors (modified from[17]).  Please
note that the pharmacological status of the a1L- and b4-adrenoceptor are unclear.
Subdivision of a-adrenoceptors
Besides the knowledge that a-adrenoceptors can produce vasoconstriction[5], already
back in the 1970’s it was shown that blockade of a-adrenoceptors (by
phenoxybenzamine or phentolamine) could produce an increase in noradrenaline
release induced by electrical stimulation, due to a direct action distinct from uptake
blockade[22, 23].  Since several a-adrenoceptor agonists (such as clonidine) caused a
decrease in noradrenaline release induced by electrical stimulation,  it became clear
that these effects were mediated by a-adrenoceptors on sympathetic nerve terminals,
by so-called presynaptic or prejunctional a-adrenoceptors[24].  Over the years, it
became evident that prejunctional a-adrenoceptors on sympathetic nerve terminals
(i.e. autoreceptors) could mediate noradrenaline release via a negative feedback
regulation, but that a-adrenoceptors could also mediate the release of other
neurotransmitters (e.g. histamine or acethylcholine), acting as heteroreceptors[see 25,
26].  Thus, the first subclassification of a-adrenoceptors into a1- and
a2-adrenoceptors was based on an anatomical location, with the a2- being
prejunctional (acting as a release modulation receptor), and the a1- being postsynaptic
ADRENOCEPTORS
a1-adrenoceptors a2-adrenoceptors b-adrenoceptors
b2 b3 b4?b1a2A a2B a2Ca1A a1B a1D a1L?
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(mediating vascular smooth muscle contraction[27]).  Already at the end of the
1970’s, it became clear that two types of vascular a-adrenoceptors existed, the
prazosin-sensitive a1- and the prazosin-insensitive a2-adrenoceptors[28].
Timmermans & Van Zwieten[29] demonstrated that yohimbine acted as an effective
antagonist of the pressor actions produced by BHT933, clonidine and phenylephrine;
in contrast, prazosin did not affect the pressor actions of BHT933, but it strongly
diminished those to phenylephrine in pithed rats.  Based on the above, it seems
evident that a-adrenoceptor classification schemes featuring anatomical[27] or
physiological function[30] were not sufficient to account for all these data.  Instead,
the currently accepted pharmacological classification of a-adrenoceptors into a1 and
a2 subtypes has been based on the affinity and relative potency of selective agonists
and antagonists[26, 31].  As discussed by Ruffolo et al.[32], an a1-adrenoceptor is
one that is activated by methoxamine, cirazoline or phenylephrine and is blocked by
low concentrations of prazosin or WB 4101.  A response elicited by BHT933,
UK 14304 or BHT 920 that is antagonised by selective concentrations of yohimbine,
rauwolscine or idazoxan should be defined as being mediated by a2-adrenoceptors[26,
31].
Thus, as described above, a-adrenoceptors can be classified into two families,
namely a1- and a2-adrenoceptors. In turn, these receptors can be further subdivided
into different subtypes (see Figure 1.1).  Eventually, detailed information on these
receptors may help to understand the effects produced by the endogenous
catecholamines and, hopefully, will lead to a better application of sympathetic ligands
in many areas of therapeutics.
Introduction Chapter 1
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Table  1.1. Summary of a1-adrenoceptor subtype characteristics (modified from Docherty[33], Bylund[34] and Alexander & Peters[19]).
a1A a1B a1D
Previous names a1a, a1c a1B a1A, a1a/d
Functional response(s) rat vas deferens contraction, rat renal
artery contraction, rat caudal artery
contraction, rat isolated perfused kidney
vasoconstriction
control of blood pressure
rat spleen contraction, role in rat tail
contraction, control of blood pressure?
rat aorta contraction, control of blood
pressure (hypertension)?
Ligand binding assay rabbit liver, rat submandibular gland rat liver and spleen, transfected CHO and
HEK 239 cells
rat aorta, transfected CHO and HEK 239
cells
Non-selective agonists phenylephrine, cirazoline, methoxamine phenylephrine, cirazoline, methoxamine phenylephrine, cirazoline, methoxamine
Selective agonists A61603, oxymetazoline none none
Non-selective antagonists prazosin prazosin prazosin
Selective antagonists e.g. 5-methylurapidil, RS 17053 L-765,314 BMY7378
Potency order noradrenaline ³ adrenaline noradrenaline = adrenaline noradrenaline > adrenaline
Receptor distribution brain, prostate, vas deferens, heart, blood
vessels
spleen, kidney, brain, heart, blood vessels brain, rat aorta, blood vessels
Tissue function(s) smooth muscle and myocardial
contraction
smooth muscle contraction smooth muscle contraction
Sensitivity to CEC + / - +++ ++
Second messenger system(s) activation of Gq/11 , increase in PI turnover with elevation of[Ca
2+]i, activation of voltage-gated Ca
2+ channels
Notes A61603 also displays high affinity at
a2-adrenoceptor subtypes;
There are four known isoforms
CEC also affects other receptors the rat aorta appears to contain other
a1-adrenoceptor subtypes
Abbreviation: CEC, Chloroethylclonidine; PI, Phosphoinositol; CHO, Chinese Hamster Ovary; HEK 293, Human Embryonic Kidney Cells.
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Heterogeneity of a1-adrenoceptors
Shortly after the division of a1- and a2-adrenoceptors, evidence began to emerge that
was inconsistent with a single vascular a1-adrenoceptor[26, 31].  The initial
subclassification of a1-adrenoceptors into a1A- and a1B-subtypes was determined by
receptor binding experiments, using the competitive antagonist WB 4101 and the
alkylating agent chloroethylclonidine (CEC).  Whereas the a1A-subtype displayed a
moderate affinity for WB 4101 and was CEC-insensitive, a1B-adrenoceptors exhibited
a low affinity for WB 4101 but were sensitive to CEC.  Following the initial cloning
of the hamster a1B-adrenoceptor[35], two additional cDNAs were cloned[36-38].  The
relationship between the pharmacologically defined (native) subtypes and the cDNA
(recombinant) clones was controversial for several years[31].  However, after the
cloning and analysis of the different human a1-adrenoceptor subtypes, together with
the development of more subtype-selective drugs, it is now generally agreed that the
three native expressed subtypes (a1A, a1B and a1D) can be distinguished
pharmacologically and exhibit equivalency to the cloned and expressed
a1-adrenoceptor subtypes in various tissues[31].  Interestingly, four splice variants of
the human a1A-adrenoceptor have recently been cloned, which differ in length and
sequence of their C-terminal domains[39, 40].  Because these splice variants of the
human a1A-adrenoceptor are awaiting further pharmacological characterisation[21],
they are not included in Figure 1.1.  However, it has been shown that human cloned
a1A-adrenoceptor isoforms display the a1L-adrenoceptor pharmacology in functional
studies[41].  The physiological significance of these a1A-adrenoceptor splice variants
is presently unknown, but may manifest interesting pharmacological features.
Table 1.1 shows a summary of the current a1-adrenoceptor pharmacological
characteristics.
Signal transduction mechanisms of a1-adrenoceptors
For some years it has been known that all three a1-adrenoceptor subtypes mediate
their responses via G-protein coupled receptors through a Gp/11 mechanism and
involves activation of phospholipase C-dependent hydrolysis of phosphatidylinositol
4,5-diphosphate[31, 42, 43] (see Table 1.1).  Activation of this enzyme results in the
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generation of inositol (1,4,5)-triphosphate, which acts on the inositol triphosphate
receptor in the endoplasmatic reticulum to release stored Ca2+ and diacylglycerol that
(together with Ca2+) can activate protein kinase C.  The production of these second
messengers results in an activation of both voltage dependent and independent
Ca2+-channels, which can cause smooth muscle contraction in particular tissues.
Additional effectors that can couple to a1-adrenoceptors include phospholipase D,
mitogen-activated protein kinase pathway or the release of arachidonic acid and other
substances, including reactive oxygen species[33, 43].  The mitogen-activated protein
kinase pathway involves a longer term response and causes increased cell growth and
may be important in vascular smooth muscle, for example the prostate[43].  However,
a given a1-adrenoceptor subtype may be coupled to a variety of different systems or
different effector mechanisms may be linked to different subtypes.  An understanding
of the mechanisms involved, the receptor subtypes (a1A, a1B or a1D) and the changes
to these under different physiological and pathological states, may provide additional
targets for therapeutic interventions.
Location and function of a1-adrenoceptor subtypes
Radioligand binding assays have shown that a1-adrenoceptors are expressed in a large
number of tissues from several species[44] (see Table 1.1).  Since highly
subtype-selective antagonists and specific antibodies to these subtypes are not yet
available[42], it has been very difficult to define the precise location of
a1-adrenoceptors in both the central and peripheral nervous systems.  Thus, mapping
the distribution of these subtypes (a1A, a1B and a1D) has been performed largely by
combining the analysis of mRNA expression patterns with results from radioligand
and functional studies, which are mainly performed in rats, mice and humans[42].
In the last decade, increasing information has become available on the expression,
distribution and functions of central a1-adrenoceptors[45].  It is relatively
straightforward to allocate physiological responses to adrenoceptor activation in the
peripheral nervous system (see below). However, it has proved more difficult to
define which of the effects of noradrenaline is mediated by a specific receptor class
(i.e. a1, a2 or b) or subclass (e.g. a1- or a2-adrenoceptor subtypes) in the central
nervous system[45].  Based on ligand autoradiography and in situ hybridisation
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studies, it has been revealed that a1-adrenoceptor subtypes are widely distributed in
the brain of several species, although there is substantial variation in subtype
expression between brain regions[46, 47].  In the central nervous system, it has been
shown that a1-adrenoceptors are located predominantly postsynaptically where they
mediate an excitatory effect[48].  In this context, drugs activating a1-adrenoceptors
have been shown to induce electrophysiological excitatory changes and to facilitate
transmission in the brain areas related to locomotion (causing arousal).  As reviewed
by Sirviö & MacDonald[45], there is a substantial amount of evidence suggesting the
role of a1-adrenoceptors in the modulation of attention and memory (see later).
Nevertheless, the series of events following activation of central sympathetic neurones
remains poorly understood.
In contrast to the central nervous system, the distribution of a1-adrenoceptor
subtypes in the periphery has been investigated more extensively[44].  Peripheral
a1-adrenoceptors are located on both vascular and non-vascular smooth muscle (e.g.
prostate, vas deferens, heart or liver) where activation of the receptor results in
contraction[49].  Investigations employing functional, radioligand binding and
molecular methods have demonstrated the existence of multiple a1-adrenoceptor
subtypes in vascular smooth muscle from several species, including rat, rabbit, dog
and human[44, 50].  It has been shown that all a1-adrenoceptor subtypes are present
throughout the arterial and venous system, a finding that substantiates the important
role of a1-adrenoceptors in blood flow regulation and the maintenance of vascular
resistance.  In general, establishing the a1-adrenoceptor subtype-specificity mediating
vasoconstriction in a particular vascular bed has been hampered, amongst others, by:
(i) the lack of highly selective agonists and/or antagonists; (ii) the co-existence of
multiple a1-adrenoceptor subtypes; and (iii) regional differences in the distribution
and density[44].  All three a1-adrenoceptor subtypes are expressed in heart, although
the a1A may be the dominant cardiac subtype in humans[17, 51].  It must be noted that
around 90% of the total a1-adrenoceptor mRNA message pool expressed at very high
levels in peripheral arteries is for a1A-adrenoceptors[52].  In agreement with the latter,
there is good evidence obtained from both in vitro and in vivo studies that the a1A is
the main a1-adrenoceptor subtype in the sympathetic regulation of vascular tone and
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blood pressure[33, 44, 53].  Human vas deferens and other smooth muscles appear to
express predominantly a1A- and a1D-adrenoceptors[42].  Some a1B-adrenoceptor
message and protein can also be found in vascular smooth muscle [54]; however,
limited information is available on the exact role of a1B-adrenoceptors in peripheral
blood vessels of humans[54].  Interestingly, recent findings obtained from
experiments using knockout mice (lacking the a1B-subtype), provide evidence that
a1B-adrenoceptors may mediate vasopressor and aorta contractile responses induced
by a1-adrenoceptor agonists[46]; whether this is species dependent needs further
investigations.  In this context, it has been reported that rat liver contains
predominantly a1B-adrenoceptors[55-57], but a1A-adrenoceptors in humans[51].  By
comparing the protein expression patterns and the results from radioligand binding
and functional experiments, it is reasonable to conclude that most tissues express
mixtures of a1-adrenoceptor subtypes[42], which complicates pharmacological
characterisation in functional studies.  Therefore, tissues that have been used as model
systems to characterise the pharmacological and signalling properties of particular
subtypes (a1A: rat vas deferens, rat submaxillary gland, rat kidney; a1B: rat spleen, rat
liver; a1D: rat aorta) most likely express multiple receptor subtypes. This may
contribute to the confusion surrounding the properties of the native subtypes[42].  The
exception appears to be the rat liver (see above), which seems to express only the
a1B-subtype[55-57].
Selective agonists and antagonists at a1-adrenoceptors
It must be emphasised that the current knowledge concerning the a1-adrenoceptor
subtype-selectivity mediating functional responses has been facilitated by the
identification of selective antagonists at these receptor subtypes.  Both the affinity and
selectivity of these compounds for a1-adrenoceptor subtypes have been determined
primarily by competition of radioligand binding to expressed recombinant subtypes in
different cell lines. The affinities of some of the commonly used antagonists for the
different human a1-adrenoceptor subtypes are shown in Table 1.2.
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Table  1.2. Binding affinity constants (pK i values) for cloned human a1- and a2-adrenoceptor subtypes.
Antagonist a1a a1b a1d a2a a2b a2c
Prazosin 9.8a
9.9n
9.6a
9.5n
10.2a
10.4n
5.3f
5.7g
6.4f
6.5g
6.7f
7.2g
5-Methylurapidil 9.0o
9.1a
7.5o
7.4a
7.9o
8.0a
6.2k 6.4k 6.9k
L-765,314 6.4b 8.7b 7.5b n.d. n.d. n.d.
BMY7378 6.6c
6.8p
7.2c
7.0p
9.4c
9.0p
5.1c* 5.1c* 5.1c*
Rauwolscine 6.3j
5.1m
6.3j
5.3m
6.3j
5.3m
9.5d
8.9h
9.4d
8.9h
9.9d
9.3h
BRL44408 n.d. n.d. n.d. 8.2e
7.6f
6.2e
6.0f
6.8e
6.4f
Imiloxan <4i <4i <4i 5.8f
6.5h
6.9f
7.2h
6.0f
6.8h
MK912 n.d. n.d. n.d. 8.9e
9.1h
8.9e
9.1h
10.2e
10.2h
Data taken from: a, Shibata et al.[58]; b, Patane et al.[59]; c, Goetz et al.[60]; d, Bylund et al.[48]; e, Uhlen et al.[61]; f, Devedjan et al.[62]; g,
Lomasney et al.[63]; h, Jasper et al.[64]; i, Michel & Whiting[65] (pA2 value); 
j, Michel & Whiting[66] (pA2 value); 
k, Hieble et al.[67];  l,
Kenny et al.[68]; m, Forray et al.[69]; n, Schwinn et al.[70]; o, Saussy et al.[71]; p, Craig et al.[72]; *, Value for rat receptor;  n.d., not
determined.  For full names of the antagonists, see list of abbreviations.
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Until a decade ago, most antagonists (including prazosin), showed little or no
selectivity between the three known a1-adrenoceptor subtypes[26].  In recent years,
however, a variety of ligands with varying degrees of selectivity have been developed
(see Table 1.1).  For example, 5-methylurapidil[73] and (+)-niguldipine[74] were
introduced as potent and selective a1A-adrenoceptor antagonists, showing 80 to
500-fold higher affinity for a1A- over the a1B-subtype and a low affinity for the
a1D-subtype[see 31].  Recently, several more potent and selective a1A-adrenoceptor
antagonists have been developed, including SNAP 5089[75], Rec 15/2739[76],
RS-17053[77], A131701[78] and RWJ-38063[79].  Similarly, several moderate to
high potent and selective a1A-adrenoceptor agonists have become available, such as
oxymetazoline (partial agonist), cirazoline[80, 81], SDZ NVI 085[82], A61603[83]
and NS-49[84].  Since the initial subclassification of a1-adrenoceptors, the alkylating
agent chloroethylclonidine has been used to characterise the a1B-adrenoceptor[26,
33].  Because chloroethylclonidine alkylates several other receptors as well[26, 85,
86], other antagonists have been developed displaying moderate selectivity at
a1B-adrenoceptors, including spiperone, cyclazosin[87] and L-765,314[88].  The
partial 5-HT1A receptor agonist BMY7378 is considered to be a selective
a1D-adrenoceptor antagonist, with about 100-fold higher affinity at a1D-adrenoceptors
over the a1A- or a1B-subtype[60].  To date, selective a1B- or a1D-adrenoceptor
agonists are, unfortunately, not available [18].  In agreement with the latter, there is a
clear need for more selective agonists and antagonists at a1B- and a1D-adrenoceptors
in order to make a more precise evaluation of the distribution and functional roles
mediated by the a1-adrenoceptor subtypes.  However, the limited number of potential
therapeutic applications seems to reduce this possibility.
Existence of other a1-adrenoceptor subtypes?
Besides the existence of a1A- a1B- and a1D-adrenoceptor subtypes (see above), several
lines of evidence suggest that the current classification of a1-adrenoceptors cannot
explain all the a1-adrenoceptor-mediated actions in a satisfactory manner.  Firstly, as
reviewed by Docherty[33], confusing evidence exists suggesting the existence of
peripheral prejunctional a1-adrenoceptors, mediating both inhibition (prostaglandines
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and adenyl purines) and facilitation of the release of several substances
(acethylcholine and noradrenaline).  In agreement with the latter, Széll et al. have
recently shown that activation of prejunctional a1A-adrenoceptors facilitates
acetylcholine release and enhances neurogenic contraction in the rat urinary
bladder[89]   However, these results need to be validated in other species[21].
Secondly, Muramatsu et al.[90] have shown that some blood vessels and other tissues
with smooth muscle (e.g. prostate) from different species may posses additional
a1-adrenoceptor subtype(s), namely, the so-called a1L-adrenoceptors.  This apparent
different subclassification of a1-adrenoceptors is based on the affinity of prazosin,
showing that a1-adrenoceptors can be subdivided into three subtypes: (i) the
 a1H-adrenoceptor having high affinity (KB < 1 nM) for prazosin (i.e. a1A, a1B and
a1D); (ii) the a1L-adrenoceptor having lower affinity prazosin (KB > 2 nM) and
yohimbine (KB > 300 nM); and (iii) the a1N-adrenoceptor that shows a comparable
affinity for prazosin as displayed at a1L-adrenoceptors, but shows higher affinity for
yohimbine (KB < 100 nM).  Furthermore, the a1L- and a1N-adrenoceptors can also be
distinguished by their affinity for HV 723, which shows higher affinity for a1N-
(KB = 0.4-1 nM) than for a1L-adrenoceptors (KB = 2-7 nM).  However, to date, any
putative additional subtype that shows low affinity for prazosin has resisted
identification by biochemical or molecular techniques[42].  Notwithstanding, the lack
of identification does not automatically imply the absence of these receptor subtype(s)
in certain tissues, keeping in mind that they could represent a therapeutic target for
selective drug action[91].
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Table  1.3. Summary of a2-adrenoceptor subtypes characteristics (modified from Docherty[33], Bylund[34] and Alexander & Peters[19]).
a2A / a2D a2B a2C
Previous name(s) a2-C10, RG20 a2-C2, RNG a2-C4
Functional response(s) prejunctional inhibition in most
adrenergic nerves, central hypotensive
action in several species
pressor responses in mutated mouse,
pressor responses in pithed rat
contraction of human saphenous vein,
inhibition of neurotransmitter release,
inhibition of adenylate cyclase in
different cell lines
Ligand binding assay human platelet (a2A), rat submandibular
gland (a2D)
neonatal rat lung, rat kidney different cell lines
Non-selective agonists clonidine, BHT933, UK 14304, BHT920 clonidine, BHT933, BHT920 clonidine, BHT933, BHT920
Selective agonists oxymetazoline (partial agonist),
moxonidine?
none none
Non-selective antagonists rauwolscine rauwolscine rauwolscine
Selective antagonists BRL44408, BRL48962 ARC239, imiloxan MK912
Potency order adrenaline > noradrenaline adrenaline > noradrenaline adrenaline > noradrenaline
Receptor distribution platelet, brain, spinal cord, adipocyte
cells, aorta, kidney, brain, spleen (human
and rat)
liver, spleen, heart (human), kidney,
neonatal rat lung (rat), thalamus,
olfactory tubercle, septum, cerebellum
(rat)
brain human and rat), heart, lung, aorta,
kidney, brain (human)
Tissue function(s) involved in hypotension, sedation,
analgesia, anaesthesia
vasoconstriction not established
Second messenger system(s) activation of Gi/o, inhibition of adenylate cyclase, decrease in cAMP levels, inhibition of voltage-gated Ca
2+ channels, activation of
Ca2+ dependent K+ channels (except for a2B-adrenoceptors)
Notes a2A- (human, dog, pig and rabbit) and
a2D-adrenoceptors (rat, mouse and cow)
are species orthologues
ARC239 also displays moderate affinity
for a2C-adrenoceptors,
prazosin display moderate affinity
Abbreviation: cAMP, cyclic Adenosine Mono Phosphate.
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Heterogeneity of a2-adrenoceptors
The first suggestion that a2-adrenoceptors could be subdivided was based on the
findings that prazosin, previously considered as a selective a1-adrenoceptor
antagonist, produced potent inhibition of[3H]rauwolscine binding in certain tissues
and cell lines[48].  Initially, the prazosin-insensitive a2-adrenoceptor (in human
platelets) was designated as the a2A-adrenoceptor subtype, while the
prazosin-sensitive a2-adrenoceptor (in neonatal rat lungs) was referred to as the
a2B-adrenoceptor subtype.  Correlating the affinity constants of several
a2-adrenoceptor antagonists with their inhibitory potency against a2-adrenoceptor
binding, two additional a2-adrenoceptor subtypes (a2C and a2D) were identified[26].
The a2C-adrenoceptor was initially identified in OK cells, an opposum kidney cell
line[92] and, subsequently, in native opossum kidney[93].  Currently, it is known that
combining ligand binding and molecular cloning studies four distinct subtypes of
a2-adrenoceptors have been identified, namely the a2A-, a2B-, a2C- and
a2D-subtype[17, 94].  Nevertheless, the a2D-adrenoceptor subtype (found in the rat,
mouse and cow) is currently believed to be a species orthologue of the human
a2A-adrenoceptor subtype (found in human, dog, rabbit and pig) and, therefore, cannot
be recognised as an additional receptor subtype[31, 95, 96].  Table 1.3 shows a
summary of the current a2-adrenoceptor pharmacological characteristics.
Signal transduction mechanisms of a2-adrenoceptors
a2-Adrenoceptors are a part of the large family of G-protein coupled receptors and
mediate their functions though a variety of G-proteins, including Gi/o[85].  In
agreement with this, several studies have shown that a2-adrenoceptor activation of
these pathways was pertussis toxin sensitive. These findings suggest that GTP-binding
proteins of the Gi/Go subfamily are responsible for eliciting these effects[85].  In
contrast, other studies have shown that pertussis toxin did not block
a2-adrenoceptor-mediated inhibition of noradrenaline release from cardiac
sympathetic neurones in pithed rats[97] or isolated mouse atria[98].  After activation
of the receptor and G-protein coupling, it has long been known that (pre- and
postsynaptically) a2-adrenoceptors are negatively coupled to adenylate cyclase,
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attenuating cAMP production in target cells[33, 85].  Regarding presynaptic
a2-adrenoceptors, several lines of evidence suggest that opening of K+-channels and
inhibition of Ca2+-channels are the two modes of action to produce presynaptic
inhibition[95].  Additional signalling pathways have also been identified for
presynaptic a2-adrenoceptors, including accelerating Na+/H+-exchange, activation of
phospholipase A2, phospholipase D and phospholipase C[85]; however, their exact
involvement in the signal transduction pathways upon presynaptic a2-adrenoceptor
(subtype) stimulation needs to be validated.  In vascular smooth muscle,
vasoconstrictor a2-adrenoceptors seem to be positively linked to Ca2+-channels,
stimulating intracellular calcium influx upon stimulation[33].  This suggestion has
been based on several in vitro studies showing that the a2-adrenoceptor-mediated
contractions are reduced by `Ca2+-channel antagonists’ and are nearly abolished in
Ca2+-free medium[85].  Other studies, however, show that a2-adrenoceptor agonists
enhance contractions to a1-adrenoceptor agonists, an effect that is not mediated by
enhancement of inositol triphosphate accumulation, but it may be mediated by
inhibition of forskolin-stimulated cAMP production[see 33, 99].
The above mentioned studies emphasise the uncertainty regarding the signalling
mechanisms that are involved in the physiological responses to stimulation of specific
a2-adrenoceptor subtypes in a given tissue.  With the development of selective
ligands, particularly antagonists, at these a2-adrenoceptor subtypes (e.g. see
Table 1.2), this matter will hopefully be elucidated in the near future[33].
Location and function of a2-adrenoceptors
As mentioned before, a2-adrenoceptors are located both pre- and postsynaptically
where they mediate an inhibitory (e.g. for adenylate cyclase) and an excitatory (e.g. an
increase in Ca2+ concentration) role in both the central and peripheral nervous
systems[95]. As reviewed by Docherty[33] and Hieble[20], prejunctional
a2-adrenoceptors (most likely the a2A- and/or a2C-subtypes, depending on species) are
located on most adrenergic nerves and primarily mediate prejunctional inhibition.  On
the other hand, postjunctional a2-adrenoceptors are located on vascular smooth
muscle and activation results in vasoconstriction[100].
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Functional presynaptic a2-adrenoceptors in rat submandibular gland, rat vas
deferens, rat cerebral cortex, pithed rat heart and mouse atria resemble the
a2D-adrenoceptor subtype, whereas those in rabbit and human cerebral cortex, dog
mesenteric artery and human saphenous vein resemble the a2A-adrenoceptor
subtype[see 33].  In contrast, other studies have shown that (postsynaptic)
a2C-adrenoceptors mediate contraction of the human isolated saphenous vein[101,
102].  Since both presynaptic a2A- and a2C-adrenoceptors are targets for the neural
release of noradrenaline (at least when the noradrenaline-transporter is blocked[103]),
it would be very interesting to elucidate their individual pharmacological profiles (e.g.
binding properties to known compounds), signal transduction pathways, second
messengers and their potential differences in function[103].  A valuable tool in
dissecting the role of these receptors in the regulation of a variety of physiological
responses, for example blood pressure[100], is by means of using genetically
engineered mice deficient in each of the a2-adrenoceptor subtypes[104-106].  The use
of these knock-out mice confirmed the earlier findings that a2A-adrenoceptors, which
appear to be the major subtype in brain areas involved in cardiovascular
regulation[107], play a critical role in regulating sympathetic outflow[106].  In
agreement with this hypothesis, it has been shown that a2A-adrenoceptor mutants or
knockout mice, which display higher blood pressure, heart rate and plasma
noradrenaline levels compared with their wild type counterparts, were unable to
exhibit hypotension in response to a2-adrenoceptor agonists[106].  The distribution of
a2B-adrenoceptors is restricted only to limited areas of the central nervous system,
namely the thalamus and the nucleus tractus solitarii area of the brain stem[107], but
is abundant in the vascular smooth muscle cells of the arterial wall and mostly
responsible for a peripheral vasoconstrictor action[108-110].  In agreement with the
latter, recent findings demonstrated that a2B-adrenoceptor-deficient anephric mice
were unable to raise their blood pressure in response to an acute hypertonic saline
stimulus[100, 106].  These data are in agreement with studies using pithed rat
preparations, where the a2B is the main subtype mediating hypertension[20, 28, 111,
112].  On the contrary, Duka[113] reported that vasoconstriction mediated by direct
activation of vascular a2-adrenoceptors in mice is attributable to the postsynaptic
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a2A-adrenoceptor subtype, which is consistent with other findings that mRNA for the
a2A-, but not a2B-, adrenoceptor could be detected on the arterial wall of rabbits[114].
In fact, the pressor responses attributed to a2B-adrenoceptor stimulation, as reported
by different investigators[108-110], could in fact be attributable to the involvement of
central, rather than peripheral, a2B-adrenoceptors[113].  As mentioned before, the
human isolated saphenous vein is a preparation in which predominantly postsynaptic
a2C-adrenoceptors mediate contraction, whereas the involvement of a1-adrenoceptors
is limited (if any)[101].  No haemodynamic responses mediated by a2C-adrenoceptors
are known so far[20, 33, 106, 109].  As for other isolated tissues, a2-adrenoceptors
contribute to a predominantly a1-adrenoceptor-mediated response[100, 115, 116],
such as the rat cremaster arterioles and venules, rat tail vasculature, rabbit corpus
cavernosum, guinea-pig cauda epididymis and mouse vas deferens[33].  In any case,
since the involvement of specific a2-adrenoceptor subtypes in any given functional
response could be species dependent (as mentioned above), further investigation will
be required to validate this matter in humans.
The development of potent and more selective a2-adrenoceptor subtype-selective
antagonists (see next section) will be very useful in the pharmacological
characterisation of specific subtypes in certain vascular beds, especially considering
potential clinical implications.
Selective agonists and antagonists at a2-adrenoceptor subtypes
Although selective compounds are now being developed to differentiate between
a2-adrenoceptor subtypes in radioligand binding assays, there is currently no ligand
available that is highly selective in functional studies (for affinity constants, see
Table 1.2).  Therefore, pharmacological characterisation is based on the affinity of a
range of compounds that exhibit different affinities for the subtypes compared to their
activity in functional studies.  Attempts have been made to develop selective
postsynaptic a2-adrenoceptor antagonists (e.g. SKF 104078)[117].  However, these
attempts failed because these antagonists also blocked presynaptic a2-adrenoceptors
in rat vas deferens, human saphenous vein, pithed heart and guinea-pig atrium, in the
same dose-range as it blocked the postsynaptic a2-adrenoceptors[see 33].  In contrast
to the a1-adrenoceptor, a few a2-adrenoceptor subtype-selective antagonists have
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been identified to date (see Table 1.2.).  Initially, prazosin had been used to
distinguish a2B- and a2A-adrenoceptors; however, other antagonists have recently
been developed showing higher selectivity for a2B- over the a2A-subtype
(e.g. ARC 239 or BRL 41992).  BRL44408 is a potent and selective
a2A/D-adrenoceptor antagonist, both in radioligand binding and functional studies[101,
118, 119], whereas moxonidine[120] and oxymetazoline (which also shows intrinsic
activity at a1A-adrenoceptors) display agonist properties at these receptors[121].  Most
of the currently available a2B-adrenoceptor antagonists (e.g. prazosin, ARC 239,
SKF 104856 or spiroxatrine) also block a1-adrenoceptors, the only current known
exception being imiloxan[122].  The pharmacological differences between a2B- and
a2C-adrenoceptors are very subtle, with currently no available antagonist showing
clear selectivity.  Examples of moderate selective a2B/C-adrenoceptor antagonists are
MK912, ARC 239 and rauwolscine [26, 33].  Although these ligands can be used in
binding studies to determine the presence of a certain a2-adrenoceptor subtype in a
particular tissue, one should be cautious when using these ligands for the
characterisation of the above receptors in in vivo studies.
Therapeutic applications of drugs interacting with a adrenoceptors
Whereas both noradrenaline and adrenaline are sometimes used for therapeutic
purposes (e.g. anaphylactic shock or cardiac arrest), most of the clinical used
sympathetic ligands (agonists and antagonists) are structural analogues, have a variety
of advantages (e.g. higher oral bioavailability, prolonged duration of action and more
subtype-selectivity) and are used in the treatment of a variety of ailments, such as
hypertension, asthma, benign prostate hypertrophy and hyperplasia and anaphylactic
reactions[see 26, 85].  Detailed information about the a1- and a2-adrenoceptor
subtypes by which these drugs are clinically efficacious could be very beneficial,
especially when the potential side effects are taken into account.
a1-Adrenoceptors have been one of the most widely studied families of receptors
because of its major physiological importance in the control of blood pressure, blood
flow, digestion, airways, reproduction, pupil diameter, endocrine and metabolic
processes and in behaviour[33].  For several decades, it is known that non-selective
a1-adrenoceptor antagonists, such as prazosin, terazosin, doxazosin or trimazosin, are
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efficacious in the treatment of hypertension[44, 85, 123, 124] and benign prostatic
hyperplasia[125-128].  However, due to the frequent occurrence of side effects using
these drugs (e.g. hypotension), there is a clear need for more a1-adrenoceptor
subtype-selective agents to treat these and other disorders[128-130].  As for the
treatment of benign prostatic hyperplasia (BPH), the relatively selective
a1A-adrenoceptor antagonist, tamsulosin, which causes only moderate blood pressure
changes, proved to be a better option than the non-selective a1-adrenoceptor
antagonists[131].  Recently, Pulito et al. demonstrated the uroselectivity of a novel
a1A-adrenoceptor subtype-selective antagonist, RWJ-38063; this compound was a
more effective agent in the treatment of BPH symptoms with minimal effects on the
vasculature and presents a more positive side effect profile than other a1-adrenoceptor
antagonists currently available[79].  In this context, further studies are required to
ascertain the mechanisms (involvement of a1L-adrenoceptors?) involved in the
functional uroselectivity (over e.g. blood pressure) of a1-adrenoceptor
antagonists[128-130].  In other words, when it is generally agreed that the a1A- is the
main subtype of a1-adrenoceptors in the sympathetic control of e.g. blood
pressure[44], which receptors mediate the reported uroselectivity of the
aforementioned selective a1A-adrenoceptor antagonists?  Similarly, several reports
from both in vitro and in vivo studies suggest that activation of a1-adrenoceptors,
particularly a1A-adrenoceptors by NS-49, increases urethral tone without causing an
associated vasopressor response[84, 132].  Interestingly, investigating potential
differences in pharmacological profiles of the four recently cloned splice variants of
the human a1A-adrenoceptor[39, 40] or the cloning and further characteristation of the
putative a1L-adrenoceptors[90], could be very helpful to clarify this matter[41].  Other
therapeutic applications of drugs which interact with peripheral a1-adrenoceptors are
urinary incontinence (agonists[72, 133]), anal fissures (antagonists[134]), erectile
dysfunction (antagonists[see 135, 136, 137]), nasal congestion (agonists), as adjunct
to local anaesthesia (agonists)[see 127, 138].  Interestingly, a1-adrenoceptors have
recently been implicated in cardiac hypertrophy (antagonists[see 20]).  Potential
clinical applications of central a1-adrenoceptors are with regard to sexual activity and
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erectile dysfunction, as reviewed by Giuliano & Rampin in 1999[139].  In this
context, the general idea is that the brain noradrenergic transmission facilitates sexual
activity.  In different animal models, it has been shown that activation of central
a1-adrenoceptors or blockade of central a2-adrenoceptors (see below) increases
sexual motivation and facilitates copulation[see 139].  However, direct evidence for
central control of penile erection by the noradrenergic transmission is not yet
available.  Besides the link with penile erection, central a1-adrenoceptors may also
play a role in the modulation of attention and memory formation[see 45, 140].
For several decades, it has been known that a2-adrenoceptor agonists, such as
moxonidine, clonidine, guanabenz, guanfacine and a-methyldopa, are effective in the
treatment of hypertension[see 141].  The underlying mechanisms of these drugs is
assumed by inducing peripheral sympathoinhibition and a reduction in elevated blood
pressure as a result of the stimulation of central a2A-adrenoceptors[141, 142].  Besides
acting at a2A-adrenoceptors, several of these compounds have been shown to display
affinity at imidazoline I1-binding sites, located in the rostroventrolateral part of the
brainstem[see 143].  The argument supporting that hypotension is induced via a
selective action at imidazoline I1-binding sites, presumes that compounds such as
rilmenidine and moxonidine act preferentially through this site[64, 144, 145].
However, based on several lines of evidence, the involvement of imidazoline I1-sites
in controlling systemic blood pressure is questionable and remains unclear[see 20,
120, 146, 147, 148].  As reviewed by Piascik et al.[85], other therapeutic applications
of drugs interacting with a2-adrenoceptors are for example as adjunct to general
anaesthesia (agonists[149]), hypertension (antagonists[20]), depression
(antagonists[150]), obesity (antagonists[see 20]), schizophrenia (antagonists[151]),
attention deficit disorder (agonists[152]), sedation/analgesia (antagonists[153]),
peripheral nociceptive responses (agonists[154, 155] or in sexual disorders such as
impotence (antagonists[138, 139, 156]).  In addition, whereas prostatic tone is mainly
mediated by a1A-adrenoceptors, as described above, in vitro studies have shown that
a2-adrenoceptors are also present in this tissue[157].  This latter finding, which
implies that presynaptic a2-adrenoceptor blockade elicits prostatic obstruction via
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a1-adrenoceptors[126], could open new possibilities for the therapeutic use of
a2-adrenoceptor agonists in the treatment of urinary dysfunction.
Possible role of a-adrenoceptors in the treatment of migraine
Migraine is a syndrome that affects a substantial fraction of the world’s population,
with a higher prevalence in women (15-18%) than in men (6%[158]).  According to
the diagnostic criteria proposed by the Headache Classification of the International
Headache Society[159], a migraine attack can be divided into distinct phases
(predromitory phase, aura phase, headache phase, resolution and recovery phase) and
is characterised by an intense, pulsating and throbbing headache, nausea, vomiting
and photo- and/or phonopobia.  For obvious reasons, the pathophysiology of migraine
has been a matter of great interest for many researchers during several decades.
Whereas limited information is available concerning the underlying mechanisms for
the initiation of a migraine attack, the subsequent events leading to the aura or
headache phase can be explained by a neurovascular hypothesis[see 160, 161, 162].
In this context, several experimental animal models have been developed to explain
the efficacy of acutely acting antimigraine drugs, as reviewed by De Vries et al.[162].
The predictive antimigraine value of these models are based on: (i) the involvement of
the trigeminovascular system (i.e. inhibition of plasma protein extravasation[163,
164] or central trigeminal inhibition[see 165]); (ii) vasoconstriction of the cranial
extracerebral vascular beds (e.g. carotid vasculature or isolated blood vessels [161,
166, 167, 168]); or (iii) a combination of both hypotheses.  It may be pointed out that
the present project (described in this thesis) is exclusively based on vasoconstriction
in the carotid vasculature of anaesthetised dogs and pigs.
Among others, Wolff[169] proposed an important role of vasodilatation of
extracranial (extracerebral) arteries that are supplied by the (external) carotid artery
(e.g. temporal artery) in migraine headache.  Recognising several clinical signs
accompanying a migraine attack (facial pallor, increased pulsations in the temporal
artery and a clearly swollen frontal vein on the side of the headache), Heyck[170]
investigated the underlying mechanisms in healthy volunteers and migraineurs.
Subsequently, measuring the oxygen saturation difference between arterial (femoral
artery) and venous (external jugular vein) blood (AVSO2 difference) before, during
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and after a migraine attack, Heyck (1969) reported a decreased AVSO2 difference
during the headache attack.  Interestingly, this decrease in AVSO2 difference was
normalised after the attack had abated (either spontaneously or after successful
treatment).  Based on these rather preliminary studies, Heyck (1969) proposed that
vasodilatation during the migraine headache phase primarily involves carotid
arteriovenous anastomoses (see Figure 1.2.), but not arterioles[see also 171].
Arteriovenous anastomoses are large precapillary communications between arteries
and veins and are present in most structures, including the cheeks, lips, forehead,
nose, ears, nasal mucosa, eyes and dura mater of several species, including humans
and pigs[161].  In conscious pigs, it has been shown that carotid arteriovenous
anastomoses are under a sympathetic constrictor
tone[172, 173], only shunting a small fraction
(< 3%) of the total carotid blood flow[174].
Whether this is also the case in humans is
unknown, but opening of carotid arteriovenous
anastomoses, leading to shunting of a large
amount of arterial blood directly into the venous
circulation, may explain the facial pallor,
lowering of facial temperature and increased
vascular pulsations.  Interestingly, it was already
shown by Wolff[175] that the reported increased
pulsations (an apparent index of quantitatively increased blood flow) in the temporal
artery in migraineurs were absent after treatment with ergotamine.  The relatively high
usage of oxygen from the blood circulating in the fronto-temporal region suggests that
the increased blood flow may serve other purposes, possibly protective, thermal
control[170]. And indeed, arteriovenous anastomoses play an important role in the
thermoregulation as established peripherally in the hind limbs of sheep[176].
Admittedly, the subsequent events leading to headache (and associated symptoms) are
not completely understood. Nevertheless, it could be argued that increased vascular
pulsations activate stretch receptors, increasing the activity of
neuropeptide-containing (e.g. CGRP) perivascular sensory nerve endings; this may,
ultimately, cause pain and other associated symptoms[see 161, 162, 167].
Figure 1.2.
Schematic representation of an
arteriovenous anastomosis[161].
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In line with the proposal that carotid arteriovenous anastomoses are dilated and
play a role in the pathogenesis of migraine (see above), it is reasonable to believe that
a-adrenoceptors could be involved in the vascular tone of the carotid circulation,
which may provide a potential avenue for the development of new antimigraine drugs.
It has been well established that several acutely acting antimigraine agents, including
the ergots (ergotamine and dihydroergotamine) and the triptans (sumatriptan and the
second generation antimigraine drugs), produce potent vasoconstriction in the canine
and porcine carotid vasculature, a response mediated by 5-HT1B/1D receptors[177-
179].  Interestingly, the canine carotid vasoconstrictor responses of the ergot alkaloids
are mediated by 5-HT1B/1D receptors and a2-adrenoceptors[177, 180].  On the other
hand, the vasoconstriction of porcine carotid arteriovenous anastomoses by
sumatriptan is mediated exclusively by 5-HT1B receptors[178]; notwithstanding, that
produced by the ergots involves, in addition to 5-HT1B/1D receptors, unidentified
receptors/mechanisms[181]. The above lines of evidence, combined with the high
affinity of ergotamine and dihydroergotamine at a-adrenoceptors[182], lead us to
suggest that their therapeutic efficacy[see 183] may be partly explained by an action
mediated via a-adrenoceptors. However, the possible involvement of a-adrenoceptors
in the porcine carotid vasculature has been hampered, mainly on the basis that porcine
carotid arteriovenous anastomoses were described to be insensitive to sympathetic
nerve stimulation or intracarotid infusions of noradrenaline[184].  This discrepancy is
striking since in conscious pigs arteriovenous anastomoses are under a vasoconstrictor
sympathetic tone, which involves a1-adrenoceptors[174].  In fact, sympathetic nerve
stimulation as well as exogenously administered noradrenaline causes
a-adrenoceptor-mediated vasoconstriction of arteriovenous anastomoses in the hind
limb of several species[172, 185-188].  Finally, several in vitro experiments have
shown that stimulation of a-adrenoceptors results in contraction of the isolated carotid
artery of several species, including the dog[189, 190], rabbit[191] and pig[192].
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Aims of this thesis
1. To investigate whether a1- and a2-adrenoceptors are operative in vivo mediating
porcine (arteriovenous anastomotic) and canine (external) carotid
vasoconstriction.
2. Based on the previous point, to identify, by pharmacological means, the specific
subtypes of a1-  (a1A, a1B or a1D) and a2-(a2A, a2B or a2C) adrenoceptors
mediating (selective) carotid vasoconstriction in these in vivo experimental
models.
3. To analyse the porcine and/or canine carotid vascular effects of some known
antimigraine drugs (e.g. isometheptene) and to investigate whether specific a1-
and/or a2-adrenoceptor subtypes mediate these potential carotid vasoconstrictor
responses.
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Chapter 2
Pharmacological evidence that a1- and a2-adrenoceptors mediate
porcine vasoconstriction of carotid arteriovenous anastomoses
Summary    Vasoconstriction of carotid arteriovenous anastomoses may
be involved in the therapeutic action of acutely acting antimigraine
agents, including the triptans and ergot alkaloids.  While 5-HT1B/1D
receptors mediate the effect of triptans, ergotamine and
dihydroergotamine also interact with a-adrenoceptors.  In the present
study, we investigated the potential role of a1- and a2-adrenoceptors in
mediating vasoconstriction of carotid arteriovenous anastomoses in
anaesthetised pigs.  Ten minute intracarotid infusions of phenylephrine
(1, 3 and 10 mg kg-1 min-1) or BHT933 (3, 10 and 30 mg kg-1 min-1)
produced dose-dependent decreases in total carotid and arteriovenous
anastomotic conductances; no changes were observed in the capillary
fraction.  The carotid vascular effects of phenylephrine and BHT933
were selectively abolished by prazosin (100 µg kg-1, i.v.) and
rauwolscine (300 µg kg-1, i.v.), respectively.  The responses to
phenylephrine and BHT933 were not affected by the selective 5-HT1B/1D
receptor antagonist GR127935 (500 µg kg-1, i.v.).  These results show
that both a1- and a2-adrenoceptors can mediate vasoconstriction of
carotid arteriovenous anastomoses in anaesthetised pigs.  Since
vasoconstrictor activity in this in vivo model is predictive of antimigraine
activity, an agonist activity at particularly the a2-adrenoceptor subtypes,
in view of their less ubiquitous nature, could provide migraine abortive
potential.  Thus, the present results may aid further understanding of the
mode of action of some current antimigraine agents and may eventually
be helpful in the development of future treatment in migraine.
Based on: Willems et al., Br. J. Pharmacol. (1999) 127, 1263-1271.
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Introduction
Vasodilatation of carotid arteriovenous anastomoses may be involved in the
pathophysiology of migraine headache[161, 170].  In line with this proposal, it has
previously been shown that several acutely acting antimigraine agents, including the
ergots (ergotamine and dihydroergotamine) and triptans, potently vasoconstrict
porcine carotid arteriovenous anastomoses predominantly via 5-HT1B/1D
receptors[166, 181].  Interestingly, the carotid vasoconstrictor effect of ergot alkaloids
involves, in addition to 5-HT1B/1D receptors, unidentified receptor mechanisms[166,
181].  Since the ergot derivatives display high affinity at a-adrenoceptors[182], their
therapeutic efficacy may be partly explained by an action mediated via these
receptors.  Indeed, we recently reported that canine external carotid vasoconstriction
by ergot alkaloids also involves a-adrenoceptors[177].  In this context, the possible
involvement of a-adrenoceptors in the porcine carotid vasculature has been
hampered, mainly on the basis that porcine carotid arteriovenous anastomoses were
described to be insensitive to sympathetic nerve stimulation or intracarotid infusions
of noradrenaline[184].  This discrepancy is striking since in conscious pigs
arteriovenous anastomoses are under a vasoconstrictor sympathetic tone[172-174].  In
fact, sympathetic nerve stimulation as well as exogenously administered
noradrenaline causes a-adrenoceptor-mediated vasoconstriction of arteriovenous
anastomoses in the hind limb of several species[185-188].
In the light of the above, the present study was designed to investigate the potential
role of a1- and a2-adrenoceptors in the vasoconstriction of carotid arteriovenous
anastomoses in anaesthetised pigs.  For this purpose, we made use of the selective
agonists, phenylephrine (a1) and BHT933 (6-ethyl-5,6,7,8-tetrahydro-4H-
oxazolo[4,5-d]azepin-2-amine dihydrochloride; a2), and the selective antagonists,
prazosin (a1), rauwolscine (a2)[85, 193], in a well-defined in vivo model predictive of
antimigraine activity[85, 161, 162, 193].  In addition, GR127935
(N-[methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4'-(5-methyl-1,2,4-
oxadiazol-3-yl)[1,1-biphenyl]-4-carboxamide was used to exclude the possible role of
5-HT1B/1D receptors[194-196].  The results obtained may provide useful information
concerning the mode of action of some currently used antimigraine agents and,
possibly, new avenues for the development of antimigraine agents.
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Methods
General
After an overnight fast, 40 domestic pigs (Yorkshire x Landrace; 10-14 kg) were
anaesthetised with azaperone (120 mg, i.m.), midazolam hydrochloride (5 mg, i.m.)
and sodium pentobarbital (600 mg, i.v.).  After tracheal intubation, the animals were
connected to a respirator (BEAR 2E, BeMeds AG, Baar, Switzerland) for intermittent
positive pressure ventilation with a mixture of room air and oxygen.  Respiratory rate,
tidal volume and oxygen supply were adjusted to keep arterial blood gas values within
physiological limits (pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2: 100-120 mmHg).
Anaesthesia was maintained with a continuous i.v. infusion of sodium pentobarbital
(20 mg kg-1 h-1).  It may be pointed out that this anaesthetic regimen, together with
bilateral vagosympathectomy (see below), leads to an increase in heart rate and
vasodilatation of arteriovenous anastomoses due to a loss of parasympathetic and
sympathetic tone, respectively.  Indeed, basal arteriovenous anastomotic blood flow is
considerably higher in sodium pentobarbital-anaesthetised pigs (70-80% of carotid
blood flow) than in those under fentanyl/thiopental anaesthesia (~19% of carotid
blood flow[174].  A high basal carotid arteriovenous anastomotic flow is particularly
useful for investigating the effects of drugs that vasoconstrict arteriovenous
anastomoses.
A catheter was placed in the inferior vena cava via the left femoral vein for
infusion of antagonists and sodium pentobarbital.  Another catheter was placed in the
aortic arch via the left femoral artery for the measurement of arterial blood pressure
(Combitrans disposable pressure transducer; Braun, Melsungen, Germany) and
arterial blood withdrawal for the measurement of blood gases (ABL-510; Radiometer,
Copenhagen, Denmark).  Subsequently, the right common carotid artery and the
external jugular vein were dissected free and the accompanying vagosympathetic
trunks were cut between two ligatures in order to prevent a possible influence via
baroreceptor reflexes on agonist-induced carotid vascular responses.  The right
external jugular vein was catheterised for withdrawal of venous blood samples for
determining blood gases (ABL-510; Radiometer, Copenhagen, Denmark).  Two
hub-less needles, each connected to a polyethylene tube, were inserted into the right
common carotid artery and used for agonist (phenylephrine or BHT933) infusion and
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radioactive microspheres injection, respectively.  The microspheres were injected
against the direction of blood flow for uniform mixing.
Blood flow was measured in the right common carotid artery with a flow probe
(internal diameter: 2.5 mm) connected to a sine-wave electromagnetic flow meter
(Transflow 601-system, Skalar, Delft, The Netherlands).  Heart rate was measured
with a tachograph (CRW, Erasmus University, Rotterdam, The Netherlands) triggered
by electrocardiogram signals.  Arterial blood pressure, heart rate and right common
carotid blood flow were continuously monitored on a polygraph (CRW, Erasmus
University, Rotterdam, The Netherlands).  During the experiment, body temperature
was kept around 37 °C and the animal was continuously infused with saline to
compensate for fluid loss.
Distribution of carotid blood flow
The distribution of common carotid blood flow was determined with 15.5±0.1 µm
(s.d.) diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN
Dupont, Boston, USA).  For each measurement, about 200,000 microspheres, labelled
with one of the radioisotopes, were mixed and injected into the right common carotid
artery.  At the end of the experiment, the animal was killed by an overdose of sodium
pentobarbital and the heart, lungs, kidneys and all ipsilateral cranial tissues were
dissected out, weighed and put in vials.  The radioactivity in these vials was counted
for 10 min in a g-scintillation counter (Packard, Minaxi autogamma 5000), using
suitable windows to discriminate the different isotopes (141Ce: 120-167, KeV, 113Sn:
355-435 KeV, 103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 46Sc: 830-965 KeV).  All
data were processed by a set of specially designed programs[197].  The fraction of
carotid blood flow distributed to the different tissues was calculated by multiplying
the ratio of tissue and total radioactivity of each radioisotope by the total common
carotid blood flow at the time of the injection of the microspheres labelled with the
respective isotope.  Since little or no radioactivity was detected in the heart and
kidneys, all microspheres trapped in lungs reached this tissue from the venous side
after escaping via carotid arteriovenous anastomoses.  Therefore, the amount of
radioactivity in the lungs was used as an index of the arteriovenous anastomotic
fraction of the common carotid blood flow[198].  Vascular conductance
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(10-2 ml min-1  mmHg-1) was calculated by dividing blood flow (ml min-1) by blood
pressure (mmHg), multiplied by hundred.
Experimental protocol
After a stabilisation period of about 60 min, baseline values of heart rate, mean
arterial blood pressure, common carotid blood flow and its distribution, as well as
arterial and jugular venous blood gases were measured.  Thereafter, the animals were
divided into four groups receiving i.v. infusions (0.5 ml min-1 for 10 min) of either
distilled water (vehicle; n=14), prazosin (100 mg kg-1; n=10), rauwolscine
(300 mg kg-1; n=10) or GR127935 (500 mg kg-1; n=6).  After a waiting period of
15 min, all variables were reassessed.  Subsequently, each group was divided into two
subgroups receiving 10-min intracarotid infusions (0.1 ml min-1) of phenylephrine
(cumulative doses: 1, 3, and 10 mg kg-1 min-1) or BHT933 (cumulative doses: 3, 10
and 30 mg kg-1 min-1).  The number of animals in the different groups receiving
phenylephrine and BHT933 infusions were: vehicle (n=7 each), prazosin (n=7 and 3,
respectively), rauwolscine (n=3 and 7, respectively) and GR127935 (n=3 each).  All
variables were collated again 10 min after the start of each agonist infusion.
It may be pointed out here that GR127935, which is a potent and selective
5-HT1B/1D receptor antagonist[194-196], was used to rule out the remote possibility
that the effects of phenylephrine and/or BHT933 were mediated via 5-HT1B/1D
receptors.  The effectiveness of the blockade of 5-HT1B/1D receptors by GR127935
was confirmed by evaluating decreases in the total carotid blood flow and
conductance by sumatriptan[196].  Sumatriptan (30, 100 and 300 mg kg-1, i.v.; every
10 min over a period of 5 min each) was administered in animals treated with
GR127935 after a near complete recovery from the effects of the last dose of
phenylephrine or BHT933 had been achieved (~90 min).
Data presentation and statistical analysis
All data have been expressed as the mean±s.e.mean.  The percent changes from
baseline (i.e. after treatment with vehicle, prazosin, rauwolscine and GR127935)
values caused by the different doses of phenylephrine or BHT933 within each group
of animals were calculated.  A two-way repeated measures ANOVA with
Bonferroni’s correction (SigmaStat 1.0, Jandel Corporation, Chicago, IL, USA) was
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used to establish whether these changes were statistically significant (P<0.05,
two-tailed) when compared with the baseline in each group as well as with the
corresponding agonist dose in the vehicle-treated group.
Drugs
Apart from the anaesthetics azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse,
Belgium), midazolam hydrochloride (Dormicum®; Hoffmann La Roche b.v.,
Mijdrecht, The Netherlands) and sodium pentobarbital (Apharmo, Arnhem, The
Netherlands), the compounds used in this study were: prazosin hydrochloride (Bufa
Chemie b.v., Castricum; The Netherlands), GR127935, sumatriptan succinate (both
from GlaxoWellcome, Ware, Herts, UK; courtesy: Dr. H.E. Connor), phenylephrine
hydrochloride, BHT933 and rauwolscine dihydrochloride (all from Sigma-Aldrich
Chemie b.v., Zwijndrecht, The Netherlands).  Finally, heparin sodium (Leo
Pharmaceutical Products, Weesp, The Netherlands) was used to prevent clotting of
blood in the catheters.  All drugs were dissolved in distilled water.  For prazosin,
rauwolscine and GR127935 a short period of heating was needed.  The doses of the
drugs refer to their respective salts.
Ethical approval
The local ethics committee dealing with the use of animals in scientific experiments
approved the protocol.
Results
Systemic and carotid haemodynamic effects of vehicle, prazosin, rauwolscine and
GR127935
As shown in Table 2.1, the administration of vehicle (5 ml of distilled water) did not
produce any change in systemic or carotid haemodynamic variables.  On the other
hand, prazosin (100 mg kg-1, i.v.), rauwolscine (300 mg kg-1, i.v.) and GR127935
(500 mg kg-1, i.v.) decreased mean arterial blood pressure by 7±2%, 9±3% and
13±2%, respectively, which only in the case of rauwolscine was accompanied by a
significant decrease in arteriovenous anastomotic blood flow by 18±5%.
Additionally, rauwolscine increased capillary blood flow and conductance by 24±7%
and 38±9%, respectively.  These effects of rauwolscine were noticed in several tissues
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(ear, skin, muscle, bones, salivary gland, fat and tongue; data not shown).  No other
significant changes were noticed with prazosin, rauwolscine or GR127935.
Table  2.1. Effects of vehicle, prazosin, rauwolscine or GR127935 on heart rate (HR;
beats min-1), mean arterial blood pressure (MABP; mmHg), AVSO2 (%) and total carotid
(Total), AVA and capillary (Cap) blood flow (BF; ml min-1) and conductance (Con;
10-2  ml min-1 mmHg-1) in anaesthetised pigs (n=40).
Variable Vehicle
(n=14)
Prazosin
(100 mg kg -1,  n=10)
Rauwolscine
(300 mg kg-1, n=10)
GR127935
(500 mg kg-1,  n=6)
Before After Before After Before After Before After
HR 102±3 100±2 103±4 100±4 101±4 100±4 97±2 94±3
MABP 96±2 93±2 98±2 90±2a 91±2 82±3a 102±2 88±2a
AVSO2 11±3 11±3 5±2 6±2 7±3 9±2 7±3 7±2
Total BF 117±8 116±7 135±6 125±6 124±12 109±10 125±20 108±14
Total Con 121±7 124±6 139±6 139±7 137±14 133±12 124±22 123±15
AVA BF 87±8 87±7 106±8 98±7 97±12 78±10a 97±17 77±13
AVA Con 90±7 93±7 109±8 109±8 107±12 94±11 96±17 87±14
Cap BF 30±2 29±2 28±4 27±3 26±3 32±2a 28±7 31±5
Cap Con 31±2 32±4 29±4 30±3 29±3 39±3a 28±8 35±5
All values have been presented as the mean±s.e.mean. a, P<0.05 vs. values before vehicle,
prazosin, rauwolscine or GR127935.
Systemic haemodynamic changes by phenylephrine and BHT933
Systemic haemodynamic variables measured before and after the two agonists in
animals treated with vehicle, prazosin, rauwolscine or GR127935 are shown in
Table 2.1.  In animals treated with vehicle, phenylephrine elicited an immediate and
dose-dependent increase in heart rate by up to 29±6%.  This increase was not affected
by treatment with prazosin, rauwolscine or GR127935.  BHT933 did not cause any
change in heart rate.  Moreover, no changes in mean arterial blood pressure were
observed after infusions of phenylephrine or BHT933.
In vehicle-treated animals, both phenylephrine and BHT933 showed a trend to
increase the difference between arterial and jugular venous oxygen saturation
(AVSO2) by up to 1036±325% and 254±140%, respectively (Table 2.2).  However,
statistical significance was achieved only with the highest dose of phenylephrine.  The
phenylephrine-induced response was selectively antagonised by treatment with
prazosin.
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Table  2.2. Changes in heart rate (beats min-1), mean arterial blood pressure (mmHg) and AVSO2 (%) induced by intracarotid phenylephrine or BHT933 in
anaesthetised pigs treated i.v. with vehicle (5 ml), prazosin (100 mg kg-1), rauwolscine (300 mg kg-1) or GR127935 (500 mg kg-1).
Treatment group Phenylephrine (mg kg-1 min-1) BHT933 (mg kg-1 min-1)
Baseline* 1 3 10 Baseline* 3 10 30
Heart rate
Vehicle 95±2 99±3 106±3 123±5a 105±4 104±4 105±4 104±4
Prazosin 98±5 99±5 103±5 115±6a 96±5 96±5 95±5 95±4
Rauwolscine 91±2 91±3 93±2 111±3a 102±6 101±6 101±6 99±5
GR127935 94±5 96±6 101±8 118±15a 96±3 95±3 92±4 93±3
Mean arterial blood pressure
Vehicle 96±2 97±3 96±4 99±5 89±2 93±3 92±3 94±3
Prazosin 86±3 84±3 83±3 79±3 92±2 94±3 92±4 93±4
Rauwolscine 83±1 82±1 82±2 81±3 79±3 78±3 78±3 79±3
GR127935 86±3 83±1 82±1 84±1 90±1 89±1 85±3 83±5
AVSO2
Vehicle 6±2 7±2 13±3 39±6a 17±4 21±4 24±4 32±2
Prazosin 4±1 4±1 4±1 7±1b 11±4 20±8 25±6 29±3
Rauwolscine 5±1 6±3 8±2 22±8 12±3 12±2 14±2 14±3
All values have been presented as the mean±s.e.mean.  *, Values after administration of vehicle, prazosin, rauwolscine or GR127935.  a, P<0.05 vs. baseline
(ANOVA);  b, P<0.05 vs. vehicle group (ANOVA).  The number of animals receiving phenylephrine and BHT933 in the vehicle, prazosin, rauwolscine and
GR127935 group were: phenylephrine (7, 7, 3 and 3, respectively); BHT933 (7, 3, 7 and 3, respectively).
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Carotid haemodynamic responses to phenylephrine and BHT933
Absolute values of total carotid vascular conductance and its arteriovenous
anastomotic and capillary fractions before and after infusions of phenylephrine and
BHT933 in the four groups of animals treated with vehicle, prazosin, rauwolscine or
GR127935 are shown in Figures 2.1 and 2.2, respectively.
Figure 2.1. Effects of 10-min intracarotid infusions of phenylephrine on total
carotid, arteriovenous anastomotic (AVA) and capillary conductances in
anaesthetised pigs treated i.v. with vehicle (Veh; n=7), prazosin (Praz;
100 µg kg-1; n=7), rauwolscine (Rauw; 300 µg kg-1; n=3) or GR127935 (GR;
500 µg kg-1 n=3).  All data are presented as mean±s.e.mean.  a, P<0.05 vs.
baseline (ANOVA); b, P<0.05 vs. vehicle group (ANOVA).
In vehicle-treated animals, both phenylephrine and BHT933 caused
dose-dependent decreases in total carotid conductance (maximum change: 74±4% and
59±4%, respectively).  These decreases were solely due to changes in arteriovenous
anastomotic conductances, since capillary (nutrient) vascular conductance remained
unchanged.  Phenylephrine-induced changes were absent in animals treated with
prazosin, but not in those treated with rauwolscine or GR127935 (Figure 2.1).
On the contrary, BHT933-induced effects were absent in animals treated with
rauwolscine, but not in those treated with prazosin or GR127935 (Figure 2.2).
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Figure 2.2. Effects of 10-min intracarotid infusions of BHT933 on total
carotid, arteriovenous anastomotic (AVA) and capillary conductances in
anaesthetised pigs treated i.v. with either vehicle (Veh), prazosin (Praz;
100 µg kg-1), rauwolscine (Rauw; 300 µg kg-1) or GR127935 (GR;
500 µg kg-1).  All data are presented as mean±s.e.mean.  a, P<0.05 vs.
baseline (ANOVA); b, P<0.05 vs. vehicle group (ANOVA).
Figure 2.3. Percent changes in arteriovenous anastomotic (AVA) conductance
induced by 10-min intracarotid infusions of phenylephrine or BHT933 in
anaesthetised pigs treated i.v. with vehicle (Veh), prazosin (Praz; 100 µg kg-1),
rauwolscine (Rauw; 300 µg kg-1) or GR127935 (GR; 500 µg kg-1).  All data are
presented as mean±s.e.mean.  a, P<0.05 vs. baseline (ANOVA); b, P<0.05 vs.
vehicle group (ANOVA).
In Figure 2.3 percent changes (from baseline) observed with phenylephrine and
BHT933 in carotid arteriovenous anastomotic conductance have been compared in the
four groups of animals.  It is clearly shown that prazosin and rauwolscine selectively
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blocked the decreases in carotid arteriovenous anastomotic conductance induced by,
respectively, phenylephrine and BHT933.  The responses to the two agonists were not
affected in animals treated with the potent and selective 5-HT1B/1D receptor antagonist
GR127935.
Figure 2.4 shows the effects of phenylephrine and BHT933 on tissue vascular
conductances in animals treated with vehicle.  Neither phenylephrine nor BHT933
induced any change in vascular conductance in the ear, skin, salivary gland, fat and
tongue.   On the other hand, phenylephrine decreased vascular conductance in bone,
eye and dura mater.  These phenylephrine-induced conductance decreases were absent
in animals treated with prazosin (data not shown).  In vehicle-treated animals
(Figure 2.4), but not in rauwolscine-treated animals (data not shown), BHT933
increased muscle and brain vascular conductances.  The responses to the two agonists
were similar in GR127935-treated animals as in animals treated with vehicle (data not
shown).
Since in the present experiments mean arterial blood pressure was not affected by
intracarotid infusion phenylephrine or BHT933, the above described agonist-induced
changes in vascular conductances were qualitatively and quantitatively similar to
those observed in blood flow (data not shown).
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Carotid vascular responses to sumatriptan in animals treated with GR127935
As reported earlier[196], sumatriptan (30, 100 and 300 µg kg-1, i.v.) did not decrease
either total carotid blood flow (% changes: -4±3, -5±3 and -6±3, respectively) or
conductance (% changes: 8±4, 5±4 and 3±3, respectively) in animals treated with
GR127935.  In several previous publications from our laboratory[166], we have
shown that these doses of sumatriptan consistently cause dose-dependent decreases in
the total carotid conductance.  For example, the changes in the carotid vascular
conductance reported by De Vries et al.[196] with 30, 100 and 300 µg kg-1, i.v. of
sumatriptan in vehicle-treated pigs (n=5) were -22±4, -42±5 and -49±7, respectively.
Figure 2.4. Effect of
10-min i.c. infusions of
phenylephrine (PHE) or
BHT933 (BHT) on the
distribution of total carotid
conductance in different
ipsilateral cranial tissues
in anaesthetised pigs
treated with vehicle (n=7
each).
All data are presented as
mean±s.e.mean.  a, P<0.05
vs. baseline (ANOVA);
b, P<0.05 vs. vehicle
group (ANOVA).
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Discussion
General
Several in vitro studies show that both a1- and a2-adrenoceptors mediate vascular
effects in carotid vessels, including those of the dog[189] and pig[192].  Nevertheless,
very few studies have investigated whether these receptors are operative in the carotid
circulation in vivo.  Verdouw et al.[184] reported that intracarotid bolus injections of
noradrenaline elicited short-lasting and phentolamine-sensitive decreases in carotid
and arteriovenous anastomotic conductance in pigs, whereas intracarotid infusions of
noradrenaline were devoid of carotid vasoconstriction.  Notwithstanding, the
mechanisms involved in this response to noradrenaline were not further analysed,
particularly in terms of different subtypes of a-adrenoceptors.  Apart from the
implications discussed below, the present study clearly shows that both a1- and
a2-adrenoceptors can mediate vasoconstriction of carotid arteriovenous anastomoses
in anaesthetised pigs.
Systemic and carotid haemodynamic effects of vehicle, prazosin and rauwolscine
Prazosin and rauwolscine produced moderate decreases in mean arterial blood
pressure, most likely due to their blocking properties at, respectively, a1- and
a2-adrenoceptors[199-201].  Importantly, no changes in carotid or arteriovenous
anastomotic conductance were observed after treatment with prazosin or rauwolscine.
This observation seems to contradict the results of Den Boer et al.[174], who reported
that prazosin causes a potent vasodilatation of carotid arteriovenous anastomoses.
However, in contrast to their study where fentanyl/thiopentane was employed as
anaesthetic, we used sodium pentobarbital, which attenuates sympathetic tone and
potently vasodilates carotid arteriovenous anastomoses (see also the Method section).
Interestingly, rauwolscine, but not prazosin, increased capillary conductance, which
was noticed in the ear, skin, muscle, bones, salivary gland, fat and tongue.  Although
we do not have a clear explanation, it may be that a2-adrenoceptors mainly maintain
vascular tone in these cranial tissues.  Alternatively, rauwolscine may have activated
5-HT1B/1D receptors, at which the compound displays partial agonist property[202].
5-HT1B/1D receptors can indeed mediate vasodilatation in porcine coronary
arteries[203] and cranial tissues[196].
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Systemic haemodynamic effects of phenylephrine and BHT 933
No changes in blood pressure or heart rate were observed after BHT 933.  In contrast,
phenylephrine produced a moderate increase in heart rate, which remained essentially
unchanged in animals treated with prazosin, rauwolscine or GR127935.  Since this
tachycardia was absent after propranolol (500 mg kg-1, i.v., n=3; unpublished
observations), it would appear that phenylephrine has a direct action at cardiac
b-adrenoceptors, as shown earlier[204].
Carotid haemodynamic changes: role of a1- and a2-adrenoceptors
Intracarotid infusions of phenylephrine and BHT 933 dose-dependently decreased
total carotid conductance, which in both cases was exclusively caused by
vasoconstriction of carotid arteriovenous anastomoses.  Consistent with the closure of
arteriovenous anastomoses[171], both phenylephrine and BHT 933 showed a trend
towards increasing A-VSO2; this was however only significant after phenylephrine.
The activity of the above agonists implies, but does not categorically prove, that a1-
and a2-adrenoceptors are involved.
The involvement of a1-adrenoceptors in the vasoconstriction of carotid
arteriovenous anastomoses is strengthened by the finding that prazosin completely
blocked the effects of phenylephrine.  It should be noted that in the dose employed
prazosin acted selectively at a1-adrenoceptors, since the drug did not modify
BHT 933-induced carotid vasoconstriction.  a1-Adrenoceptors also mediate
vasoconstriction within the canine external carotid vascular bed[200] and seem to
maintain vascular tone in porcine carotid arteriovenous anastomoses[174].  On similar
grounds, the fact that rauwolscine completely antagonised BHT 933-induced
responses indicates that a2-adrenoceptors also mediate carotid arteriovenous
anastomotic vasoconstriction.  This conclusion is substantiated by previous results
demonstrating that clonidine vasoconstricts porcine carotid arteriovenous
anastomoses[184] and that a2-adrenoceptors partly mediate canine external carotid
vasoconstriction by ergotamine and dihydroergotamine[177].  Furthermore, prazosin
selectively attenuated the phenylephrine-induced increases in A-VSO2.
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Taken together, the results of the present study clearly show that activation of both
a1- and a2-adrenoceptors results in a vasoconstriction of carotid arteriovenous
anastomoses.  Interestingly, our results seem in contradiction with earlier experiments
in pigs, where intracarotid infusions of noradrenaline did not induce carotid
vasoconstriction, but rather increased total carotid and arteriovenous anastomotic
blood flow[184].  The suggestion that the absence of noradrenaline-induced
vasoconstrictor effect was due to the putative a1-blocking properties of the
anaesthetic azaperone[174] seems not to be the case, as we used similar anaesthetic
regimen as Verdouw and colleagues[184].  A more likely explanation could be that
noradrenaline, when continuously and slowly infused, also induces a
b-adrenoceptor-mediated vasodilator effect in the carotid circulation, which negates
carotid vasoconstriction.  Interestingly, Cohen & Coffman[205] have provided
evidence for the presence of b-adrenergic vasodilator mechanism in human digital
arteriovenous shunts.
Possible interactions of phenylephrine and BHT 933 with 5-HT1B/1D receptors
As pointed out earlier, 5-HT1B/1D receptors mediate the potent and selective
vasoconstriction of carotid arteriovenous anastomoses caused by acutely acting
antimigraine drugs in the pig[161, 162].  One could therefore argue that a part of the
phenylephrine- and/or BHT 933-induced carotid vasoconstriction might also involve
5-HT1B/1D receptors.  This possibility can however be discounted as treatment of the
animals with the potent and selective 5-HT1B/1D receptor antagonist GR127935[194,
195, 206] did not modify carotid vascular haemodynamic changes induced by either
phenylephrine or BHT 933.   Importantly, the dose of GR127935 used in this study
(500 µg kg-1, i.v.) completely blocks sumatriptan-induced decreases in total carotid
(and arteriovenous anastomotic) blood flow and conductance[196].   This was
apparently also the case in our present experiments where no changes in total carotid
blood flow and conductance were observed with sumatriptan in animals treated with
GR127935.  From these data we can exclude the possibility that 5-HT1B/1D receptors
play a role in the phenylephrine- or BHT 933-induced vasoconstriction of carotid
arteriovenous anastomoses in anaesthetised pigs.
a-Adrenoceptors and porcine carotid AVAs Chapter 2
- 16 -
Effects of phenylephrine and BHT 933 on cranial tissue conductances
Although the effects of a-adrenoceptor stimulation have been extensively studied on
isolated blood vessels, the use of intracarotid injection of radiolabelled microspheres
allowed us to study these effects in the different cranial tissues in vivo.  Stimulation of
prazosin-sensitive a1-adrenoceptors resulted in vasoconstriction in bones, dura mater
and, to a lesser extent, in the eye, whereas BHT 933 was devoid of tissue
vasoconstrictor effects.  In fact, BHT 933 produced vasodilatation in brain
vasculature, as also reported after clonidine [184].  This may be due to an interaction
with endothelial vasodilator a2-adrenoceptors as previously reported in other blood
vessels[192, 207-209].  Indeed, the increase in brain vascular conductance was absent
in the rauwolscine-treated group.
Possible clinical implications
Lastly, we would like to consider the possible clinical relevance of the
vasoconstriction of the carotid arteriovenous anastomoses induced by phenylephrine
and BHT 933. It has been suggested that vasodilatation of these ‘shunt’ vessels may
play an important role in the pathophysiology of migraine[161, 170].  Indeed, to date
all migraine abortive agents vasoconstrict carotid arteriovenous anastomoses in
different animal species[161, 210].  While carotid arteriovenous anastomoses cannot
be directly investigated in humans, sumatriptan has been shown to vasoconstrict
arteriovenous anastomoses in the human forearm[211].  In addition, ergotamine,
dihydroergotamine, clonidine and isometheptene (only dogs), all of which produce
vasoconstriction in the carotid vascular bed in dogs and pigs [177, 181, 184, 212],
interact with a-adrenoceptors.  At least, a part of the therapeutic effect of these drugs
may be related to their agonist action at these receptors.  Thus, our results
demonstrating the role of a1- and a2-adrenoceptor in mediating vasoconstriction of
carotid arteriovenous anastomoses imply that selective agonists at, particularly,
a2-adrenoceptors (in view of the less ubiquitous nature of a2-adrenoceptors compared
to a1-adrenoceptors) should have potential antimigraine properties.  In this
connection, further studies, which fall beyond the scope of the present investigation,
will be required to ascertain the specific subtypes of a1- (a1A, a1B, a1D) and a2- (a2A,
a2B, a2C) adrenoceptors mediating the vasoconstrictor response mentioned above.
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Eventually, these results may be helpful in the development of antimigraine agents in
the future.
- 1 -
Chapter 3
a1-Adrenoceptor subtypes mediating vasoconstriction in the carotid
circulation of anaesthetised pigs: possible avenues for antimigraine
drug development
Summary    It has recently been shown that the a-adrenoceptors
mediating vasoconstriction of porcine carotid arteriovenous anastomoses
resemble both a1- and a2-adrenoceptors, but no attempt was made to
identify the specific subtypes involved.  Therefore, the present study was
designed to elucidate the specific subtype(s) of a1-adrenoceptors
involved in the above response, using the a1-adrenoceptor agonist
phenylephrine and a1-adrenoceptor antagonists 5-methylurapidil (a1A),
L-765,314 (a1B) and BMY 7378 (a1D).  Ten-min intracarotid infusions of
phenylephrine (1, 3 and 10 mg kg-1.min-1) induced a dose-dependent
decrease in total carotid and arteriovenous anastomotic conductance.
These carotid vascular effects were potently attenuated by
5-methylurapidil (1000 mg kg-1; i.v.), abolished by L-765,314
(1000 mg kg-1; i.v.) and only slightly attenuated by BMY 7378
(1000 mg kg-1; i.v.).  These results, coupled to the binding affinities of the
above antagonists at the different a1-adrenoceptors, suggest that both
a1A- and a1B-adrenoceptors mediate vasoconstriction of carotid
arteriovenous anastomoses in anaesthetised pigs.  In view of less
ubiquitous nature of a1B- compared to a1A-adrenoceptors, the
development of potent and selective a1B-adrenoceptor agonists may
prove to be important for the treatment of migraine.
Based on: Willems et al., Cephalalgia (2000) submitted.
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Introduction
Although the pathophysiology of migraine has not yet been completely unravelled,
there is little doubt that vasodilatation of large cephalic arteries and, possibly,
arteriovenous anastomoses is involved in the headache phase of migraine[170, 213-
215].  Indeed, over the years we have shown that two important groups of drugs that
are highly effective in the acute treatment of migraine, i.e. the triptans and ergot
alkaloids, potently constrict carotid arteriovenous anastomoses[161, 215, 216].  While
the carotid vasoconstrictor effect of sumatriptan as well as some other triptans is
mediated by the 5-HT1B receptor[167, 178, 215], the ergot-induced vasoconstriction
involves, in addition to 5-HT1B receptors[217], also a-adrenoceptors[177].
There are several reasons to believe that a-adrenoceptors may regulate vascular
tone of carotid arteriovenous anastomoses, providing a potential avenue for the
development of new antimigraine drugs.  It is well known that stimulation of
a-adrenoceptors results in vasoconstriction of the isolated carotid artery[189-192,
218].  Administration of a-adrenoceptor antagonists to conscious pigs as well as pigs
under thiopentone anaesthesia results in an increase in arteriovenous anastomotic
blood flow[173, 174].  More recently, we have shown that both a1- and
a2-adrenoceptors mediate the vasoconstriction of carotid arteriovenous anastomoses
in anaesthetised pigs [219].
The objective of the present study was to elucidate the subtype(s) of
a1-adrenoceptors –a1A-, a1B- and a1D-adrenoceptor subtypes[26, 33, 42, 95] –
involved in the vasoconstriction of carotid arteriovenous anastomoses in anaesthetised
pigs.  For this purpose, we investigated the effects of 5-methylurapidil, L-765,314 and
BMY 7378, which are preferential antagonists, respectively, at a1A-, a1B- and
a1D-adrenoceptors (see Table 1.2 for affinity cons tants[60, 88, 220]), on the carotid
vasoconstriction induced by the a1-adrenoceptor agonist phenylephrine in a
well-defined in vivo animal model predictive for antimigraine activity[161, 221].
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Materials and methods
General
After an overnight fast, 41 domestic pigs (Yorkshire x Landrace; female; 10-14 kg)
were anaesthetised with azaperone (120 mg, i.m.), midazolam hydrochloride (5 mg,
i.m.) and sodium pentobarbital (600 mg, i.v.).  After tracheal intubation, the animals
were connected to a respirator (BEAR 2E, BeMeds AG, Baar, Switzerland) for
intermittent positive pressure ventilation with a mixture of room air and oxygen.
Respiratory rate, tidal volume and oxygen supply were adjusted to keep arterial blood
gas values within physiological limits (pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2:
100-120 mmHg).  Anaesthesia was maintained with a continuous i.v. infusion of
sodium pentobarbital (20 mg kg-1.h-1).  It may be pointed out that this anaesthetic
regimen, together with bilateral vagosympathectomy (see below), leads to an increase
in heart rate and vasodilatation of arteriovenous anastomoses due to a loss of
parasympathetic and sympathetic tone, respectively.  Indeed, basal arteriovenous
anastomotic blood flow is considerably higher in sodium pentobarbital-anaesthetised
pigs (70-80% of carotid blood flow; present results) than in conscious (<5% of carotid
blood flow[173]) or fentanyl/thiopental anaesthetised (~19% of carotid blood
flow[174]) pigs.  A high basal carotid arteriovenous anastomotic blood flow is
particularly useful for investigating the effects of drugs that constrict these 'shunt'
vessels.
A catheter was placed in the inferior vena cava via the left femoral vein for the
administration of sodium pentobarbital, vehicle (distilled water) or the antagonists.
Another catheter was placed in the aortic arch via the left femoral artery for the
measurement of arterial blood pressure (Combitrans disposable pressure transducer;
Braun, Melsungen, Germany) and arterial blood withdrawal for the measurement of
blood gases (ABL-510; Radiometer, Copenhagen, Denmark).  Subsequently, bilateral
vagosympathectomy was performed in order to prevent the possible influence via
baroreceptor reflexes on phenylephrine-induced carotid vascular responses.  Two
hub-less needles, each connected to a polyethylene tube, used for the administration
of radioactive microspheres and phenylephrine, respectively, were inserted into the
right common carotid artery against the direction of blood flow for uniform mixing.
Total common carotid blood flow was measured with a flow probe (internal
diameter: 2.5 mm) connected to a sine-wave electromagnetic flow meter (Transflow
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601-system, Skalar, Delft, The Netherlands).  Heart rate was measured with a
tachograph (CRW, Erasmus University, Rotterdam, The Netherlands) triggered by
electrocardiogram signals.  Arterial blood pressure, heart rate and total carotid blood
flow were continuously monitored on a polygraph (CRW, Erasmus University,
Rotterdam, The Netherlands).  During the experiment, body temperature was kept
about 37 °C and the animal was continuously infused with physiological saline to
compensate fluid losses.
The Ethical Committee of the Erasmus University Rotterdam, dealing with the use
of animals in scientific experiments, approved the protocols followed in this
investigation.
Distribution of carotid blood flow
The distribution of carotid blood flow was determined with 15.5±0.1 µm (s.d.)
diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN Dupont,
Boston, USA).  For each measurement, about 200,000 microspheres, labelled with
one of the radioisotopes, were mixed and injected into the right common carotid
artery.  At the end of the experiment, the animal was killed by an overdose of sodium
pentobarbital and the heart, lungs, kidneys and all ipsilateral cranial tissues were
dissected out, weighed and put in vials.  The radioactivity in these vials was counted
for 10 min in a g-scintillation counter (Packard, Minaxi autogamma 5000), using
suitable windows to discriminate the different isotopes (141Ce: 120-167 KeV, 113Sn:
355-435 KeV, 103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 46Sc: 830-965 KeV).  All
data were processed by a set of specially designed computer programs[197].  The
fraction of carotid blood flow distributed to the different tissues was calculated by
multiplying the ratio of tissue and total radioactivity of each radioisotope by the
carotid blood flow at the time of the injection of the microspheres, labelled with the
respective isotope.  Since little or no radioactivity was detected in the heart and
kidneys, all microspheres trapped in lungs reached this tissue from the venous side
after escaping via carotid arteriovenous anastomoses.  Therefore, the amount of
radioactivity in the lungs was used as an index of the arteriovenous anastomotic
fraction of the total carotid blood flow[161].  Vascular conductance
(ml min-1 mmHg-1) was calculated by dividing blood flow (ml min-1) by mean arterial
blood pressure (mmHg).
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Experimental protocol
After a stabilisation period of at least 60 min, baseline values of heart rate, mean
arterial blood pressure, total carotid blood flow and its distribution into arteriovenous
anastomotic and capillary fractions, as well as arterial blood gases were measured.
Thereafter, the animals were divided into seven groups, receiving i.v. infusions
(0.5 ml min-1 for 10 min) of either vehicle (distilled water; n=8), 5-methylurapidil
(300 or 1000 mg kg-1; n=6 each dose), L-765,314 (300 or 1000 mg kg-1; n=6 and 3,
respectively) or BMY 7378 (300 or 1000 mg kg-1; n=6 each dose).  After a waiting
period of 15 min, all variables were reassessed.  Subsequently, the animals received
cumulative doses of phenylephrine (1, 3 and 10 µg kg-1.min-1) infused into the right
common carotid artery (0.1 ml min-1 for 10 min).  All variables were collated again
10 min after the start of each agonist infusion.
At least 90 min after the last microsphere injection, the animals received i.v. bolus
injections of phenylephrine (3 and 10 mg kg-1) and peak changes in mean arterial
blood pressure were noted.
Data presentation and statistical analysis
All data have been expressed as means±s.e.m.  In order to correct for potential
baseline differences caused by the antagonists or vehicle, the percent changes induced
by phenylephrine from the values after administration of the different antagonists or
vehicle were calculated in each group.  The significance of the percent changes
induced by the different doses of phenylephrine within one group was evaluated with
Duncan's new multiple range test, once an analysis of variance (randomised block
design) had revealed that the samples represented different populations[222].  Percent
changes caused by phenylephrine in the different treatment groups were compared to
the percent changes caused by the corresponding phenylephrine dose in the
vehicle-treated group using Student's unpaired t-test.  Statistical significance was
accepted at P<0.05 (two-tailed).
Drugs
Apart from the anaesthetics azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse,
Belgium), midazolam hydrochloride (Dormicum®; Hoffmann La Roche b.v.
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Mijdrecht, The Netherlands) and sodium pentobarbital (Apharmo, Arnhem, The
Netherlands), the compounds used in this study were: L-phenylephrine hydrochloride,
5-methylurapidil, BMY 7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-
8-azaspiro [4,5]decane-7,9-dione dihydrochloride) dihydrochloride (all from
Sigma-Aldrich Chemie b.v., Zwijndrecht, The Netherlands) and L-765,314 (4-amino-
2-[4-[1-(benzyloxycarbonyl)-2(S)-[[(1,1-dimethylethyl)amino] carbonyl]-
piperazinyl]-6,7-dimethoxyquinazoline hydrochloride; Merck & Co., Inc., West Point,
PA 19486, USA).  Finally, heparin sodium (Leo Pharmaceutical Products, Weesp,
The Netherlands) was used to prevent clotting of blood in the catheters.
All drugs were dissolved in distilled water.  A short period of heating was needed
to dissolve 5-methylurapidil (acidified to pH=6.8-7.0 with 0.1 M HCl) and L-765,314.
The doses of the drugs refer to their respective salts.
Results
Baseline values and effect of antagonists per se
Baseline values of haemodynamic variables in anaesthetised pigs (n=41) were: heart
rate (100±2 beats.min-1), mean arterial blood pressure (93±2 mmHg), total carotid
blood flow (123±6 ml min-1) and conductance (132±6 10-2 ml min-1 mmHg-1),
arteriovenous anastomotic blood flow (95±6 ml min-1) and conductance
(102±6 10-2 ml min-1  mmHg-1) and capillary blood flow (28±2 ml min-1) and
conductance (30±2 10-2 ml min-1  mmHg-1).  There were no major differences between
the baseline values in the different groups of animals.
No haemodynamic changes were observed with vehicle or BMY 7378 (data not
shown).  5-Methylurapidil (1000 µg kg-1) slightly decreased mean arterial blood
pressure (-8±4%) and increased heart rate (9±1%) as well as capillary blood flow
(35±4%) and conductance (49±9%).  L-765,314 (1000 µg kg-1) decreased mean
arterial blood pressure (-9±4%) and increased capillary conductance (27±11%).
Systemic haemodynamic responses to intracarotid infusions of phenylephrine
As shown in Table 3.1, after treatment with vehicle intracarotid infusions of
phenylephrine (1, 3 and 10 mg kg-1.min-1) caused a dose-dependent increase in heart
rate by up to 28±5%, without affecting mean arterial blood pressure.  This
phenylephrine-induced tachycardia was slightly less (maximal increase: 11±3%) after
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300 mg kg-1 of 5-methylurapidil (probably due to higher initial value), but was not
different after the highest dose of 5-methylurapidil (1000 mg kg-1).  In animals treated
with either 1000 mg kg-1 of L-765,314 or BMY7378, a small decrease in mean arterial
blood pressure (9±1 or 8±4%, respectively) was observed with phenylephrine;
however, when compared to the corresponding blood pressure change in
vehicle-treated animals, statistical significance was not reached.
Carotid haemodynamic responses to intracarotid infusions of phenylephrine
Absolute values of total carotid, arteriovenous anastomotic and capillary vascular
conductances in the different groups of animals before and after intracarotid infusions
of phenylephrine are shown in Figure 3.1.  In animals treated with vehicle,
phenylephrine produced a dose-dependent decrease in total carotid conductance by up
to 75±4%.  Since phenylephrine did not change the vascular conductance in the
capillary fraction, the decrease in total carotid conductance was exclusively caused by
a decrease in the arteriovenous anastomotic fraction (maximal response: 92±3%).
Carotid haemodynamic responses to intracarotid infusions of phenylephrine
Absolute values of total carotid, arteriovenous anastomotic and capillary vascular
conductances in the different groups of animals before and after intracarotid infusions
of phenylephrine are shown in Figure 3.1.  In animals treated with vehicle,
phenylephrine produced a dose-dependent decrease in total carotid conductance by up
to 75±4%.  Since phenylephrine did not change the vascular conductance in the
capillary fraction, the decrease in total carotid conductance was exclusively caused by
a decrease in the arteriovenous anastomotic fraction (maximal response: 92±3%).
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Table 3.1. Changes in heart rate and mean arterial blood pressure induced by 10-min
intracarotid infusions of phenylephrine in anaesthetised pigs treated i.v. with either
vehicle, 5-methylurapidil, L-765,314 or BMY 7378.
Treatment group
Dose
(µg kg-1) Baseline* Phenylephrine (mg kg-1 min-1)
1 3 10
Heart rate (beats.min-1)
Vehicle 5 ml 95±2 98±2 105±3a 121±5a
5-Methylurapidil 300 112±5 111±6b 112±5b 123±4ab
1000 101±3 103±4 106±4 117±3a
L-765,314 300 98±5 101±5 107±5a 129±7a
1000 93±2 93±3 97±4 112±6a
BMY 7378 300 99±4 101±3 104±3 119±5a
1000 109±6 112±6 117±6a 127±6a
Mean arterial blood pressure (mmHg)
Vehicle 5 ml 97±2 97±3 96±3 99±5
5-Methylurapidil 300 80±5 82±5 79±6 83±6
1000 95±5 89±5b 87±5 89±6
L-765,314 300 84±6 83±7 84±8 87±8
1000 84±3 80±4a 78±2a 79±4a
BMY 7378 300 85±3 85±4 84±3 90±3
1000 91±5 88±5 86±4 84±4a
*, Values after treatment with respective antagonist or vehicle; a, P<0.05 vs.
baseline; b, P<0.05 vs. response (% response from respective baseline) to the
corresponding phenylephrine dose in animals treated with vehicle.
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Figure 3.1. Effects of 10-min intracarotid infusions of phenylephrine on total
carotid, arteriovenous anastomotic (AVA) and capillary vascular conductances in
anaesthetised pigs treated i.v. with either vehicle (Veh), 5-methylurapidil (5-MU;
300 or 1000 µg kg-1), L-765,314 (L; 300 or 1000 µg kg-1) or BMY 7378 (BMY;
300 or 1000 µg kg-1).  a, P<0.05 vs. baseline (B; values after treatment);
b, P<0.05 vs. response (% response from respective baseline) of the
corresponding phenylephrine dose in vehicle -treated animals.
As shown in Figures 3.1 and 3.2, the constrictor effect of phenylephrine on
carotid arteriovenous anastomoses was not affected by 300 µg kg-1 of either
5-methylurapidil or BMY 7378, but was significantly attenuated by 300 µg kg-1 of
L-765,314 and 1000 µg kg-1 of 5-methylurapidil and BMY 7378.  Furthermore, after
the highest dose of L-765,314, the responses to phenylephrine were clearly abolished
and the values did not significantly differ from those before phenylephrine infusion.
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Figure 3.2. Percent changes in arteriovenous anastomotic (AVA) conductance
induced by 10-min intracarotid infusions of phenylephrine in anaesthetised pigs
treated i.v. with either vehicle (Veh), 5-methylurapidil (5-MU; 300 or
1000 µg kg-1; left graph), L-765,314  (L; 300 or 1000 µg kg-1; middle graph) or
BMY 7378 (BMY; 300 or 1000 µg kg-1; right graph).  a, P<0.05 vs. baseline (B;
values after treatments); b, P<0.05 vs. response (% response from respective
baseline) of the corresponding phenylephrine dose in vehicle -treated animals.
Note that the control curves are identical in each graph.
Since in the present experiments mean arterial blood pressure was not affected by
the intracarotid infusions of phenylephrine, the responses in vascular conductances
were qualitatively and quantitatively similar to those in blood flow (data not shown).
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Changes in mean arterial blood pressure by i.v. bolus administration of
phenylephrine
In vehicle-treated animals, bolus injections of phenylephrine (3 and 10 µg kg-1, i.v)
produced a dose-dependent increase in mean arterial blood pressure, yielding peak
responses of 28±3 and 51±3%, respectively (Figure 3.3). These
phenylephrine-induced vasopressor responses were significantly attenuated by
1000 µg kg-1 of 5-methylurapidil (peak responses: 17±3 and 31±4%, respectively),
but were not affected by L-765,314 (300 or 1000 µg kg-1), BMY 7378 (300 or
1000 µg kg-1) or 300 µg kg-1 of 5-methylurapidil.
Figure 3.3. Peak changes in mean arterial blood pressure (MAP) induced by
bolus injection of phenylephrine (3 or 10 µg kg-1, i.v.) in animals treated i.v. with
either vehicle (Veh), 5-methylurapidil (5-MU; 300 or 1000 µg kg-1), L-765,314
(L; 300 or 1000 µg kg-1) or BMY 7378 (BMY; 300 or 1000 µg kg-1).  a, P<0.05
vs. percent response of the corresponding phenylephrine dose in vehicle -treated
animals.
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Discussion
General
We have recently shown that both a1- and a2-adrenoceptors mediate vasoconstriction
of arteriovenous anastomoses within the carotid vascular bed in anaesthetised
pigs[219].  This conclusion was based on the findings that (i) intracarotid
administration of phenylephrine (a1-adrenoceptor agonist) and BHT933
(a2-adrenoceptor agonist) decreased total carotid blood flow exclusively confined to
the arteriovenous anastomotic fraction, without affecting mean arterial blood pressure;
and (ii) these effects of phenylephrine and BHT933 were selectively antagonised by
the a1- and a2-adrenoceptor antagonists, prazosin and rauwolscine, respectively[219].
This is also in agreement with findings previously reported in the external carotid
vascular bed of anaesthetised dogs [223].
Based on radioligand binding, molecular biology and isolated tissue experiments, it
is known that a1-adrenoceptors are a heterogeneous group of receptors, currently
subdivided into a1A, a1B and a1D subtypes[26, 31].  As reviewed by Vargas and
Gorman[44], the a1A-adrenoceptor subtype, which is widely distributed throughout
the body and is the major subtype regulating systemic vascular resistance and blood
pressure; a1D-adrenoceptors seem to play only a minor role in blood pressure
regulation[224].  Whereas there is limited information concerning the vascular effects
mediated by a1B-adrenoceptors, it has been shown that vasoconstriction of the
isolated carotid artery of the dog and rabbit mainly resembles the cloned
a1B-adrenoceptor[44].  However, no information is available on the subtype
mediating vasoconstrictor effects within the carotid arterial bed in vivo.  Therefore,
the objective of the present study was to identify the a1-adrenoceptor subtype(s) that
mediate vasoconstriction in the carotid vasculature in anaesthetised pigs, with
particular emphasis on the arteriovenous anastomotic fraction, which may be of
relevance to migraine therapy[161, 162, 170, 216].
In recent years, some selective antagonists at a1-adrenoceptor subtypes have been
developed (Table 1.2).  In the present study, we made use of 5-methylurapidil and
BMY 7378, which have frequently been used to characterise a1A- and
a1D-adrenoceptors, respectively (Table 1.2[26, 42, 60, 68-70, 225]).  To block
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a1B-adrenoceptors, we employed L-765,314, which shows a moderate to high
selectivity for cloned a1b-adrenoceptors over cloned a1a- or a1d-adrenoceptors[88].
Many studies have used the clonidine derivative, chloroethylclonidine, for this
purpose[26, 33].  However, it is now evident that chloroethylclonidine alkylates
several other receptors as well[26, 85, 86].
Systemic and carotid haemodynamic effects of different antagonists
Whereas the vehicle was devoid of any systemic and carotid haemodynamic effects,
administration of the a1A-adrenoceptor antagonist 5-methylurapidil produced a small
hypotension and tachycardia.  Similar hypotensive effect was observed earlier with
5-methylurapidil[226] and may be related to either blockade of vascular smooth
muscle a1A-adrenoceptors, which play an important role in the maintenance of
vascular tone[44] or to its agonist properties at central 5-HT1A receptors[227].
Admittedly, we do not have a clear-cut explanation for the slight hypotension and
increase in capillary conductance produced by L-765,314, since it has been shown by
Piascik et al.[54] that a1B-adrenoceptors play only a minor role in the contraction of
peripheral blood vessels in vitro.
Changes in heart rate and mean arterial blood pressure by phenylephrine
Intracarotid infusions of phenylephrine produced only minor systemic haemodynamic
responses in vehicle-treated animals.  The tachycardia (Table 3.1), which was also
observed with i.v. phenylephrine (data not shown), most likely involves an interaction
with b-adrenoceptors[219].  Furthermore, i.v. administration of phenylephrine (3 and
10 mg kg-1) induced a dose-dependent increase in blood pressure (Figure 3.3), which
was antagonised by 100 µg kg-1 of prazosin (100 g kg-1), but not by 300 µg kg-1 of
rauwolscine (Willems et al., unpublished observations).  In view of the antagonism of
this response by 5-methylurapidil, but not by L-765,314 (a1B-adrenoceptor
antagonist) or BMY 7378 (a1D-adrenoceptor antagonist) (Figure 3.3), the pressor
response to phenylephrine is likely to be mediated by a1A-adrenoceptors.  In keeping
with the approximately 10-fold higher affinity at the cloned a1a-adrenoceptor
displayed by prazosin compared to 5-methylurapidil (Table 1.2), a 10-fold higher
dose of 5-methylurapidil (1000 µg kg-1) was needed to produce antagonism of the
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phenylephrine-induced vasopressor response.  Thus, as previously discussed[44],
these results support the role of a1A-adrenoceptors in the increase in peripheral
vascular resistance and concomitant hypertensive effect upon activation.
Carotid haemodynamic responses to intracarotid infusions of phenylephrine
As previously reported[219], phenylephrine caused a pronounced and dose-dependent
decrease in total carotid conductance, which was exclusively caused by
vasoconstriction of carotid arteriovenous anastomoses; nutrient vascular conductance
was not modified (Figure 3.1). These carotid vasoconstrictor responses were not
affected by treatment with 300 µg kg-1 of the a1D-adrenoceptor antagonist BMY 7378.
This dose of BMY 7378 should be sufficient to block a1D-adrenoceptors in view of
comparable affinities of prazosin and BMY 7378 at the cloned human
a1d-adrenoceptor (Table 1.2) and the fact that 100  µg kg-1 of prazosin abolished this
response[219].  On this basis, the involvement of a1D-adrenoceptors in the cranial
vasoconstriction induced by phenylephrine in anaesthetised pigs seems highly
unlikely.  Nevertheless, as shown in Figures 3.1 and 3.2, the higher dose of
BMY 7378 (1000 µg kg-1) produced a slight, but significant, attenuation in the
phenylephrine-induced total carotid and arteriovenous anastomotic vasoconstriction.
Since BMY7378 displays a moderate affinity at a1A- and a1B-adrenoceptors (pKi: 6.6
and 7.2, respectively; Table 1.2), a non-selective blockade of these receptors (which
can mediate carotid vasoconstriction; see below) is a likely explanation.  Indeed, in 2
experiments a combination of 5-methylurapidil (1000 µg kg-1) and BMY 7378
(1000 µg kg-1) did not cause any more attenuation of the phenylephrine-induced
arteriovenous vasoconstriction than 5-methylurapidil (1000 µg kg-1) alone (see
below).
The a1B-adrenoceptor antagonist L-765,314 abolished the vasoconstriction of
carotid arteriovenous anastomoses by phenylephrine, a finding that supports the role
of a1B-adrenoceptors in this effect.  Interestingly, the a1A-adrenoceptor antagonist,
5-methylurapidil was also able to antagonise the cranial vasoconstrictor effects of
phenylephrine, but in contrast to L-765,314, the highest dose of phenylephrine still
elicited a 50% decrease in arteriovenous anastomotic conductance (Figures 3.2
and 3.3).  Thus, at similar doses, L-765,314 acted as a more potent antagonist when
compared to 5-methylurapidil.  The above findings lead us to conclude that both a1A-
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and a1B-adrenoceptors mediate the phenylephrine-induced vasoconstriction of carotid
arteriovenous anastomoses, whereas the a1D-adrenoceptor plays a minor role, if any.
Admittedly, a critique of the above conclusion may be that, unlike in vitro studies,
the exact concentration of a1-adrenoceptor antagonists at the receptor site can be
influenced by pharmacokinetic differences in such an in vivo investigation.  However,
current techniques do not allow us to study carotid arteriovenous anastomoses in vitro
and, to some extent, we have tried to ensure effective antagonist concentration at the
receptor site by using as high dose of antagonists as possible.
Possible clinical implications
Lastly, we would like to consider possible clinical implications of the present results
showing that a1A- and a1B-adrenoceptors mediate the vasoconstriction of carotid
arteriovenous anastomoses in anaesthetised pigs.  To date all acutely acting
antimigraine agents, such as the triptans and ergot alkaloids, potently constrict carotid
arteriovenous anastomoses[210, 216].  Moreover, vasodilatation of these 'shunt'
vessels may be involved in the pathophysiology of the headache phase of
migraine[161, 170, 216].  Since a vasoconstrictor effect in this experimental model
seems to be highly predictive for antimigraine efficacy, an a1A- (such as A61603[83])
or a1B-adrenoceptor agonist (which is yet to be developed) should be able to abort
migraine headaches.  Of the two a1-adrenoceptor subtypes, the a1B-adrenoceptor is an
interesting target for future antimigraine drugs, especially when considering that this
receptor, unlike the a1A-adrenoceptor, does not seem to be much involved in the
vasoconstriction of the peripheral blood vessels[44, 54].  Indeed, our results suggest
that the hypertensive effect produced by intravenous administration of phenylephrine
is predominantly mediated via the a1A-, but not a1B-adrenoceptor (Figure 3.3).  An
a1B-adrenoceptor agonist may have a major advantage over the currently available
acute antimigraine drugs, which all constrict human isolated coronary artery[228],
where, importantly, the a1B-adrenoceptor is not present[50].
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In conclusion, the present study shows that both a1A- and a1B-adrenoceptors mediate
vasoconstriction of porcine carotid arteriovenous anastomoses produced by
phenylephrine.  Since the a1B-adrenoceptor subtype is not much involved in
vasoconstriction of the systemic vasculature, a cranioselective vasoconstriction may
be achieved using selective a1B-adrenoceptor agonists, which may prove effective in
migraine.
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Chapter 4
A61603-induced vasoconstriction in porcine carotid vasculature:
possible involvement of novel receptor(s)
Abstract    It has recently been shown that the pharmacological profile of
a1-adrenoceptors mediating vasoconstriction of porcine carotid
arteriovenous anastomoses resembles that of a1A- and a1B-adrenoceptor
subtypes.  In an attempt to verify the involvement of a1A-adrenoceptors,
we used the potent a1A-adrenoceptor agonist A61603
(N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydro-
naphthalen-1-yl]methane sulphonamide) and found that intracarotid (i.c.)
administration of A61603 (0.3-10 µg kg-1) dose-dependently decreased
porcine carotid blood flow and vascular conductance.  This decrease was
exclusively due to a vasoconstriction of carotid arteriovenous
anastomoses; the capillary blood flow and conductance remained
unchanged.  Surprisingly, the responses to A61603 were little modified
by prior i.v. treatment with 5-methylurapidil (1000 mg kg-1), prazosin
(100 mg kg-1) or a combination of prazosin and rauwolscine (100 and
300 mg kg-1, respectively).  The 5-HT1B/1D receptor antagonist GR127935
(N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4' (5-methyl-
1, 2,4-oxadiazol-3-yl) [1,1,-biphenyl]-4-carboxamide hydrochloride
monohydrate; 500 mg kg-1) and ketanserin (500 mg kg-1) also failed to
modify carotid vascular responses to A61603, but, interestingly,
methiothepin (3000 mg kg-1) proved to be a potent antagonist.  Taken
together, the present results show that A61603 is a relatively poor agonist
at the a1A-adrenoceptor in anaesthetised pigs and that the carotid
vasoconstriction produced by A61603 is mediated by novel,
methiothepin-sensitive receptor(s).
Based on: Willems et al., Eur. J. Pharmacol. (2000) Submitted.
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Introduction
There seems to be little doubt that the headache phase of migraine is associated with
vasodilatation of cranial blood vessels.  Indeed, sumatriptan as well as all
‘second-generation’ triptans potently constrict human isolated cranial arteries as well
as carotid arteriovenous anastomoses in anaesthetised animals, mainly via the 5-HT1B
receptor[196, 215].  In an attempt to explore new avenues for the development of
antimigraine agents, we recently reported that phenylephrine and BHT933 (6-ethyl-
5,6,7,8-tetrahydro-4H-oxazolo [4,5-d] azepin-2-amine dihydrochloride) constrict
carotid arteriovenous anastomoses in anaesthetised pigs via a1- and a2-adrenoceptors,
respectively[219].  Subsequent studies suggest that the phenylephrine-induced
response is mediated by the a1A- and a1B- adrenoceptor subtypes, but not by the a1D
subtype[229].
To confirm the involvement of a1A-adrenoceptors, in the present study we studied
the effects of a potent and selective a1A-adrenoceptor agonist, A61603
(N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]
methane sulphonamide) (see Table 4.1[33, 83], on regional carotid blood flow in
anaesthetised pigs.
Table 4.1. Chemical structure and pharmacological profile, i.e. binding affinity (pKi),
potency (pEC50) and intrinsic activity (i.a.), of A61603 at several cloned human
receptor subtypes*.
Chemical
structure
a1A a1B a1D a2A a2B a2C 5-HT1
B
5-HT1
D
pKi 7.1 4.8 4.9 7.3 6.5 6.2 5.2 5.6
pEC50 8.9 4.4 4.6 7.5 7.1 7.7 ND ND
Br
HN
S
N NH
CH3
O O
HO
i.a. 1.2 0.1 0.1 0.8 0.8 0.9 ND ND
Data were taken from[72]; *, Affinity (pKi value) of A61603 at other receptor
subtypes (H1/2, D1/2/3 , 5-HT1/2/7  or b) was < 5.5; ND; not determined.
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The response to A61603 was characterised by using selective a-adrenoceptor
antagonists, 5-methylurapidil (a1A), prazosin (a1) and a combination of prazosin (a1)
and rauwolscine (a2).  Similarly, the effects of GR127935
(N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4' (5-methyl-1,
2,4-oxadiazol-3-yl) [1,1,-biphenyl]-4-carboxamide hydrochloride monohydrate;
5-HT1B/1D), ketanserin (5-HT2, a1) and methiothepin (5-HT1/2), in doses sufficient to
block their respective receptors[219, 230, 231], were also investigated.  Surprisingly,
the results suggest that A61603 constricts porcine arteriovenous anastomoses by a
non-adrenergic mechanism.
Materials and Methods
General
After an overnight fast, 33 domestic pigs (Yorkshire x Landrace; female; 10-14 kg)
were anaesthetised with azaperone (120 mg, i.m.), midazolam hydrochloride
(5 mg, i.m.) and sodium pentobarbital (600 mg, i.v.).  After tracheal intubation, the
animals were connected to a respirator (BEAR 2E, BeMeds AG, Baar, Switzerland)
for intermittent positive pressure ventilation with a mixture of room air and oxygen.
Respiratory rate, tidal volume and oxygen supply were adjusted to keep arterial blood
gas values within physiological limits (pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2:
100-120 mmHg).  Anaesthesia was maintained with a continuous i.v. infusion of
sodium pentobarbital (20 mg kg-1.h-1).  It may be pointed out that this anaesthetic
regimen, together with bilateral vagosympathectomy (see below), leads to an increase
in heart rate and vasodilatation of carotid arteriovenous anastomoses due to a loss of
parasympathetic and sympathetic tone, respectively.  Indeed, basal carotid
arteriovenous anastomotic blood flow is considerably higher in sodium
pentobarbital-anaesthetised pigs (70-80% of carotid blood flow; present results) than
in conscious (<5% of carotid blood flow[173] or fentanyl/thiopental anaesthetised
pigs(~19% of carotid blood flow[174].  A high basal carotid arteriovenous
anastomotic blood flow is particularly useful for investigating the effects of drugs that
constrict these 'shunt' vessels.
A catheter was placed in the inferior vena cava via the left femoral vein for
infusion of vehicle (distilled water), the antagonists and sodium pentobarbital.
Another catheter was placed in the aortic arch via the left femoral artery for the
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measurement of arterial blood pressure (Combitrans disposable pressure transducer;
Braun, Melsungen, Germany) and arterial blood withdrawal for the measurement of
blood gases (ABL-510; Radiometer, Copenhagen, Denmark).  Subsequently, the right
common carotid artery was dissected free and bilateral vagosympathectomy was
performed in order to prevent a possible influence via baroreceptor reflexes on
A61603-induced carotid vascular responses.  Two hub-less needles, each connected to
a polyethylene tube, used for the administration of radioactive microspheres and
A61603, respectively, were inserted into the right common carotid artery against the
direction of blood flow for uniform mixing.
Total common carotid blood flow was measured with a flow probe (internal
diameter: 2.5 mm) connected to a sine-wave electromagnetic flow meter (Transflow
601-system, Skalar, Delft, The Netherlands).  Heart rate was measured with a
tachograph (CRW, Erasmus University, Rotterdam, The Netherlands) triggered by
electrocardiogram signals.  Arterial blood pressure, heart rate and carotid blood flow
were continuously monitored on a polygraph (CRW, Erasmus University, Rotterdam,
The Netherlands).  During the experiment, body temperature was kept at about 37 °C
and the animal was continuously infused with physiological saline to compensate
fluid losses.
The Ethical Committee of the Erasmus University Medical Centre Rotterdam,
dealing with the use of animals in scientific experiments, approved the protocols
followed in this investigation.
Distribution of total common carotid blood flow
The distribution of total common carotid blood flow was determined with
15.5±0.1 µm (s.d.) diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or
46Sc (NEN Dupont, Boston, USA).  For each measurement, about 200,000
microspheres, labelled with one of the radioisotopes, were mixed and injected into the
right common carotid artery.  At the end of the experiment, the animal was killed by
an overdose of sodium pentobarbital and the heart, lungs, kidneys and all ipsilateral
cranial tissues were dissected out, weighed and put in vials.  The radioactivity in these
vials was counted for 10 min in a g-scintillation counter (Packard, Minaxi autogamma
5000), using suitable windows to discriminate the different isotopes (141Ce:
120-167 KeV, 113Sn: 355-435 KeV, 103Ru: 450-548 KeV, 95Nb: 706-829 KeV and
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46Sc: 830-965 KeV).  All data were processed by a set of specially designed
programs[197].  The fraction of right common carotid blood flow distributed to the
different tissues was calculated by multiplying the ratio of tissue and total
radioactivity of each radioisotope by the common carotid blood flow at the time of the
injection of microspheres, labelled with the respective isotope.  Since little or no
radioactivity was detected in the heart and kidneys, all microspheres trapped in lungs
reached this tissue from the venous side after escaping via carotid arteriovenous
anastomoses.  Therefore, the amount of radioactivity in the lungs was used as an index
of the arteriovenous anastomotic fraction of the total common carotid blood
flow[161].  Vascular conductance (10-2 ml min-1  mmHg-1) was calculated by dividing
blood flow (ml min-1) by mean arterial blood pressure (mmHg) multiplied by hundred.
Experimental protocol
After a stabilisation period of at least 60 min, values of heart rate, mean arterial blood
pressure, total common carotid blood flow, as well as arterial blood gases were
measured.  Thereafter, the animals (n=33) were divided into seven groups, receiving
i.v. infusions (0.5 ml min-1  for 10 min) of either vehicle (distilled water; 5 ml, n=6),
5-methylurapidil (1000 mg kg-1, n=6), prazosin (100 mg kg-1, n=3), a combination of
prazosin and rauwolscine (100 and 300 mg kg-1, respectively, n=6), GR127935
(500 mg kg-1, n=3), ketanserin (500 mg kg-1, n=3) or methiothepin (3000 mg kg-1, n=6).
After 15 min, baseline values of heart rate, mean arterial blood pressure, arterial blood
gases, total common carotid blood flow and its distribution into arteriovenous
anastomotic and capillary fractions (injection of the first batch of microspheres) were
measured.  Subsequently, all animals received of A61603 (cumulative total doses: 0.3,
1, 3 and 10 µg kg-1 at the rate of 0.1 ml min-1 over 10 min infused into the right
common carotid artery).   Ten min after the start of each A61603 infusion, the animals
received a different batch of microspheres and all variables were collated again.
After the carotid and systemic haemodynamic variables had been returned to
baseline values, we analysed the systemic haemodynamic effects of i.v. bolus
injections of A61603 (1, 3, 10 and 30 µg kg-1) in the different groups of animals.
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Data presentation and statistical analysis
All data are presented as the mean±s.e.mean.  Percent changes from baseline values
(i.e. after vehicle or the antagonists) caused by the different doses of A61603 within
each group of animals were calculated.  Duncan new multiple-range test, together
with two-way ANOVA (SigmaStat 1.0, Jandel Corporation, Chicago, IL, USA), was
used to establish whether these changes were statistically significant (P<0.05,
two-tailed) when compared to the baseline in each group as well as with the
corresponding dose of A61603 in the vehicle-treated group.
Drugs
Apart from the anaesthetics azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse,
Belgium), midazolam hydrochloride (Dormicum®; Hoffmann La Roche b.v.,
Mijdrecht, The Netherlands) and sodium pentobarbital (Apharmo, Arnhem, The
Netherlands), the compounds used in this study were: A61603 hydrobromide (Tocris
Cookson Ltd., Bristol, UK), rauwolscine hydrochloride (Sigma-Aldrich Chemie b.v.,
Zwijndrecht, The Netherlands), 5-methylurapidil (Byk Gulden, Konstanz, Germany),
prazosin hydrochloride (Bufa Chemie b.v., Castricum, The Netherlands), GR127935,
sumatriptan succinate (both from GlaxoWellcome, Herts, UK; courtesy:
Dr. H.E. Connor), ketanserin tartrate (Janssen Pharmaceutica, Beerse, Belgium) and
methiothepin maleate (Hoffman La Roche b.v., Mijndrecht, The Netherlands).
Finally, heparin sodium (Leo Pharmaceutical Products, Weesp, The Netherlands) was
used to prevent clotting of blood in the catheters.
All drugs were dissolved in distilled water (vehicle).  A short period of heating was
needed to dissolve prazosin, rauwolscine, GR127935, 5-methylurapidil (acidified to
pH=6.8-7.0 with 0.1 M HCl) and methiothepin (1 % of ascorbic acid was added).  The
doses of the drugs refer to their respective salts.
Results
Systemic and carotid haemodynamic variables after different antagonists
Baseline values of these variables in the 33 pigs used in the present investigation
were: mean arterial blood pressure, 94±3 mmHg; heart rate, 101±3 beats min-1; total
common carotid blood flow, 133±7 ml min-1 and total common carotid conductance,
144±8 10-2 ml min-1 mmHg-1.  No significant differences were observed between the
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values of haemodynamic variables collated before and after the administration of the
vehicle (distilled water) or different antagonists used in this study (Table 4.2).
Table 4.2. Absolute values in mean arterial blood pressure, heart rate and total carotid blood
flow before and after i.v. administration of vehicle and various antagonists used in
anaesthetised pigs.
Treatment Dose
(mg kg-1)
Mean arterial
blood pressure
(mmHg)
Heart rate
(beats min-1)
Total carotid
blood flow
(ml min-1)#
Before After Before After Before After
Vehicle 5 ml 96±4 94±5 106±3 105±3 145±13 139±12
5-Methylurapidil 1000 102±4 95±7 103±5 116±6 149±12 152±15
Prazosin 100 92±5 77±7 112±6 108±5 147±11 128±13
Prazosin and
rauwolscine
100 and
300
105±4 93±5 104±6 100±6 125±12 104±14
GR127935 500 102±3 91±7 96±3 92±3 183±31 178±26
Ketanserin 500 105±5 98±5 94±4 89±5 134±10 129±7
Methiothepin 3000 103±4 108±4 105±6 105±6 134±10 120±10
a, P<0.05 vs. the vehicle-treated group.  #, The corresponding values of total carotid
conductance ‘Before’ and ‘After’ were not significantly different (P>0.05) for any of the
treatments and are not shown in the Table.
Systemic haemodynamic responses to A61603
A61603 (0.3, 1, 3 and 10 µg kg-1, i.c.) produced a dose-dependent increase in mean
arterial blood pressure (Figure 4.1; upper panel), without affecting heart rate (data not
shown).  This vasopressor response was antagonised (even reverted to hypotension)
after treatment with methiothepin (3000 µg kg-1), but remained by 5-methylurapidil
(1000 µg kg-1), prazosin (100 µg kg-1), a combination of prazosin and rauwolscine
(100 and 300 µg kg-1, respectively), GR127935 (500 µg kg-1) or ketanserin
(500 µg kg-1).
The pressor responses following i.v. bolus injection of A61603 (1, 3, 10 and 30
µg kg-1) are shown in Figure 4.1 (lower panel); heart rate remained unaffected (data
not shown).  Treatment with 5-methylurapidil slightly attenuated these responses,
which were markedly reduced by methiothepin; the other antagonists were ineffective.
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Figure 4.1. Changes in mean arterial blood pressure (MABP) produced by i.c.
(upper panel) or i.v. (lower panel) administration of A61603 in anaesthetised
pigs, treated i.v. with either vehicle (Veh; distilled water), 5-methylurapidil
(5-MU; 1000 µg kg-1), prazosin (Praz; 100 µg kg-1), a combination of prazosin
and rauwolscine (P+R; 100 and 300 µg kg-1, respectively), GR127935 (GR;
500 µg kg-1), ketanserin (KET; 500 µg kg-1) or methiothepin (MET;
3000 µg kg-1).  Data is presented as mean±s.e.mean.  a, P<0.05 vs.  baseline;
b, P<0.05 vs. the response produced by the corresponding dose of A61603 in the
vehicle-treated group.
Carotid haemodynamic responses to A61603
Absolute values of total carotid, arteriovenous anastomotic and capillary
conductances before and after i.c. infusions of A61603 (0.3-10 mg kg-1) in the seven
groups of animals are shown in Figure 4.2.  In animals treated with vehicle, A61603
produced a dose-dependent decrease in total carotid conductance.  This effect was
restricted to the carotid arteriovenous anastomotic fraction, since the capillary fraction
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remained unmodified.  The A61603-induced changes were clearly attenuated in
animals treated with methiothepin, but not in those treated with prazosin, GR127935
or ketanserin.  5-Methylurapidil only attenuated the decrease in the total carotid blood
flow by the highest dose of A61603.  The treatment with prazosin and rauwolscine
combination affected the A61603-induced decreases in the total carotid (highest two
doses) and its carotid arteriovenous anastomotic fraction (highest dose).
Figure 4.2. Porcine cotal carotid, arteriovenous anastomotic and capillary
vascular conductances before and after i.c. administration of A61603.
Treatments: vehicle (Veh; 5 ml distilled water), 5-methylurapidil (5-MU;
1000 µg kg-1), prazosin (Praz; 100 µg kg-1), a combination of prazosin and
rauwolscine (P+R; 100 and 300 µg kg-1 , respectively), GR127935 (GR;
500 µg kg-1), ketanserin (KET; 500 µg kg-1) or methiothepin (MET;
3000 µg kg-1).  Data is presented as mean±s.e.mean.  a, P<0.05 vs.  baseline;
b, P<0.05 vs. the response produced by the corresponding dose of A61603 in the
vehicle-treated group.
Figure 4.3 compares decreases in carotid arteriovenous anastomotic blood flow by
A61603 as percent changes from baseline values in control pigs (vehicle-treatment)
and in pigs treated with the different antagonists.  It can be observed that the
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responses to A61603 were clearly antagonised by methiothepin and only slightly by
the combination of prazosin and rauwolscine; 5-methylurapidil, prazosin, GR127935
and ketanserin were ineffective.
Figure 4.3. Changes in carotid arteriovenous anastomotic (AVA) conductance
following i.c. administration of A61603 in anaesthetised pigs treated i.v. with
either vehicle (Veh; 5 ml distilled water), 5-methylurapidil (5-MU; 1000 µg kg-1),
prazosin (Praz; 100 µg kg-1), a combination of prazosin and rauwolscine (P+R;
100 and 300 µg kg-1 , respectively), GR127935 (GR; 500 µg kg-1), ketanserin
(KET; 500 µg kg-1) or methiothepin (MET; 3000 µg kg-1).  Data is presented as
mean±s.e.mean.  a, P<0.05 vs.  baseline; b, P<0.05 vs. the response produced by
the corresponding dose of A61603 in the vehicle -treated group.
Discussion
Consideration of known receptors that mediate carotid vasoconstriction
A number of studies have shown that sumatriptan produces vasoconstriction in the
carotid vasculature of several species via GR127935-sensitive 5-HT1B/1D receptors;
these species include the dog[232], pig[196]and rabbit[233, 234].  It is now known
that these receptors mediating vasoconstriction are of the 5-HT1B subtype[177, 178,
217].  In line with this proposal, the therapeutic efficacy of sumatriptan in migraine
may be explained by carotid vasoconstriction mediated by the 5-HT1B receptor.
Furthermore, the canine external carotid vasoconstriction by ergotamine and
dihydroergotamine involves 5-HT1B/1D receptors as well as a-adrenoceptors[177].
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Since the ergots display reasonable affinity at a-adrenoceptors[182], their carotid
vasoconstrictor effects in the pig may also be explained by these receptors.  In this
respect, we recently showed that: (i) both a1- and a2-adrenoceptors mediate
vasoconstriction of porcine carotid arteriovenous anastomoses[219]; and (ii) these
a1-adrenoceptors belong to a1A and a1B subtypes, but not the a1D subtype[229].
Except for A61603 (a1A-adrenoceptor agonist), potent and selective agonists at
a1-adrenoceptor subtypes are unfortunately not available in order to verify this
hypothesis.  Therefore, in the present study we used A61603 to confirm the possible
involvement of a1A-adrenoceptors in the vasoconstriction of porcine carotid
arteriovenous anastomoses.
Pharmacological profile of A61603
A61603 (Table 4.1) is a tetrahydro-1-napthyl imidazoline derivative that has been
reported to show potent a1A-adrenoceptor-agonist properties[33, 83].  As described
previously[83, 235], A61603 is 35-fold more potent at human cloned a1a- than at a1b-
or a1d-adrenoceptors in radioligand binding studies and 100 to 300-fold more potent
than noradrenaline and phenylephrine in isolated canine prostate strips and rat vas
deferens (a1A-adrenoceptors).  In contrast, A61603 is only 40-fold more potent than
phenylephrine at a1B-adrenoceptors (rat spleen) and 35-fold less potent at
a1D-adrenoceptors (rat aorta)[83, 235].  Although the compound displays low affinity
(pKi<6) for other receptors (see Table 4.1), it has been shown to display a reasonable
affinity and agonist property at a2-adrenoceptor subtypes[72].  In anaesthetised dogs,
A61603 increases intra-urethral as well as diastolic arterial blood pressure[83].  In
agreement with the latter, A61603 produces pressor responses in conscious rats at 50-
to 100-fold lower doses than those of phenylephrine, and tamsulosin
(a1A-adrenoceptor antagonist) causes a marked shift of the A61603-induced response
curve[83].
Systemic and carotid haemodynamic effects of A61603;  involvement of a new
receptor
A61603 produced a dose-dependent increase in blood pressure when administered by
either i.c. (0.3-10 mg kg-1) or i.v. (1-30 µg kg-1) routes (Figure 4.1).  In view of the
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high affinity of A61603 at the a1A-adrenoceptor (Table 4.1) and the important role of
a-adrenoceptors in the regulation of vascular tone[44], it was surprising that the
hypertensive response to A61603 was little affected by 5-methylurapidil, prazosin or a
combination of prazosin and rauwolscine.    On the other hand, A61603-induced
pressor response was markedly attenuated (i.v.) or even converted to hypotension
(i.c.) by methiothepin.
Similar results were obtained with respect to the carotid haemodynamics.  As
shown in Figure 4.2, A61603 (0.3-10 mg kg-1, i.c.) produced a dose-dependent
decrease in the porcine carotid blood flow, exclusively due to a vasoconstriction of
carotid arteriovenous anastomoses.  This selective carotid vasoconstriction was
apparently maximal because a higher dose of A61603 (30 mg kg-1) did not produce an
additional decrease in total carotid conductance (maximal change: 80±4%; n=6).
The A61603-induced vasoconstriction of carotid arteriovenous anastomoses was,
unexpectedly, resistant to blockade by the potent and selective a1A-adrenoceptor
antagonist 5-methylurapidil[26, 42].  Since prazosin was also ineffective in
attenuating this response, it seems plausible to conclude that a1-adrenoceptors do not
play an important role.  As mentioned before, both a1- and a2-adrenoceptors can
mediate vasoconstriction in the porcine carotid arterial bed[219].  For this reason and
for the fact that A61603 also has affinity for a2-adrenoceptors (see Table 4.1[72]), we
applied a combination of prazosin and rauwolscine to investigate the possible
involvement of a2-adrenoceptors.  The combination of prazosin and rauwolscine
produced only a slight attenuation in the A61603-induced vasoconstriction of carotid
arteriovenous anastomoses, which implies, at most, a limited involvement of
a2-adrenoceptors.  Similarly, the fact that GR127935 as well as ketanserin did not
significantly modify this response excludes the possible involvement of 5-HT1B/1D and
5-HT2 receptors, respectively.  Although A61603 shows only a low affinity at these
receptors (see Table 4.1[72]), the exclusion of 5-HT1B/1D receptors is of interest,
considering the affinity of benzylimidazoline derivatives related in structure to
A61603 at 5-HT1B/1D receptors[236].  As reported elsewhere, the involvement of
5-HT1F receptors in the carotid vasoconstriction of pigs and dogs (external) carotid
vascular bed has been categorically excluded[162, 166, 180, 231].  Moreover, an
endothelium-dependent vasoconstriction via the release of pro-constrictor
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cyclo-oxygenase products[237, 238] seems also unlikely, based on the lack of effect
of indomethacin (3000 µg kg-1, i.v.; data not shown) on A61603-induced decrease in
total carotid conductance.  Similarly, a combination of indomethacin, prazosin,
rauwolscine, GR127935 and ketanserin, at the doses previously mentioned, also failed
to attenuate the decreases in total carotid conductance produced by i.c. infusions of
A61603 (data not shown).
To strengthen the hypothesis that a-adrenoceptors and 5-HT receptors do not play
a role in this response, we decided to test methiothepin in this porcine model.  This
drug displays high affinity at 5-HT1/2 receptors[227] as well as a1/2
adrenoceptors[182].  It may be noted that a relatively high dose of methiothepin
(3000 µg kg-1) was required to abolish sumatriptan-induced carotid vasoconstriction
in anaesthetised dogs and pigs[180, 182, 231, 239]; while a lower dose (1000 µg kg-1)
was ineffective.  As shown in Figs. 4.2 and 4.3, treatment of the animals with
methiothepin markedly attenuated the A61603-induced vasoconstriction in the
porcine carotid vascular bed.  Since all currently known vasoconstrictor
receptors/mechanisms were blocked by their respective antagonist/inhibitor, this latter
finding may in turn imply the involvement of another, possibly novel, receptor and/or
mechanism in the vasoconstriction of carotid arteriovenous anastomoses by A61603.
Since this in vivo animal model is predictive for antimigraine activity[161], this
possible novel receptor could be a potential new target for the development of
antimigraine agents in the future.  Admittedly, as an antimigraine drug, such an
agonist must be devoid of systemic vasoconstrictor properties.
In conclusion, the present results show that A61603 does not behave as a potent
and selective a1A-adrenoceptor agonist in the pig and that the vasoconstriction of
porcine carotid arteriovenous anastomoses by A61603 is primarily mediated by a
novel methiothepin-sensitive receptor/mechanism.
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Chapter 5
Porcine carotid and systemic haemodynamic effects of S19014: an
experimental study to assess its antimigraine potential
Abstract    Taking into account the drawbacks associated with the use of
triptans (5-HT1B/1D receptor agonists), particularly the cardiovascular
liability, attempts are being made to explore other avenues for the
treatment of migraine.  Recently, it has been shown that both a1- and
a2-adrenoceptors can mediate vasoconstriction of porcine carotid
arteriovenous anastomoses, which has effectively served as an
experimental model predictive of antimigraine activity.  The present
study was set out to investigate the carotid vascular effects of a newly
synthesised a-adrenoceptor agonist S19014 (spiro[(1,3-diazacyclopent-
1-ene)-5:2’-(4’,5’-dimethylindane)]) in this model.  Intravenous
administration of S19014 (1-30 µg kg-1) produced a dose-dependent,
initial short lasting vasopressor response and a decrease of total carotid
blood flow and conductance.  The decrease of total carotid blood flow by
S19014 was exclusively due to vasoconstriction of carotid arteriovenous
anastomoses; the total capillary blood flow (especially in muscles, fat,
bone, salivary gland and dura mater) was increased.  Whereas prazosin
was ineffective, rauwolscine attenuated the carotid haemodynamic and
initial vasopressor responses poduced by S19014.  The above results
suggest that the systemic and carotid vascular effects produced by
S19014 in anaesthetised pigs are mainly mediated by a2-adrenoceptors
and that S19014 could be effective in the treatment of migraine.
Based on: Kapoor et al., Communicated to Servier (Paris, France).
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Introduction
Vasodilatation of cranial large arteries and arteriovenous anastomoses has been
proposed to play an important role in the pathophysiology of migraine headache[161,
170].  Indeed, to date all acutely acting antimigraine agents, i.e. the triptans and
ergots, constrict isolated cranial vessels as well as arteriovenous anastomoses within
the carotid vasculature[167, 177, 216, 231].   While the effect of triptans seems to be
mediated exclusively by the 5-HT1B receptor[178, 217], that of ergot alkaloids also
involves other receptors[181, 240], including the a-adrenoceptors, which mediate the
carotid vasoconstriction in anaesthetised dogs [177].
Stimulation of a-adrenoceptors produces contraction of isolated carotid artery of
several species, including the dog[189, 190], rabbit[241, 242] and pig[192].  Also, in
vivo studies have shown that exogenously administered a-adrenoceptors agonists (e.g.
phenylephrine and BHT933) potently constrict carotid arteriovenous
anastomoses[219] and there is evidence that a-adrenoceptors may regulate the
vascular tone of carotid arteriovenous anastomoses[174].  Thus, it may be possible
that a-adrenoceptors may provide a potential target for the development of novel
antimigraine drugs.
Cordi et al.[243] have described a series of compounds with a-adrenoceptor
agonist affinity/activity.  One such compound, S19014 (spiro[(1,3-diazacyclopent-
1-ene)-5:2’-(4’,5’-dimethylindane)]), displays high affinities at the different a1- and
a2-adrenoceptor subtypes (for structure and affinity values, see Table 5.1).
Interestingly, S19014 shows a wide variation in its efficacy (maximum effect, Emax)
and potency (EC50, concentration needed to cause 50% of Emax) in contracting rabbit,
dog and human isolated saphenous vein (EC50: 18, 79 and 8500 nM, respectively;
Emax: 92, 49 and 36% of K+-induced contraction, respectively), rabbit aorta (EC50:
816 nM; Emax: 36% of K+-induced contraction) and dog femoral artery (practically
inactive)[244].
The present study was designed to investigate the systemic and carotid
haemodynamic effects of S19014 in anaesthetised pigs in order to assess its potential
as an antimigraine agent.
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Table 5.1. Chemical structure of S19014 and its binding affinities (pKi) at human
cloned a1- and a2-adrenoceptor subtypes.
Chemical structure pKi values*
a1a: 7.66 a2a: 8.98
a1b: 7.80 a2b: 8.33
a1d: 7.65 a2c: 8.75
*, Unpublished data from Institut de Recherches Servier (Paris, France).
Methods
General
After an overnight fast, 27 domestic pigs (Yorkshire x Landrace; 10-14 kg) were
anaesthetised with azaperone (120 mg, i.m.), midazolam hydrochloride (10 mg, i.m.)
and sodium pentobarbital (600 mg, i.v.).  After tracheal intubation, the animals were
connected to a respirator (BEAR 2E, BeMeds AG, Baar, Switzerland) for intermittent
positive pressure ventilation with a mixture of room air and oxygen.  Respiratory rate,
tidal volume and oxygen supply were adjusted to keep arterial blood gas values within
physiological limits (pH: 7.35-7.48; pCO2: 35-48 mmHg; pO2: 100-120 mmHg).
Anaesthesia was maintained with a continuous i.v. infusion of sodium pentobarbital
(20 mg kg-1 h-1).  It may be pointed out that this anaesthetic regimen, together with
bilateral vagosympathectomy, leads to an increase in heart rate and vasodilatation of
arteriovenous anastomoses due to a loss of parasympathetic and sympathetic tone,
respectively.  Indeed, basal arteriovenous anastomotic blood flow is considerably
higher in sodium pentobarbital-anaesthetised pigs (70-80% of carotid blood flow)
than in those under fentanyl/thiopental anaesthesia (~19% of carotid blood
flow[174]).  A high basal carotid arteriovenous anastomotic flow is particularly useful
for investigating the effects of drugs that vasoconstrict these shunt vessels.
A catheter was placed in the inferior vena cava via the left femoral vein for the
infusions of the different treatments (Table 5.2) and S19014.  Another catheter was
placed in the aortic arch via the left femoral artery for the measurement of arterial
blood pressure (Combitrans disposable pressure transducer; Braun, Melsungen,
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Germany) and arterial blood withdrawal for the measurement of blood gases
(ABL-510; Radiometer, Copenhagen, Denmark).  Subsequently, both the common
carotid artery and the external jugular vein were dissected free and bilateral
vagosympathgectomy was performed in order to prevent a possible influence via
baroreceptor reflexes on S19014-induced carotid vascular responses.  The right
external jugular vein was catheterised for withdrawal of venous blood samples for
determining blood gases in order to determine arterio-jugular oxygen saturation
difference (A-VSO2).  A hub-less needle, was connected to a polyethylene tube and
inserted into the right common carotid artery and was used for radioactive
microspheres injection.  The microspheres were injected against the direction of blood
flow for uniform mixing.
Right common carotid blood flow was determined with a flow probe (internal
diameter: 2.5 mm) connected to a sine-wave electromagnetic flow meter (Transflow
601-system, Skalar, Delft, The Netherlands).  Heart rate was measured with a
tachograph (CRW, Erasmus University, Rotterdam, The Netherlands) triggered by
electrocardiogram signals.  Arterial blood pressure, heart rate and right common
carotid blood flow were continuously monitored on a polygraph (CRW, Erasmus
University, Rotterdam, The Netherlands).  During the experiment, body temperature
was kept around 37 °C and the animal was continuously infused with saline to
compensate for fluid loss.
Distribution of carotid blood flow
The distribution of common carotid blood flow was determined with 15.5±0.1 µm
(s.d.) diameter microspheres labelled with 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN
Dupont, Boston, USA).  For each measurement, about 200,000 microspheres, labelled
with one of the radioisotopes, were mixed and injected into the right common carotid
artery.  At the end of the experiment, the animal was killed by an overdose of sodium
pentobarbital and the heart, lungs, kidneys and all ipsilateral cranial tissues were
dissected out, weighed and put in vials.  The radioactivity in these vials was counted
for 5 min in a g-scintillation counter (Packard, Minaxi autogamma 5000), using
suitable windows to discriminate the different isotopes (141Ce: 120-167, KeV, 113Sn:
355-435 KeV, 103Ru: 450-548 KeV, 95Nb: 706-829 KeV and 46Sc: 830-965 KeV).  All
data were processed by a set of specially designed programs[197].  The fraction of
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carotid blood flow distributed to the different tissues was calculated by multiplying
the ratio of tissue and total radioactivity of each radioisotope by the total common
carotid blood flow at the time of the injection of the microspheres labelled with the
respective isotope.  Since little or no radioactivity was detected in the heart and
kidneys, all microspheres trapped in lungs reached this tissue from the venous side
after escaping via carotid arteriovenous anastomoses.  Therefore, the amount of
radioactivity in the lungs was used as an index of the arteriovenous anastomotic
fraction of the common carotid blood flow[198].  Vascular conductance
(ml min-1 mmHg-1) was calculated by dividing blood flow (ml min-1) by mean arterial
blood pressure (mmHg).
Experimental protocol
After a stabilisation period of at least 60 min, values of heart rate, blood pressure and
total carotid blood flow and conductance were measured.  Thereafter, the animals
(n=27) were divided into four groups.  Whereas the first (n=6) and second groups
(n=6) remained untreated, the animals in the third (n=8) and fourth group (n=7) were
treated intravenously (0.5 ml min-1 for 10 min) with prazosin (100 µg kg-1) and
rauwolscine (300 µg kg-1), respectively.  After a waiting period of fifteen minutes,
baseline values of blood pressure, heart rate and total carotid blood flow were collated
and the distribution of carotid blood flow into arteriovenous anastomotic and capillary
fractions as well as A-VSO2 difference were determined.  Subsequently, the animals
in the first group received four consecutive intravenous infusions (1 ml min-1 for
5 min) of distilled water (vehicle), whereas those in the second, third and fourth group
received intravenous infusions (1 ml min-1 for 5 min) of S19014 (1, 3, 10 and
30 µg kg-1) in a cumulative manner.  Systemic and carotid haemodynamic variables
were reassessed 10 min after every administration of vehicle (first group) or S19014
dose (other three groups).
Data presentation and statistical analysis
All data have been expressed as the mean ± s.e.mean.  The significance of the
difference between the variables within one group was evaluated with Duncan’s new
multiple range test, once an analysis of variance (randomised block design) had
revealed that the samples represented different populations[222].   Percent changes
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(from baseline values) caused by S19014 (1, 3, 10 or 30 µg kg-1) in the animals
treated with either prazosin or rauwolscine were compared with the corresponding
doses in the control group using Student's unpaired t-test.  Statistical significance was
accepted at P<0.05 (two-tailed).
Drugs
Apart from the anaesthetics azaperone (Stresnil®; Janssen Pharmaceuticals, Beerse,
Belgium), midazolam hydrochloride (Dormicum®; Hoffmann La Roche b.v.,
Mijdrecht, The Netherlands) and sodium pentobarbital (Sanofi Sante b.v., Maasluis,
The Netherlands,), the compounds used in this study were: prazosin hydrochloride
(Bufa Chemie b.v., Castricum; The Netherlands), rauwolscine dihydrochloride (RBI,
Natick, USA) and S19014 (spiro[(1,3-diazacyclopent-1-ene)-5:2’-(4’,5’-
dimethylindane)]; Gift from Dr. C. Rochat, Institut de Recherches Servier, Paris,
France).  Finally, heparin sodium (Leo Pharmaceutical Products, Weesp, The
Netherlands) was used to prevent clotting of blood in the catheters.
All drugs were dissolved in distilled water (vehicle), however a short period of
heating was needed to dissolve prazosin.  The doses of the drugs refer to their
respective salts.
Ethical approval
The local ethics committee dealing with the use of animals in scientific experiments
approved the protocol.
Results
Baseline values
Baseline values in anaesthetised pigs (n=27) before any treatment were: heart rate
(105±2 beats min-1), mean arterial blood pressure (101±2 mmHg), total carotid blood
flow (148±6 ml min-1) and total carotid vascular conductance (140±6
ml min-1 mmHg-1).
Systemic and carotid haemodynamic effects of the treatments per se
Table 5.2 shows the systemic and carotid haemodynamic effects before and after
intravenous administration of vehicle (distilled water), prazosin (100 µg kg-1) or
rauwolscine (300 µg kg-1).  Whereas treatment of the animals with either vehicle or
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prazosin did not produce any changes, rauwolscine elicited a small, but significant,
decrease in mean arterial blood pressure (9±2%).
Table 5.2. Absolute values of heart rate, mean arterial blood pressure and total
carotid blood flow in anaesthetised pigs, before and after intravenous infusions of
vehicle (distilled water), prazosin or rauwolscine.
Treatment
group
Vehicle Prazosin
(100 µg kg-1)
Rauwolscine
(300 µg kg-1)
Before After Before After Before After
Heart rate
(beats min-1)
102±2 101±3 114±3 112±3 98±4 99±5
MABP
(mmHg)
97±3 95±3 98±3 91±4 108±2 99±2a
Total CBF
(ml min-1)
140±13 142±13 140±14 126±12 154±7 136±6
A-VSO2 (%) 9±2 8±2 8±2 10±2 6±3 6±2
MABP, mean arterial blood pressure; Total CBF, total carotid artery blood flow; A-
VSO2, arterio-jugular venous oxygen saturation difference. a, P<0.05 ‘Before’ vs.
‘After’ administration of treatment (5 ml of each).
Systemic haemodynamic and A-VSO2 effects of S19014
As shown in Table 5.3, intravenous administration of vehicle produced only moderate
decreases in heart rate (maximum change: 4±1%) and mean arterial blood pressure
(maximum change: 47±1%).  On the other hand, S19014 (1, 3, 10 and 30 µg kg-1)
produced a small, but significant, decrease in heart rate (maximal response: 3±1%)
and an initial, dose-dependent increase in mean arterial blood pressure (maximal
responses were: 4±0, 8±1, 14±1, 21±2%, respectively).  However, blood pressure was
constant and back to baseline values at the time of microsphere injection (see
Table 5.3); we even observed a small, but significant, hypotension (maximal
response: -5±2%).  The time for S19014 to produce this initial vasopressor response
was 2.9±0.3 min.  In addition, S19014 produced an increase in arterial jugular venous
oxygen saturation difference (A-VSO2; maximal response: 10±2%).
The effects of S19014 on heart rate and mean arterial blood pressure were not
affected by prazosin, however, we observed (at the time of microsphere injection) a
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small hypotension after rauwolscine, produced by the highest of S19014 (-7±4%).
Interestingly, treatment of the animals with rauwolscine produced a right-ward shift of
the above mentioned initial vasopressor response (maximal responses were: -9±1,
-5±3, 1±3 and 14±1%, respectively), while prazosin was ineffective (data not shown).
It may be noted that whereas prazosin was ineffective, rauwolscine showed a
tendency to attenuate the S19104-induced increase in AVSO2, however, this latter
effect was not significant (see Table 5.3).
Table 5.3. Systemic haemodynamic effects of vehicle per se and S19014 in the
absence (control) or presence of either prazosin (100 µg kg-1) or rauwolscine
(300 µg kg-1).
S19014 (µg kg-1, i.v.)Treatment
Baseline 1 3 10 30
Heart rate (beats min-1)
Vehicle† 102±2 101±3 100±3a 98±3a 98±4a
Control 102±4 102±5 101±4a 100±4a 100±4a
Prazosin 112±3 110±3 110±3 110±3 108±2
Rauwolscine 99±5 98±5b 98±6 98±6 98±6
Mean arterial blood pressure (mmHg)
Vehicle† 97±3 95±3 96±3a 96±3a 90±3a
Control 101±3 99±3 96±4a 96±4a 96±3a
Prazosin 91±4 88±4 86±4a 84±4a 83±3a
Rauwolscine 98±2 94±2 93±3 93±3 91±3b
Arterio-jugular venous oxygen saturation difference (%)
Vehicle† 9±2 8±2 8±2 8±2 10±3
Control 7±2 8±2 8±2 9±3* 10±2a
Prazosin 10±2 11±3 13±2a 12±2a 15±2a
Rauwolscine 6±2  6±2 6±1 7±2  8±2a
a, P<0.05 vs. baseline; b, P<0.05 vs. control; †, four consecutive infusions of 5 ml of
distilled water were given after baseline.
Carotid haemodynamics of S19014
Absolute values of total carotid, arteriovenous anastomotic and capillary blood flow
and conductance in the different groups of animals are shown in Figure 5.1.  Whereas
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vehicle was devoid of any carotid haemodynamic effects, S19014 (1, 3, 10 and
30 µg kg-1) produced dose-dependent decreases in total carotid and arteriovenous
anastomotic blood flow (maximum change: 18±2 and 34±5%, respectively) and
conductance (maximum change: 14±2 and 30±4%, respectively.  In contrast, S19014
increased capillary blood flow and conductance (maximum change: 40±23 % and
49±27%, respectively).  These changes in vascular conductance were particularly
noted in muscle (maximum change: 18±9%), bone (maximum change: 55±26%), fat
(maximum change: 168±142%), salivary gland (maximum change: 91±57%) and dura
mater (maximum change: 636±593%), while those in the others (skin, eye, brain, ear
or tongue) remained unchanged.  These S19014-induced haemodynamic responses
were attenuated in animals treated with rauwolscine, while treatment with prazosin
was without effect.
Figure 5.2 depicts percent changes (from baseline values) in carotid arteriovenous
anastomotic conductance by S19014 (1, 3, 10 and 30 µg kg-1) in control and prazosin-
or rauwolscine-treated animals.  While prazosin (100 µg kg-1) did not modify the
vasoconstrictor effect of S19014 on carotid arteriovenous anastomoses, treatment of
the animals with rauwolscine (300 µg kg-1) clearly did.
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Discussion
General
It is generally agreed that a-adrenoceptors are divided into a1- and a2-adrenoceptors
and play an important role in the regulation of the vascular resistance and blood
pressure[17, 20, 26, 31, 33, 245].  Recently, we have shown that both a1- and
a2-adrenoceptors can mediate canine (external) and porcine (arteriovenous
anastomotic) carotid vasoconstriction[219, 223].  In this context, several lines of
evidence have demonstrated that vasoconstriction in this vascular bed is predictive for
antimigraine activity[167].  The present study was designed to investigate the carotid
Figure 5.1. Effects of four consecutive i.v. infusions of
vehicle (distilled water) per se and S19014 (1, 3, 10
and 30 µg kg-1) in the absence (control) or presence of
prazosin (Praz; 100 µg kg-1) or rauwolscine (Rauw;
300 µg kg-1) on porcine total carotid, arteriovenous
anastomotic (AVA) and capillary fraction blood flow
and conductance. All values are expressed as
mean±s.e.mean. * P<0.05 vs. baseline; #  vs. response
produced by corresponding dose in control animals.
Figure 5.2. Effect (% change compared to
baseline) of S19014 (1, 3, 10 and 30 µg kg-1)
on porcine arteriovenous anastomotic (AVA)
conductance in the absence (control) or
presence of prazosin (Praz; 100 µg kg-1) or
rauwolscine (Rauw; 300 µg -1kg). All values
have been expressed as mean±s.e.mean.
*, P<0.05 vs. baseline, #  P<0.05 vs. response
produced by corresponding dose in control
animals.
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and systemic haemodynamic effects of the newly developed a-adrenoceptor agonist
S19104 in anaesthetised pigs and whether the effects of S19104 involve a1- and/or
a2-adrenoceptors.
The major findings of the present study were: (i) S19014 caused relatively little
systemic haemodynamic changes; (ii) S19014 caused vasoconstriction of porcine
carotid arteriovenous anastomoses in a model predictive for antimigraine activity; and
(iii) this vasoconstrictor effect was markedly attenuated by rauwolscine, but not by
prazosin.  The doses of prazosin (100 µg kg-1) and rauwolscine (300 µg kg-1) are
sufficient to selectively block a1- and a2-adrenoceptors, respectively[246].
Systemic haemodynamic effects of S19014
As described earlier[246], the treatments used in the present study (vehicle, prazosin
and rauwolscine) were devoid of major systemic haemodynamic effects.  It may be
noted that the S19014-induced bradycardia and hypotension are probably due to its
vehicle (see Table 3).  In any case, the comparable bradycardic effect produced by
sumatriptan (5±1%) in the same experimental set-up[240, 247] is of little clinical
relevance in migraine therapy[215].
On the other hand, intravenous administration of S19014 produced a moderate
short-lasting dose-dependent vasopressor response, which, being amenable to
blockade by rauwolscine but not prazosin, was mediated by a2-adrenoceptors.
Indeed, pressor responses can be elicited via both a1- and a2-adrenoceptor
subtypes[33].  It may be pointed out that in our previous experiments[246] no pressor
changes were observed with either phenylephrine (a1-adrenoceptor agonist) or
BHT933 (a2-adrenoceptor agonist) in anaesthetised pigs.  This apparent discrepancy
is due to the fact in these experiments phenylephrine and BHT933 were slowly
infused into the carotid artery[Willems, 1999 #7], while we injected S19014
intravenously.
Carotid haemodynamic effects of S19014
As reported previously[246], intravenous administration of vehicle, prazosin or
rauwolscine did not produce major carotid haemodynamic changes (Table 5.2).  On
the other hand, S19014 produced a dose-dependent vasoconstriction in the carotid
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vasculature of anaesthetised pigs, an effect exclusively caused by vasoconstriction of
carotid arteriovenous anastomoses; the vascular conductance in the capillary fraction
was increased.  In accordance with the vasoconstriction of carotid arteriovenous
anastomoses[161, 170], S19014 produced an increase in A-VSO2 difference.
Although, as shown in Table 5.1, S19014 displays only a little less affinity at the three
a1-adrenoceptor subtypes (pKi: 7.65-7.80) than at the three a2-adrenoceptor subtypes
(pKi: 8.33-8.98), the vasoconstriction of carotid arteriovenous anastomoses by
S19014 was antagonised by rauwolscine and not at all by prazosin.  Interestingly, the
vasoconstrictor responses to S19014 are variable in potency and efficacy[244], and
this may suggest that a-adrenoceptor subtypes at which S19014 is efficacious may be
unevenly distributed throughout the body.
Possible clinical implications
Both in vitro[248, 249] and in vivo[161, 167, 177, 250] experimental models
demonstrating vasoconstrictor properties have consistently shown their value in
predicting therapeutic potential of drugs in the acute treatment of migraine.
Therefore, the results obtained with S19014 in the present experiments suggest that
this compound may well have antimigraine properties.  In this connection, it is
interesting to compare the efficacy of S19014 with that of triptans and ergot alkaloids
in the present porcine model.  As can be observed in Figure 5.3, S19014 (30 µg kg-1)
and sumatriptan (30 µg kg-1) were equi-effective in constricting porcine carotid
arteriovenous anastomoses, but we do not know if higher doses of S19014 will exhibit
higher efficacy with relatively little systemic haemodynamic effects
(e.g. hypertension). Our experience with this porcine model is largely limited to
5-HT1B/1D receptor agonists and, in view of the fact that porcine a-adrenoceptors have
not yet been cloned and compared with the human receptors, we do not know how the
porcine carotid vascular responses mediated via a-adrenoceptors would be predictive
of antimigraine efficacy in humans.  Nevertheless, it will be worthwhile to explore
this aspect with S19014, which mainly acts via a2-adrenoceptors, which are less
ubiquitous than a1-adrenoceptors.
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Figure 5.3 Comparison of the contractile effect of S19014 (present experiments)
and some antimigraine drugs[167] on porcine carotid arteriovenous anastomoses.
As with the currently available antimigraine agents[215, 228], we are aware of the
potential liability of a-adrenoceptor agonists in constricting periphe ral blood vessels,
for example the coronary artery[251, 252].  However, in contrast to sumatriptan,
S19014 (in concentration less than 1 µM) did not contract human isolated coronary
arteries (MaassenVanDenBrink et al., unpublished data).  In agreement with the latter,
except for a dose-dependent decrease in the blood flow to the lungs, S19104 did not
affect the distribution of cardiac output to the different tissues of anaesthetised pigs
(Kapoor et al., unpublished data).
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Chapter 6
Pharmacological identification of the major subtypes of
adrenoceptors involved in the canine external carotid vascular effects
of adrenaline and noradrenaline
Summary    This study investigated the potential effects of adrenaline
and noradrenaline on the external carotid blood flow of
vagosympathectomised dogs and the receptor mechanisms involved. One
minute (1 min) intracarotid infusions of adrenaline and noradrenaline
produced dose-dependent decreases in external carotid blood flow
without changes in blood pressure or heart rate. These responses, which
remained unaffected after saline, were: (i) mimicked by the adrenoceptor
agonists, phenylephrine (a1) and BHT933 (6-Ethyl- 5,6,7,8-
 tetrahydro- 4H- oxazolo [4,5-d] azepin-2-amine dihydrochloride; a2);
(ii) abolished after phentolamine (2000 µg kg-1) unmasking a vasodilator
component (subsequently blocked by propranolol; 1000 µg kg-1); and
(iii) partly blocked by rauwolscine (30 and 100 µg kg-1), and
subsequently abolished by prazosin (100 µg kg-1).  Accordingly,
rauwolscine (100 and 300 µg kg-1) markedly blocked the responses to
BHT933 without affecting those to phenylephrine; likewise, prazosin
(100 µg kg-1) markedly blocked the responses to phenylephrine without
affecting those to BHT933. These results show that both a1- and
a2-adrenoceptors mediate vasoconstriction within the canine external
carotid circulation. Moreover, after blockade of a1/a2-adrenoceptors,
both adrenaline and noradrenaline exhibit a b-adrenoceptor-mediated
vasodilator component.
Based on:  Willems et al., Life Sci. (2000) In Press.
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Introduction
In contrast to the established role of serotonin (5-hydroxytryptamine; 5-HT) receptors
in the carotid vascular beds of dogs and pigs[167, 231, 253], little is known about the
receptors and/or mechanism(s) by which adrenaline and noradrenaline produce their
effects in these vascular beds. In this respect, it has been recently shown that both a1-
and a2-adrenoceptors mediate the vasoconstriction to, respectively, phenylephrine and
BHT933 in the carotid circulation of anaesthetised pigs [219].
To the best of our knowledge, however, no study has reported whether the above
catecholamines produce external carotid vascular effects in anaesthetised dogs via
adrenoceptors.  In view of the relevance that the canine external carotid model has
had in the development of anti-migraine drugs[161, 162, 177, 216], the present study
in the canine external carotid circulation investigates: (i) the effects produced by
intracarotid infusions of adrenaline and noradrenaline as well as by the adrenoceptor
agonists phenylephrine (a1) and BHT933 (a2); and (ii) the mechanisms involved in
the effects (if any) produced by the above compounds.  For the latter purpose, we
made use of the classical adrenoceptor antagonists, phentolamine (a) and propranolol
(b) and of the more specific antagonists, prazosin (a1) and rauwolscine (a2).
Methods
General methods
Experiments were carried out in 33 dogs (15-31 kg) not selected for breed or sex.
The animals were anaesthetised with an intravenous (i.v.) bolus injection of sodium
pentobarbitone (30 mg kg-1) and additional amounts (1 mg kg-1) were provided when
required. All dogs were intubated with an endotracheal tube and artificially respired with
room air using a Palmer ventilation pump at a rate of 20  strokes min-1 and a stroke
volume of 13-16 ml kg-1, as previously established by Kleinman & Radford[254].
Catheters were placed in the inferior vena cava via a femoral vein for the administration
of the antagonists and in the aortic arch via a femoral artery, connected to a Statham
pressure transducer (P23 ID), for the measurement of blood pressure.  After each drug
administration, the venous catheter was flushed with 3 ml of saline.  Mean blood
pressure (MAP) was calculated from the systolic (SAP) and diastolic (DAP) arterial
pressures: MAP = DAP + (SAP-DAP)/3.  Heart rate was measured with a tachograph
(7P4F, Grass Instrument Co., Quincy, MA, U.S.A.) triggered from the blood pressure
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signal.  The right common carotid artery was dissected free and the corresponding
internal carotid and occipital arteries were ligated. Thereafter, an ultrasonic flow probe
(4 mm, R-Series) connected to an ultrasonic T201D flowmeter (Transonic Systems Inc.,
Ithaca, N.Y., U.S.A.) was placed around the right common carotid artery and the flow
through this artery was considered as the external carotid blood flow[255]. Bilateral
cervical vagosympathectomy was systematically performed in order to prevent possible
baroreceptor reflexes induced by the intracarotid administration of the different
sympathomimetic agents; these were administered into the carotid artery by a WPI
model sp100i pump (World Precision Instruments Inc., Sarasota, FL, U.S.A.) with a
catheter inserted into the right cranial thyroid artery.  Blood pressure, heart rate and
external carotid blood flow were recorded simultaneously by a model 7D polygraph
(Grass Instrument Co., Quincy, MA, U.S.A.).  Body temperature of the animals was
maintained between 37-38°C.
Experimental protocol
After the animals had been in a stable haemodynamic condition for at least 60 min,
baseline values of heart rate, mean blood pressure and external carotid blood flow
were determined. Then, the animals (n=33 in total) were divided into two groups.
The first group (n=15) received consecutive 1 min intracarotid infusions of
adrenaline (0.1, 0.3, 1 and 3 µg min-1) and noradrenaline (0.1, 0.3, 1 and 3 µg min-1)
and the changes produced in external carotid blood flow, mean blood pressure and
heart rate were noted. At this point, the dogs were subdivided into three subgroups
which received i.v. bolus injections of, respectively: (i) physiological saline (0.03, 0.1
and 0.3 ml kg-1; n=3); (ii) phentolamine (2000 µg kg-1; followed by a continuous
infusion of 1000 µg kg-1.h in order to maintain a continuous blockade of
a-adrenoceptors,) and, subsequently, propranolol (1000 µg kg-1) (n=6);
and (iii) rauwolscine (30 and 100 µg kg-1) and, subsequently, prazosin (100 µg kg-1)
(n=6). Then, the responses to adrenaline and noradrenaline, at the doses and sequence
listed above, were elicited again 15 minutes after each dose of saline or the above
mentioned antagonists.
The second group (n=18)  received consecutive 1 min intracarotid infusions of
phenylephrine (0.3, 1, 3 and 10 µg min) and BHT933 (3, 10, 30 and 100 µg min-1)
and the changes produced in the above haemodynamical parameters were noted. Then
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the dogs we subdivided into three subgroups which received i.v. bolus injections of,
respectively: (i) physiological saline (0.03 and 0.1 ml kg-1; n=6); (ii) prazosin (100
µg kg-1; n=6); and (iii) rauwolscine (100 and 300 µg kg-1; n=6).  15 min later, the
responses to phenylephrine and BHT933 were elicited again.
The dose-intervals between the different doses of agonists ranged from 5 and 15
min, as in each case we waited until the changes in external carotid blood flow has
returned to baseline values. The dosing with the agonists was sequential, whereas that
with physiological saline and the antagonists was cumulative. The Ethical Committee
of the Department of Pharmacology (CINVESTAV-IPN), dealing with the use of
animals in scientific experiments, approved the protocol of this investigation..
Data presentation and statistical evaluation
All data in the text, figures and tables are presented as the mean±s.e.mean. The peak
changes in external carotid vascular conductance (external carotid blood flow divided by
mean blood pressure; calculated as percent change from baseline) produced by the
different doses of agonists before and after a particular dose of saline or antagonist
within one group of animals were compared using an analysis of variance followed by
the Student-Newman-Keuls test[222]. Statistical significance was accepted at P < 0.05
(two-tailed).
Drugs
Apart from the anaesthetic (sodium pentobarbitone), the compounds used in this study
were: (-)-adrenaline, (-)-noradrenaline tartrate, L-phenylephrine hydrochloride,
BHT933 dihydrochloride, rauwolscine hydrochloride and propranolol hydrochloride
(all from RBI/Sigma Chemical Company, St. Louis, MO, USA); phentolamine
mesylate (Research Biochemicals International, Natick, MA, USA); and prazosin
hydrochloride (Bufa Chemie b.v., Castricum; The Netherlands).
All drugs were dissolved in physiological saline. The doses of the antagonists refer
to their respective salts, while those of the agonists refer to their free base.
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Results
Systemic and carotid haemodynamic responses produced by the different treatments
Baseline values of heart rate, blood pressure and external carotid blood flow in the
thirty three anaesthetised dogs were: 161±7 beats min-1, 131±9 mmHg,
139±18 ml min-1, respectively (Table 1). The specific systemic and external carotid
haemodynamic values observed after different treatments (saline, phentolamine,
propranolol, prazosin and rauwolscine) are shown in Table 1. Phentolamine and
prazosin produced a decrease in blood pressure (20±8 and 13±5%, respectively),
while propranolol caused a decrease in heart rate (29±5%).  It must be pointed out,
however, that none of the treatments affected external carotid blood flow (see
Table 1) or the corresponding vascular conductance (data not shown).
Table 6.1. Absolute values of heart rate, mean blood pressure and external carotid
blood flow in vagosympathectomised dogs before (baseline) and after treatment with
phentolamine (2000 µg kg-1), propranolol (1000 µg kg-1), prazosin (100 µg kg-1) or
rauwolscine (300 µg kg-1).
Treatment
group
Heart rate
(beats min-1)
Mean arterial blood
pressure (mmHg)
External carotid
blood flow (ml min-
1)*
Before After Before After Before After
Salinec 119±9 119±9 109±7 109±7 131±12 131±12
Phentolamine 170±8 187±7 152±7 122±10a 128±9 106±8
Propranololb 160±8 113±5a 119±6 117±8 128±10 116±12
Prazosin 178±5 182±4 129±10 115±15a 185±40 175±41
Rauwolscinec 180±3 185±7 145±17 145±17 125±20 131±19
a, The corresponding carotid conductances were not significantly different (P>0.05)
for any of the treatments, but are not shown for the sake of clarity;  b, effect of the
first dose, but the subsequent doses were similarly without significant effect;  c,
given after phentolamine; d,  30 or 100 µg kg-1 were similarly without significant
effect; *, P<0.05 before versus after.
Systemic and haemodynamic changes to the agonists in the different groups of
animals
As shown in Figure 6.1, 1 min intracarotid infusions of adrenaline, noradrenaline,
phenylephrine and BHT933 produced dose-dependent decreases in external carotid
conductance with a rank order of agonist potency of: adrenaline = noradrenaline >
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phenylephrine ³ BHT933.  These effects were not accompanied by significant
changes in heart rate or mean arterial blood pressure (data not shown).
Figure 6.1. Percent changes in external carotid conductance (compared to
baseline) produced by consecutive 1-min intracarotid infusions of adrenaline
(n=15), noradrenaline (n=15), phenylephrine (n=18) and BHT933 (n=18) in
anaesthetised, vagosympatectomised dogs.
Figure 6.2 shows that adrenaline and noradrenaline produced dose-dependent
decreases in external carotid conductance which remained without significant changes
after saline (maximal percent changes were: -72±3 and -76±4%, respectively). After
phentolamine (2000 µg kg-1), the vasoconstrictor responses to adrenaline and
noradrenaline were abolished and, in both cases, a dose-dependent vasodilator effect
was unmasked (maximal responses were: 76±12 and 22±5%, respectively). This
vasodilator component was abolished by the subsequent administration of propranolol
(1000 µg kg-1; see Figure 6.2). Moreover, after rauwolscine (30 and 100 mg kg-1) a
partial blockade of the responses to adrenaline and noradrenaline was produced, and
the subsequent administration of prazosin (100 µg kg-1) abolished these responses.  It
may be noted that in the case of adrenaline a vasodilator component was unmasked,
as observed with phentolamine (see above).
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Figure 6.2. Effect of i.v. administration of saline (0.03, 0.1 and 0.3 ml kg-1, n=3;
left panel); phentolamine (Phen; 2000 µg kg-1) followed by propranolol (Prop;
1000 µg kg-1) (n=6; middle panel); or rauwolscine (Rauw; 30 and 100 µg kg-1)
followed by prazosin (Praz; 100 µg kg-1) (n=6; right panel) on the responses to
1 min intracarotid infusions of adrenaline (upper graphs) and noradrenaline (lower
graphs) in anaesthetised vagosympathectomised dogs. a, Significantly different
from the corresponding control response; b, significantly different from the
corresponding response after phentolamine (2000 µg kg-1; middle panel) or
rauwolscine (100 µg kg-1; right panel).
Similarly, Figure 6.3 shows that intracarotid infusions of the adrenoceptor agonists,
phenylephrine (a1; 0.3-10 µg min-1) and BHT933 (a2; 3-100 µg min-1) produced
dose-dependent decreases in external carotid conductance (maximal percent changes
were: -64±5 and -68±4%, respectively). After saline, the external carotid
vasoconstrictor responses to these agonists remained without significant changes (see
Figure 6.3, left panel). Moreover, after prazosin (100 µg kg-1), the vasoconstrictor
responses to phenylephrine were markedly blocked whilst those to BHT933 remained
essentially unaltered (see Figure 6.3, middle panel). Similarly, after rauwolscine
(100 and 300 µg kg-1) the responses to BHT933 were markedly blocked whilst those
to phenylephrine remained unaltered (see Figure 6.3, right panel). It is noteworthy
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that after 100 µg kg-1 of rauwolscine, 300 µg kg-1 did not produce a further blockade
on the responses to BHT933 (see Figure 6.3., right panel).
Figure 6.3. Effect of i.v. administration of saline (0.03 and 0.1 ml kg-1, n=6; left
panel), prazosin (Praz; 100 µg kg-1, n=6; middle panel) or rauwolscine (Rauw;
100 and 300 µg kg-1, n=6; right panel) on the external carotid vasoconstrictor
responses elicited by consecutive 1 min intracarotid infusions of phenylephrine
(upper graphs) and BHT933 (lower graphs) in anaesthetised
vagosympathectomised dogs. a, Significantly different from the corresponding
control response.
Discussion
General
Several studies have demonstrated that stimulation of a-adrenoceptors produces
contraction of isolated carotid artery rings, including those of the dog[189, 190],
rabbit [241] and pig[192]. Others have shown in vivo that a-adrenoceptors mediate
vasoconstriction in the carotid circulation of anaesthetised cats[184] and pigs[219].
However, these in vivo studies, instead of using adrenaline and/or noradrenaline (the
endogenous ligands), employed synthetic agonists (e.g. clonidine) in their
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pharmacological approach. Curiously enough, this has also been the case for the
canine external carotid circulation. Thus, it has been shown that buspirone and
ipsapirone (both anxiolytic agents) as well as ergotamine and dihydroergotamine
(both antimigraine agents) produce external carotid vasoconstriction mediated by,
respectively, a1-[256] and a2-[223] adrenoceptors. To the best of our knowledge, no
study has reported the effects produced by adrenaline and noradrenaline on the canine
external carotid bed. Thus, the significance of this experimental model in the
development of antimigraine drugs [161, 162, 177, 216], coupled to the established
heterogeneity of a1 and a2 adrenoceptors (see below), led us to pose a future problem,
namely: the formal pharmacological characterisation of the subtypes of a1- and
a2-adrenoceptors mediating canine external carotid vasoconstriction. Within this
framework it should be firstly demonstrated whether this vascular bed is responsive to
adrenaline and noradrenaline. If so, then the effects of agonists/antagonists at a1
(e.g. phenylephrine/prazosin) and a2 (e.g. BHT933/rauwolscine) adrenoceptors
should be investigated. Indeed, the present study undertook this approach including
the analysis of the effects by the classical adrenoceptor antagonists, phentolamine (a)
and propranolol (b). The doses used of the above antagonists were sufficient to block
their respective receptors[180, 219, 231]. Apart from the implications discussed
below, this study shows that both a1- and a2-adrenoceptors mediate the
vasoconstriction caused by adrenaline and noradrenaline within the external carotid
circulation of anaesthetised vagosympathectomised dogs.
Systemic and carotid haemodynamic changes produced by different treatments
Treatment with saline or rauwolscine did not produce significant changes on systemic
or carotid haemodynamics (see Table 6.1). In contrast, the significant hypotension
produced after prazosin or phentolamine can be explained by blockade of
a1-adrenoceptors which regulate vascular tone and blood pressure[33, 44]. Similarly,
the significant bradycardia produced after propranolol is most likely explained by
blockade of cardiac b1-adrenoceptors[17].
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External carotid responses produced by adrenaline and noradrenaline
The vasoconstrictor responses to adrenaline and noradrenaline were reproducible as
they were not significantly modified after three i.v. bolus injections of saline
(Figure 6.2, left panel). Thus, the fact that the a1/2-adrenoceptor antagonist,
phentolamine, abolished these responses unmasking a vasodilator component suggests
the involvement of vasoconstrictor a1/2-adrenoceptors (Figure 6.2, middle panel).
Since the subsequent administration of propranolol completely blocked this
vasodilator component (Figure 6.2, middle panel), the involvement of vasodilator
b-adrenoceptors is established. Although several lines of evidence have shown that
b1-adrenoceptors may mediate vasodilatation in vivo in the dog coronary artery[257]
and rat choroidal vasculature[258], the b1-adrenoceptor antagonist, metoprolol, did
not block the above adrenaline-induced external carotidvasodilatator response
(unpublished observations). Thus, the possible involvement of b2- (rather than b1)
adrenoceptors is supported by the rank order of agonist vasodilator potency of
adrenaline>>noradrenaline[259] (Figure 6.2). Obviously, this hypothesis requires
further experiments. In any case, our results are in agreement with those reported in
several human vascular beds (e.g. forearm or digital vessels), where a- and
b-adrenoceptors have been shown to mediate vasoconstriction and vasodilatation,
respectively [205, 260, 261].
Which a-adrenoceptor subtype(s) mediate(s) external carotid vasoconstriction?
The fact that rauwolscine partly blocked the responses to adrenaline and
noradrenaline (Figure 6.2, right panel) may be explained by the capability of these
catecholamines to stimulate both a1- and a2-adrenoceptors. Thus, after rauwolscine,
the remaining stimulation of a1-adrenoceptors may have overshadowed the blockade
of a2-adrenoceptors. Hence, the subsequent administration of prazosin abolished the
remaining a1-adrenoceptor-mediated responses. The vasodilator responses unmasked
after prazosin (Figure 6.2, right panel) were smaller than those obtained after
phentolamine (Figure 6.2, middle panel) perhaps because the latter is a much less
selective antagonist. Thus, phentolamine may have blocked additional vasoconstrictor
mechanisms resistant to rauwolscine and/or prazosin. In any case, the above results
clearly suggest that  both a1- and a2-adrenoceptors mediate external carotid
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vasoconstriction. This suggestion is indeed reinforced when considering that the same
doses of prazosin and rauwolscine selectively antagonised the responses to
phenylephrine and BHT933 (see Figure 6.3), as previously shown in anaesthetised
pigs[219]. A higher dose of prazosin (300 µg kg-1; data not shown) or rauwolscine
(300 µg kg-1; see Figure 6.3) did not produce a further blockade of the responses to
phenylephrine and BHT933, respectively.
Possible clinical implications
Finally, we would like to discuss the possible clinical implications of the present results
in terms of the (neuro)vascular theory of migraine[160, 162, 215].  In this context,
several experimental models have been developed to explain the efficacy of acutely
acting antimigraine drugs[161, 162, 177, 216].  The predictive antimigraine value of
these models seems to be higher in those considering the vasoconstriction of cranial
extracerebral vascular beds such as the carotid vasculature [161, 166, 168].
Accordingly, some acute antimigraine agents, including the triptans (sumatriptan and
the second generation triptans), ergot alkaloids (ergotamine and dihydroergotamine)
and others (clonidine and isometheptene) produce carotid vasoconstriction in the dog
and pig [166, 168, 177, 215, 262]. Interestingly, the canine external carotid
vasoconstriction to ergotamine and dihydroergotamine involves 5-HT1B/1D receptors
and a2-adrenoceptors[177]. Thus, since both a1- and a2-adrenoceptors mediate
vasoconstriction in the carotid circulation of dogs (present results) and pigs[219], it is
tempting to hypothesise that selective agonists at these receptors (or their respective
subtypes; see conclusion below) may have antimigraine potential. Evidently, this
hypothesis will be validated with the advent of subtype-selective agonists at a1- or
a2-adrenoceptors, which are not yet available.
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In conclusion, the canine external carotid vasoconstrictor responses to adrenaline and
noradrenaline are mediated by both a1- and a2-adrenoceptors. Moreover, both
catecholamines produced external carotid vasodilatation after blockade of a1- and
a2-adrenoceptors with phentolamine, which most likely involves b- (probably b2)
adrenoceptors. Further studies, which fall beyond the scope of the present
investigation, will be required to ascertain the specific subtypes of a1- (a1A, a1B, a1D),
a2- (a2A, a2B, a2C), and b- (b1,  b2, b3, b4)-adrenoceptors mediating the above
mentioned vascular responses.
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Chapter 7
The role of several a1- and a2-adrenoceptor subtypes mediating
vasoconstriction in the canine external carotid circulation
Summary    It has recently been shown that both a1- and
a2-adrenoceptors mediate vasoconstriction in the canine external carotid
circulation.  The present study set out to identify the specific subtypes
(a1A, a1B and a1D as well as a2A, a2B and a2C) mediating the above
response.  Consecutive 1 min intracarotid infusions of phenylephrine
(a1-adrenoceptor agonist) and BHT933 (a2-adrenoceptor agonist)
produced dose-dependent decreases in external carotid blood flow,
without affecting mean arterial blood pressure or heart rate.  The
responses to phenylephrine were selectively antagonised by the
antagonists, 5-methylurapidil (a1A) or BMY7378 (a1D), but not by
L-765,314 (a1B), BRL44408 (a2A), imiloxan (a2B) or MK912 (a2C).  In
contrast, only BRL44408 or MK912 affected the responses to BHT933.
The above results support our contention that mainly the a1A, a1D, a2A
and a2C-adrenoceptor subtypes mediate vasoconstriction in the canine
external carotid circulation.
Based on: Willems et al., Br. J. Pharmacol. (2000) In Press.
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Introduction
Although the underlying mechanisms for the initiation of a migraine attack are poorly
understood, the clinical efficacy of several acute antimigraine agents can be explained
by their ability to produce a cranio-selective vasoconstriction[162, 168, 215].  This
has been shown for the triptans (e.g. sumatriptan) and the ergots (ergotamine and
dihydroergotamine) in dogs as well as pigs[167, 177, 215, 240].  In this respect, the
carotid vasoconstrictor responses to sumatriptan are exclusively mediated by
serotonin 5-HT1B receptors[178, 217], whilst those to the ergots seem to involve both
5-HT1B and a2-adrenoceptors[177].
Since both a1- and a2-adrenoceptors mediate the vasoconstriction to adrenaline
and noradrenaline in the canine external carotid circulation[246], the present study
was designed to identify the specific subtypes (a1A, a1B and a1D as well as a2A, a2B
and a2C) mediating the above response.  For this purpose, the external carotid vascular
bed vasoconstrictor responses to the a-adrenoceptor agonists, phenylephrine (a1) and
BHT933 (a2), were analysed before and after administration of selective antagonists
at a1- and a2-adrenoceptor subtypes (see Table 1.2).  The results obtained may open
new avenues for the development of future antimigraine agents.
Materials and methods
General
Experiments were carried out in a total of 42 dogs (16-30 kg) not selected for breed or
sex.  The animals were anaesthetised with an intravenous (i.v.) bolus injection of sodium
pentobarbitone (30 mg kg-1) and additional amounts (1 mg kg-1, i.v.) were provided
when required throughout the experiment.  All dogs were intubated with an endotracheal
tube and artificially respired with room air; for this purpose, a Palmer ventilation pump
was used at a rate of 20 strokes min-1 and a stroke volume of 13-16 ml kg-1, as previously
established by Kleinman & Radford[254].  Catheters were placed in the inferior vena
cava via a femoral vein for the administration of antagonists and in the aortic arch via a
femoral artery, connected to a Statham pressure transducer (P23 ID), for the
measurement of blood pressure.
After administration of each antagonist dose, the venous catheter was flushed with
3 ml of saline.  Mean blood pressure (MAP) was calculated from the systolic (SAP)
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and diastolic (DAP) arterial pressures: MAP = DAP + (SAP-DAP)/3.  Heart rate was
measured with a tachograph (7P4F, Grass Instrument Co., Quincy, MA, U.S.A.)
triggered from the blood pressure signal.  The common carotid artery was dissected
free and the corresponding internal carotid and occipital arteries were ligated.
Bilateral cervical vagosympathectomy was systematically performed in order to
prevent possible baroreceptor reflexes produced by the intracarotid infusions of
phenylephrine or BHT933.  These compounds were administered into the carotid
artery by a WPI model sp100i pump (World Precision Instruments Inc., Sarasota, FL,
U.S.A.) with a catheter inserted into the right cranial thyroid artery.  Thereafter, an
ultrasonic flow probe (4 mm R-Series) connected to an ultrasonic T201D flowmeter
(Transonic Systems Inc., Ithaca, N.Y., U.S.A.) was placed around the common carotid
artery and the flow through this artery was considered as the external carotid blood
flow[255].  Blood pressure, heart rate and external carotid blood flow were recorded
simultaneously by a model 7D polygraph (Grass Instrument Co., Quincy, MA,
U.S.A.).  The body temperature of the animals was maintained between 37-38°C.
Experimental protocol
After the animals (n=42) had been in a stable haemodynamic condition for at least 60
min, baseline values of mean blood pressure, heart rate and external carotid blood
flow were determined.  After collecting these data, the animals were divided into two
groups.  The first group (n=36) received consecutive intracarotid infusions
(1 ml min-1 ; during 1 min) of phenylephrine (0.3, 1, 3 and 10 µg min-1) and BHT933
(3, 10, 30 and 100 µg min-1).  At this point, the dogs were subdivided into six subgroups
(n=6 each) and the effects produced by the above infusions of phenylephrine and
BHT933 were elicited again after i.v. treatment with each dose of either:
(i) 5-methylurapidil (100 and 300 µg kg-1); (ii) L-765,314 (100 and 300 µg kg-1);
(iii) BMY7378 (100 and 300 µg kg-1); (iv) BRL44408 (300 and 1000 µg kg-1);
(v) imiloxan (300 and 1000 µg kg-1); or (vi) MK912 (100 and 300 µg kg-1).
The second group (n=6) was subdivided into two subgroups (n=3 each).  The first
subgroup received consecutive intracarotid infusions of phenylephrine (0.3, 1, 3 and
10 µg min-1) as previously described.  Then, the responses elicited by these infusions of
phenylephrine were elicited again after i.v. administration of 5-methylurapidil (100
µg kg-1) and, subsequently, BMY7378 (100 µg kg-1).  Likewise, the second subgroup
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received consecutive intracarotid infusions of BHT933 (3, 10, 30 and 100 µg min-1)
and the responses produced were elicited again after i.v. administration of BRL44408
(1000 µg kg-1) and, subsequently, MK912 (100 µg kg-1).
The dose-intervals between the different doses of agonists ranged between 5 and
15 min, as in each case we waited until the external carotid blood flow had returned
completely to baseline values.  Moreover, after administration of a specific dose of an
antagonist, a period of 15-25 min was allowed to elapse before the responses to the
respective agonists were elicited again.  The dosing with the agonists was sequential,
whereas that with the antagonists was cumulative.  The Ethical Committee of the
CINVESTAV-IPN dealing with the use of animals in scientific experiments approved
the protocols of the present investigation.
Data presentation and statistical analysis
All data in the text, figures and tables are presented as mean±s.e.mean.  The peak
changes in external carotid blood flow were expressed as percent change from baseline.
The difference between the variables within one group of animals was compared using
an analysis of variance (randomised block design) followed by the
Student-Newman-Keuls test[222].  Statistical significance was accepted at P < 0.05
(two-tailed).
Drugs
Apart from the anaesthetic (sodium pentobarbitone), the compounds used in this study
were: L-phenylephrine hydrochloride, BHT933, 5-methylurapidil and BMY7378
dihydrochloride (all purchased from RBI, Zwijndrecht, The Netherlands); L-765,314
(gift: Merck & Co., Inc., West Point, PA, U.S.A.); BRL44408 (gift:
Dr. T.J. Verbeuren; Servier, Suresnes, France); imiloxan hydrochloride (gift: Dr. R.
Eglen; Roche Bioscience, Palo Alto, CA, U.S.A.) and MK912 (gift: Dr.
W.L. Henckler; Merck & Co.; New Jersey, NJ, U.S.A.).  All drugs were dissolved in
physiological saline; a short period of heating was needed to dissolve
5-methylurapidil or L-765,314 (acidified to pH=6.8-7.0 with 0.1 M HCl).  The doses
of the antagonists refer to their respective salts, whilst those of the agonists refer to
their free base.
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Results
Systemic and carotid haemodynamic effects of the different treatments
Baseline values of heart rate, mean arterial blood pressure and external carotid blood
flow in the 42 dogs were, respectively, 131±4 beats min-1, 132±3 mmHg and
134±9 ml min-1.  The systemic and carotid haemodynamic values before and 15-25
min after i.v. administration of the different compounds are shown in Table 7.1.  None
of the compounds produced significant changes under these conditions (P>0.05).
However, immediately after its administration, BRL44408 (1000 µg kg-1) produced a
transient, though significant, increase (35±10%) in mean blood pressure (from
128±13 mmHg to 170±14 mmHg; n=6).  This vasopressor effect, which was not
accompanied by significant changes in heart rate and external carotid blood flow or
conductance (data not shown), returned to baseline values after 25 min.  In contrast,
no immediate haemodynamic changes were observed in the other subgroups.
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Table  7.1. Absolute values of heart rate, mean arterial blood pressure and external carotid blood flow and conductance in anaesthetised dogs
before and after i.v. treatment with 5-methylurapidil (300 µg kg-1), L-765,314 (300 µg kg-1), BMY7378 (300 µg kg-1), BRL44408 (1000 µg kg-1),
imiloxan (300 µg kg-1) or MK912 (300 µg kg-1).
Treatment
(n=6 each)
Heart rate
(beat min-1)
Mean arterial blood
pressure
(mmHg)
External carotid blood flow
(ml min-1)
External carotid
conductance
(ml min-1 mmHg-1)
Before After Before After Before After Before After
5-Methylurapidil 131±5 117±7 136±9 122±8 146±17 103±10 111±18 86±9
L-765,314 130±5 131±5 138±8 138±7 144±28 144±30 112±30 111±30
BMY7378 142±10 134±10 129±8 122±8 124±16 126±20 99±16 106±21
BRL44408 117±13 112±11 128±13 148±10 141±40 102±27 127±48 51±21
Imiloxan 109±5 118±6 131±7 128±10 106±14 131±16 84±15 108±20
MK912 158±12 163±12 133±5 122±11 149±11 135±7 113±9 115±10
Note that none of the above treatments produced significant changes (P>0.05).  The lower doses of the above compounds were similarly without
significant effect.  Non-significant effects were also produced by the administration of 5-methylurapidil followed by BMY7378 or of BRL44408
followed by MK912 (not shown).
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Systemic and haemodynamic changes to the agonists in the different groups of
animals
Intracarotid infusions of phenylephrine (a1-adrenoceptor agonist; 0.3-10 µg min-1 ;
Figure 7.1) and BHT933 (a2-adrenoceptor agonist; 3-100 µg min-1 ; Figure 7.2)
produced dose-dependent decreases in external carotid blood flow (maximal percent
changes were: -64±5 and -68±4%, respectively).  These responses to phenylephrine
and BHT933, which were not accompanied by significant changes in heart rate or
blood pressure (not shown), have been previously demonstrated to remain unaffected
after two i.v. bolus injections of physiological saline[246].
Figure 7.1. The effect of subsequent i.v. administration of 5-methylurapidil
(5MU; 100 and 300 µg kg-1), L-765,314 (L; 100 and 300 µg kg-1), BMY7378
(BMY; 100 and 300 µg kg-1), BRL44408 (BRL; 300 and 1000 µg kg-1), imiloxan
(IMI; 300 and 1000 µg kg-1) or MK912 (MK; 100 and 300 µg kg-1) on the
external carotid vasoconstrictor responses produced by consecutive 1 min
intracarotid (i.c.) infusions of phenylephrine in anaesthetised dogs.
*, P<0.05 vs. corresponding dose in control curve.
Figures 7.1 and 7.2 also show the effects of subsequent i.v. administration of the
antagonists, 5-methylurapidil (a1A), L-765,314 (a1B), BMY7378 (a1D), BRL44408
(a2A), imiloxan (a2B) or MK912 (a2C) on the external carotid vasoconstrictor
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responses produced by the above agonists.  The vasoconstrictor responses to
phenylephrine remained unaffected after L-765,314 (up to a dose of 300 µg kg-1), but
were significantly attenuated after 5-methylurapidil or BMY7378 (both 100 µg kg-1)
(maximal responses: -35±10 and -42±5%, respectively; Figure 7.1, upper panel).  The
blockade produced by 100 µg kg-1 of these antagonists was maximal, since a higher
dose (300 µg kg-1) of either antagonist did not produce a further blockade (maximal
responses: -24±4 and -48±7%, respectively; Figure 7.1, upper panel).  Similarly, a
higher dose of L-765,314 (1000 µg kg-1) did not affect the phenylephrine-induced
vascular responses (data not shown).  It is worth noting that the blockade produced by
the above antagonists was specific, as their corresponding doses did not significantly
modify the external carotid vasoconstrictor responses to BHT933 (Figure 7.2, upper
panel).
Figure 7.2. The effect of subsequent i.v. administration of 5-methylurapidil
(5MU; 100 and 300 µg kg-1), L-765,314 (L; 100 and 300 µg kg-1), BMY7378
(BMY; 100 and 300 µg kg-1), BRL44408 (BRL; 300 and 1000 µg kg-1), imiloxan
(IMI; 300 and 1000 µg kg-1) or MK912 (MK; 100 and 300 µg kg-1) on the
external carotid vasoconstrictor responses produced by consecutive 1 min
intracarotid (i.c.) infusions of BHT933 in anaesthetised dogs.
*, P<0.05 vs. corresponding dose in control curve.
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Moreover, the vasoconstrictor responses to BHT933 remained unaffected after
imiloxan (up to 1000 µg kg-1), but were significantly attenuated after BRL44408
(1000 µg kg-1) or MK912 (100 µg kg-1) (maximal responses: -56±5 and -37±4%,
respectively; Figure 7.2, lower panel).  The blockade produced by 100 µg kg-1 of
MK912 was maximal, since a higher dose (300 µg kg-1) did not produce a further
blockade (maximal response: -28±6%).  It should be highlighted that the antagonism
produced by BRL44408 or MK912 (at the doses mentioned above) was specific, as
they did not significantly modify the external carotid vasoconstrictor responses to
phenylephrine (Figure 7.1, lower panel).  Based on its affinity profile at the different
a2-adrenoceptor subtypes (see Table 1.2), we did not test a higher dose of BRL44408.
It should be pointed out that the decreases in external carotid blood flow produced
by phenylephrine or BHT933 were similar to those observed in the corresponding
vascular conductance (data not shown).
Figure 7.3. The effect of subsequent i.v. administration of: (i) BMY7378 (BMY;
100 µg kg-1) and 5-methylurapidil (5MU; 100 µg kg-1) on the external carotid
vasoconstrictor responses to intracarotid (i.c.) infusions of phenylephrine (left
panel); or (ii) BRL44408 (BRL; 1000 µg kg-1) and MK912 (MK; 100 µg kg-1) on
the vasoconstrictor responses to i.c. infusions of BHT933 (right panel) in
anaesthetised dogs.  *, P<0.05 vs. corresponding dose of agonist in control curve.
**, P<0.05 vs. corresponding dose of agonist after administration of the first
antagonist (i.e. BMY7378 in the left panel or BRL44408 in the right panel).
Figure 7.3 (left panel) shows that the vasoconstrictor responses to phenylephrine
were significantly attenuated by BMY7378 (100 µg kg-1), as previously observed
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(Figure 7.1, upper panel).  It is noteworthy that the subsequent administration of
5-methylurapidil (100 µg kg-1) produced a further blockade of the
phenylephrine-induced responses over the one previously produced by BMY7378
(Figure 7.3, left panel).  By analogy, Figure 7.3 (right panel) shows that the responses
to BHT933 were significantly attenuated by BRL44408 (1000 µg kg-1), as previously
shown (Figure 7.2, lower panel).  The subsequent administration of MK912
(100 µg kg-1) produced a further blockade of the responses to BHT933 over the one
previously produced by BRL44408 (Figure 7.3, right panel).
Discussion
General
According to the International Union of Pharmacology Subcommittee on
Nomenclature for Adrenoceptors, a-adrenoceptors have been divided into a1-  and
a2-adrenoceptors with subdivisions into a1A, a1B and a1D and a2A, a2B and a2C
subtypes, respectively[17, 26, 31, 33, 245].  We recently demonstrated that both a1-
and a2-adrenoceptors mediate vasoconstrictor responses in the porcine[219] as well as
canine[246] carotid arterial bed.  The present study set out to identify which a1- and
a2-adrenoceptor subtypes mediate this latter vasoconstrictor response, employing
antagonists with a moderate to high subtype selectivity: 5-methylurapidil (a1A),
L-765,314 (a1B), BMY7378 (a1D), BRL44408 (a2A), imiloxan (a2B) and MK912
(a2C); Table 1.2.  Our results show that mainly a1A- and a1D-adrenoceptors mediate
the canine external carotid vasoconstrictor responses to phenylephrine, whereas those
to BHT933 are mainly mediated by a2A- and a2C-adrenoceptors.  Admittedly, the
differences in antagonist potency observed against phenylephrine- and
BHT933-induced vascular responses may be partly due to differences in the
metabolism of antagonists or by affinity differences between canine and human a1-
and a2-adrenoceptor subtypes; however, these data are not available at present.
Systemic and carotid haemodynamic effects of the treatments
Apart from the a2A-adrenoceptor antagonist, BRL44408, none of the antagonists used
in this investigation produced any significant haemodynamic response.  Even with
BRL44408, the immediate increase in blood pressure was short lasting.  This effect
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may have been due to a direct activation of vascular a1-adrenoceptors, as shown with
other a2-adrenoceptor antagonists in anaesthetised rats[263].  Alternatively, such a
vasopressor effect could also be explained by a blockade of prejunctional
a2-adrenoceptors leading to an enhancement of neuronal release of
noradrenaline[201].
Role of a1- and a2-adrenoceptor subtypes in canine external carotid vasoconstriction
The blockade produced by 5-methylurapidil and BMY7378 (both 100 µg kg-1) of the
responses to phenylephrine, being maximal as a higher dose (300 µg kg-1) did not
produce a further blockade, was selective as these compounds failed to antagonise the
responses to BHT933.  These results favour a predominant involvement of a1A- and
a1D-adrenoceptors.  Admittedly, since 5-methylurapidil shows a reasonable affinity at
a1A- and a1D-adrenoceptors (pKi: 9.0 and 7.9, respectively), we cannot categorically
exclude a possible blockade of phenylephrine-induced responses resulting from
antagonism of both receptors.  However, the fact that 5-methylurapidil produced a
further blockade of the responses to phenylephrine after a high dose of BMY7378
suggests the additional role of a1A-adrenoceptors.  Thus, after BMY7378 and
5-methylurapidil (both 100 µg kg-1) the maximal response to phenylephrine (-20±8%;
Figure 7.3) did not significantly differ from that after prazosin (maximal response:
-11±3%[246]).  In the light of these findings, the role of a1B-adrenoceptors seems
questionable, a view consistent with the fact that L-765,314 (up to 1000 µg kg-1; data
not shown) did not affect the responses to phenylephrine.
The blockade produced by BRL44408 (1000 µg kg-1) and MK912 (100 and
300 µg kg-1) of the responses to BHT933 was selective as these compounds failed to
antagonise the responses to phenylephrine.  It should be pointed out that the blockade
after 100 µg kg-1 of MK912 was maximal, since a higher dose (300 µg kg-1) did not
produce a further blockade.  We decided not to test a higher dose of BRL44408, since
it displays a reasonable affinity at a2A-adrenoceptors (pKi: 8.2) and the doses used
(300 and 1000 µg kg-1) should be sufficient to block a2A-adrenoceptors.  These results
imply the coexistence of a2A- and a2C-adrenoceptor subtypes.  This suggestion gains
weight when considering that MK912 produced a further blockade of the responses to
BHT933 (particularly at its highest dose) after the blockade produced by a high dose
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of BRL44408.  Accordingly, after BRL44408 (1000 µg kg-1) and MK912
(100 µg kg-1) the maximal response to BHT933 (-20±3%; Figure 7.3) did not
significantly differ from that after rauwolscine (maximal response: -15±3;[246]).
Considering the above, the role of a2B-adrenoceptors seems unlikely, a view
reinforced by the fact that imiloxan (up to 1000 µg kg-1) failed to block the responses
to BHT933.
Resemblance of the canine external carotid a1A, a1D, a2A and a2C-adrenoceptors to
other contractile a1- and a2-adrenoceptor subtypes
As reviewed by Vargas & Gorman[44] as well as Docherty[33], a number of studies
shows that both a1- and a2-adrenoceptor subtypes can mediate smooth muscle
contraction.  Some of the pharmacological preparations employed include rat vas
deferens (a1A[264]), rat aorta (a1D[152]), porcine common digital artery (a2A[265]) and
dog saphenous vein (a2C[266]).  Other blood vessels suggest a functional coexistence
a1A- and a1D-adrenoceptor subtypes, e.g. rat renal artery[267].  The a1B and a2B
subtypes, although not involved in canine external carotid vasoconstriction, seem to
mediate vasoconstriction of the rabbit cutaneous resistance arteries (a1B[268]) and the
rat kidney (a2B[33]).
In a number of tissues, admittedly, a2-adrenoceptors contribute to a predominantly
a1-adrenoceptor mediated response[33].  However, to the best of our knowledge, the
present study seems to be one of the first to show in vivo the functional role of
specific a1 (a1A and a1D)- and a2 (a2A and a2C)-adrenoceptor subtypes mediating
vasoconstriction in a vascular preparation (the canine external carotid bed).
Possible clinical implications
To date, all acutely-acting antimigraine agents, including the triptans and the ergots
alkaloids, produce a potent vasoconstriction in the carotid circulation of dogs [166,
177, 269] and pigs[161, 167].  In contrast to the well-established role of serotonin
5-HT1B receptors in the carotid vasoconstrictor effects of the triptans [178, 217], the
ergots seem to involve both 5-HT1B and a2-adrenoceptors[177].   However,
irrespective to the mechanisms involved, a selective vasoconstriction within the
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carotid circulation is an important property of antimigraine drugs.  Therefore, we
submit that the development of selective agonists at a1A, a1D, a2A and
a2C-adrenoceptor subtypes may have potential therapeutic usefulness in the treatment
of migraine.
Taken together, the present results suggest that both a1A- and a1D-adrenoceptors
mediate the canine external carotid vasoconstrictor responses to phenylephrine, while
those to BHT933 are mainly mediated by a2A- and a2C-adrenoceptors.
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Chapter 8
Pharmacological profile of the mechanisms involved in the external
carotid vascular effects of the antimigraine agent isometheptene in
anaesthetised dogs
Abstract    The present study set out to investigate the external carotid
vascular effects of isometheptene in vagosympathectomised dogs,
anaesthetised with pentobarbital. 1 min intracarotid (intra-arterial; i.a.)
infusions of isometheptene (10, 30, 100 and 300 µg min-1) produced
dose-dependent decreases in external carotid blood flow, without
affecting blood pressure or heart rate.  The vasoconstrictor responses to
100 and 300 µg min-1  of isometheptene were clearly attenuated in
animals pretreated with reserpine (5000 µg kg-1).  Moreover, after
prazosin (an a1-adrenoceptor antagonist; 100 µg kg-1), the responses to
isometheptene remained unaltered in either untreated or reserpine-treated
dogs.  In contrast, the responses to isometheptene were attenuated by
rauwolscine (an a2-adrenoceptor antagonist; 300 µg kg-1) in untreated
animals, and were practically abolished in reserpine-treated dogs. Further
investigation into the specific a2-adrenoceptor subtypes, using selective
antagonists, showed that BRL44408 (a2A) and MK912 (a2C) markedly
attenuated this response, while imiloxan (a2B) was ineffective.  The
involvement of 5-HT1B and 5-HT1D receptors seems highly unlikely since
antagonists at 5-HT1B (SB224289) and 5-HT1D (BRL15572) receptors
(both at 300 µg kg-1) were ineffective.  On this basis, it is concluded that
isometheptene-induced canine external carotid vasoconstriction is
mediated by both indirect (a tyramine-like action) and direct (acting at
receptors) mechanisms, which mainly involve a2A- and
a2C-adrenoceptors.  The involvement of a1- and a2B-adrenoceptors as
well as 5-HT1B/1D receptors seems limited, if any.
Based on: Willems et al., Naunyn-Schmied. Arch. Pharmacol. (2000) Submitted.
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Introduction
Based on several animal studies, it has been suggested that vasoconstriction in the
carotid circulation is predictive for antimigraine activity[166, 216].  Indeed, the
triptans (e.g. sumatriptan) and the ergots (ergotamine and dihydroergotamine)
produce potent vasoconstriction in porcine (arteriovenous anastomoses), rabbit and
canine (external) carotid vasculature[177, 215].  Whereas the sumatriptan-induced
carotid vasoconstriction in anaesthetised dogs and pigs is mainly mediated by
5-HT1B receptors[178, 215, 217], the responses to the ergots in anaesthetised dogs also
involve a2-adrenoceptors[177].  We have shown that both a1- and a2-adrenoceptors
mediate vasoconstriction in the carotid vasculature of anaesthetised pigs [219] and
dogs[246].  The pharmacological profile of a1- and a2-adrenoceptors mediating
canine external carotid vasoconstriction resembles that of the a1A/D- and
a2A/C-adrenoceptor subtypes, respectively[270].
In the light of the above developments, it is important to examine the
pharmacological properties isometheptene (for chemical formulae, see Figure 8.1),
which is employed, either alone or in combination with an analgesic (acetaminophen,
paracetamol) and a sedative (dichloralphenazone), in the treatment of migraine[271-
275].
CH3
CH3
NH
H3C
CH3
*
It is believed that isometheptene owes its therapeutic effect to a sympathomimetic
action leading to cranial blood vessel vasoconstriction, which is observed at dose
levels below those affecting arterial blood pressure[272].  Indeed, we have also
reported that isometheptene can constrict carotid arteriovenous anastomoses in
anaesthetised cats[212].  Therefore, the present study was designed to investigate
whether isometheptene can produce canine external carotid vasoconstriction in a
model predictive for antimigraine activity and, if so, to elucidate its mechanism of
Figure 8.1. Chemical
formulae of isometheptene
(methyl-iso-octenylamine); a
racemic mixture of two
stereoisomers (chiral centre
denoted by asterisks).
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action using different antagonists at a1-, a2-adrenergic and 5-HT1B/1D receptor
subtypes (Table 1.2) and the monoamine depletor reserpine.
Materials and methods
General
Experiments were carried out in a total of 59 dogs (15-31 kg-1) not selected for breed
or sex.  The animals were anaesthetised with an intravenous (i.v.) bolus injection of
sodium pentobarbitone (30 mg kg-1) and additional amounts (1 mg kg-1, i.v.) were
provided when required throughout the experiment.  All dogs were intubated with an
endotracheal tube and artificially respired with room air; for this purpose, a Palmer
ventilation pump was used at a rate of 20 strokes min and a stroke volume of 13-16
ml kg-1, as previously established by Kleinman & Radford[254].  Catheters were
placed in the inferior vena cava via a femoral vein for the administration of antagonist
doses and in the aortic arch via a femoral artery, connected to a Statham pressure
transducer (P23 ID), for the measurement of blood pressure.  After the administration
of each treatment (vehicle or antagonists), the venous catheter was flushed with 3 ml
of saline.  Mean blood pressure (MAP) was calculated from the systolic (SAP) and
diastolic (DAP) arterial pressures: MAP = DAP + (SAP-DAP)/3.  Heart rate was
measured with a tachograph (7P4F, Grass Instrument Co., Quincy, MA, U.S.A.)
triggered from the arterial blood pressure signal.  The common carotid artery was
dissected free and the corresponding internal carotid and occipital arteries were
ligated.  Cervical vagosympathectic trunks were cut in order to prevent possible
baroreceptor reflexes produced by isometheptene.  Thereafter, an ultrasonic flow
probe (4 mm R-Series), connected to an ultrasonic T201D flowmeter (Transonic
Systems Inc., Ithaca, N.Y., U.S.A.), was placed around the common carotid artery and
the blood flow through this artery was considered as the external carotid blood
flow[255].  A catheter was inserted into the cranial thyroid branch of the common
carotid artery for infusions (1 ml min, for 1 min) of isometheptene using a Harvard
model 901 pump (Harvard Apparatus Co. Inc., Millis, MA, U.S.A.).  Blood pressure,
heart rate and external carotid blood flow were recorded simultaneously by a model
7D polygraph (Grass Instrument Co., Quincy, MA, U.S.A.).  The body temperature of
the animals was maintained between 37-38°C.
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Experimental protocol
After the animals had been in a stable haemodynamic condition for at least 60 min,
baseline values of mean blood pressure, heart rate and external carotid blood flow
were determined.  The animals were then divided into two groups: the first remained
untreated (n=48) and the second was pretreated with reserpine (5 mg kg-1, i.p.) 24 h
prior to the start of experiments (n=11).  The animals in first group were further
divided into eight subgroups (n=6 each), receiving i.v. infusions (1 ml min-1, during
5 min) of vehicle (physiological saline; 0.03 ml kg-1), prazosin (100 µg kg-1),
rauwolscine (300 µg kg-1), BRL44408 (1000 µg kg-1), imiloxan (1000 µg kg-1),
MK912 (300 µg kg-1), SB224289 (300 µg kg-1) or BRL15572 (300 µg kg-1).  The
reserpinised animals (second group) received either vehicle (n=5), prazosin (n=3) or
rauwolscine (n=3).  Subsequently, after a waiting period of 15 min, each animal
received consecutive intracarotid infusions (1 ml min-1 ; during 1 min) of
isometheptene (10, 30, 100 and 300 µg min-1) and the changes in systemic and carotid
haemodynamic variables were determined.  The dose-intervals between the different
doses of isometheptene ranged between 5 and 15 min, as in each case we waited until
the external carotid blood flow had returned to baseline values.  Moreover, after
administration of a specific dose of an antagonist, a period of 15-25 min was allowed
to elapse before the responses to isometheptene were elicited again.
The Ethical Committee of CINVESTAV-IPN dealing with the use of animals in
scientific experiments approved the protocols of the present investigation.
Data presentation and statistical analysis
All data in the text and figures are presented as mean±s.e.mean.  The peak changes in
external carotid blood flow were expressed as percent changes from baseline.  The
significance of the percent changes induced by the different doses of isometheptene
within one (sub)group was evaluated with Duncan's new multiple range test, once an
analysis of variance (randomised block design) had revealed that the samples
represented different populations[222].  Percent changes caused by isometheptene in
the different treatment groups were compared to the percent changes caused by the
corresponding isometheptene dose in the vehicle-treated group using Student's
unpaired t-test.  Statistical significance was accepted at P<0.05 (two-tailed).
- 5 -
Drugs
Apart from the anaesthetic sodium pentobarbitone, the compounds used in this study
were: isometheptene (Carnick Laboratories, Cedar Knolls, NJ, USA), prazosin
hydrochloride (Bufa Chemie b.v., Castricum; The Netherlands), rauwolscine
hydrochloride, reserpine (RBI, Zwijndrecht, The Netherlands), BRL44408
(2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole; gift:
Dr. T.J. Verbeuren; Servier, Suresnes, France), imiloxan hydrochloride (gift:
Dr. R. Eglen; Roche Biosience, Palo Alta, CA, USA), MK912 ((2S,12bS)- 1’3’-
dimethylspiro (1,3,4,5’,6,6’,7,12b-octahydro- 2H-benzo[b] furo[2,3-a] quinazoline)-
2,4-pyrimidin-2’-one (L-657743; gift: Dr. W.L. Henckler; Merck & Co.; NJ, USA),
SB224289 (2,3,6,7-tetrahydro-1’-methyl-5-[2’-methyl-4’(5-methyl-1,2,4-oxadiazol-
3-yl)biphenyl-4-carbonyl]furo[2,3-f]indole-3-spiro-4`-piperidine hydrochloride) and
BRL15572 (1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl)
piperazine] hydrochloride (both gifts: Dr. A.A. Parsons, SmithKline Beecham
Pharmaceuticals, Harlow, Essex, UK).  Reserpine was dissolved in 5% v v-1 acetic
acid, while 20% v v-1 propylene glycol was used for SB224289 and BRL15572.  All
other drugs were dissolved in physiological saline (vehicle).  A short period of heating
was needed to dissolve prazosin.  The doses of the antagonists refer to their respective
salts, while those of isometheptene and reserpine refer to free base.
Results
Systemic and carotid haemodynamic changes following administration of antagonists
Baseline values of heart rate, mean arterial blood pressure and external carotid blood
flow in anaesthetised dogs (group 1, n=48) were: 149±5 beats min-1, 132±3 mmHg
and 158±7 ml min-1, respectively.  In animals treated with reserpine (n=11), heart rate
(89±6 beats min-1), mean arterial blood pressure (87±7 mmHg) and external carotid
blood flow (89±7 mlmin-1) were significantly (P<0.05) lower.
The systemic and carotid haemodynamic values in anaesthetised dogs before and
15-25 min after i.v. administration of vehicle (saline) or the different treatments
(prazosin, rauwolscine, BRL44408, imiloxan, MK912, SB224289 and BRL15572)
remained unchanged (data not shown), except for a moderate hypotensive response
after prazosin (13±5%). However, immediately after its administration, BRL44408
(1000 µg kg-1) produced an increase (35±10%) in mean arterial blood pressure.  This
vasopressor effect, which was not accompanied by significant changes in heart rate or
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external carotid blood flow (data not shown), returned to baseline values within
25 min.
Systemic and carotid haemodynamics of isometheptene
As shown in Figure 8.2, intracarotid infusions of isometheptene (10, 30, 100 and
300 µg min-1) produced a dose-dependent decrease in external carotid blood flow
(maximal response: 60±3%); no changes were observed in blood pressure and heart
rate (data not shown).  At doses that selectively block a1- and a2-adrenoceptors,
respectively[246], prazosin (100 µg kg-1) did not modify, while rauwolscine
(300 µg kg-1) clearly attenuated the responses to isometheptene.  Furthermore,
pretreatment of the animals with the monoamine depletor reserpine produced a
marked attenuation of the isometheptene-induced responses.  Whereas subsequent
treatment of the reserpinised animals with prazosin was without any effect, the
external carotid vasoconstrictor effect of isometheptene was absent in animals treated
with rauwolscine.
Figure 8.2. Effects of prazosin (100 µg kg-1) and rauwolscine (300 µg kg-1) on
the external carotid vasoconstrictor effects produced by consecutive 1-min
intracarotid (i.c.) infusions of isometheptene in control (A and B, respectively)
and in animals treated with reserpine (5000 µg kg-1, i.p. 24 h prior to the
experiments) (C and D, respectively). *, P<0.05 vs.  corresponding dose in
control curve;  **, P<0.05 vs.  corresponding dose in reserpine curve.
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We did not investigate the involvement of the a1-adrenoceptor subtypes (a1A, a1B
and a1D), since prazosin was ineffective against isometheptene.  On the other hand,
because rauwolscine produced a marked attenuation, the involvement of specific
a2-adrenoceptor subtypes (a2A, a2B, a2C) in isometheptene-induced carotid
vasoconstriction in anaesthetised dogs was elucidated using a2-adrenoceptor
subtype-selective antagonists, BRL44408 (a2A), imiloxan (a2B) and MK912 (a2C); see
Table 1.2.  As presented in Figure 8.3, imiloxan (1000 µg kg-1) was ineffective, but
BRL44408 (1000 µg kg-1) as well as MK912 (300 µg kg-1) markedly attenuated
isometheptene-induced decreases in external carotid blood flow (maximal response:
-29±4 or -37±3%, respectively).
Figure 8.3. Effects of BRL44408 (1000 µg kg-1; left panel), imiloxan
(1000 µg kg-1; middle panel) and MK912 (300 µg kg-1; right panel) on the
external carotid vasoconstrictor effects produced by consecutive 1-min
intracarotid (i.c.) infusions of isometheptene in anaesthetised dogs. *, P<0.05 vs.
corresponding dose in control curve.
The selective 5-HT1B (SB224289) and 5-HT1D (BRL15572) receptor antagonists,
both at a dose of 300 µg kg-1, did not attenuate the isometheptene-induced external
carotid vasoconstriction (Figure 8.4).
As mentioned before, mean arterial blood pressure (or heart rate) was not affected
by intracarotid infusions of isometheptene in the present experiments.  Therefore, the
changes in external carotid blood flow described above were qualitatively and
- 8 -
quantitatively similar to those observed in external carotid vascular conductance (data
not shown).
Figure 8.4.  Effects of i.v. administration of SB224289 (300 µg kg-1; left panel)
or BRL15572 (300 µg kg-1; right panel) on the external carotid vasoconstrictor
effects produced by consecutive 1-min intracarotid (i.c.) infusions of
isometheptene in anaesthetised dogs.  There was no significant difference
(P>0.05) between the effects of isometheptene in control and antagonist-treated
animals.
Discussion
Systemic and carotid haemodynamic changes after antagonists
As demonstrated previously[246], treatment of the animals with vehicle (saline) did
not cause any change in blood pressure, heart rate or external carotid blood flow in
anaesthetised dogs.  The lower baseline in heart rate and blood pressure observed in
animals pretreated with reserpine is apparently due to depletion of sympathetic
neurotransmitter noradrenaline[201].
The slight hypotension in control (reserpine-untreated) animals after prazosin can
be explained by blockade of a1-adrenoceptors that regulate vascular tone and blood
pressure[33, 44].  On the other hand, the observed short-lasting hypertension after
BRL44408 (35±10%), which was not accompanied by any change in heart rate or
external carotid blood flow, was returned to baseline value (P>0.05) after 25 min.
This response can most likely be explained by activation of vascular
a1-adrenoceptors, as reported in anaesthetised rats[263].  The other antagonists used
in the present study were devoid of any systemic or carotid haemodynamic changes.
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External carotid vascular effects of isometheptene
Intracarotid infusions of isometheptene produced a dose-dependent vasoconstriction
in the external carotid circulation in anaesthetised dogs.  Since this vasoconstrictor
response was not accompanied by changes in heart rate or mean arterial blood
pressure, it may be concluded that isometheptene produced a cranio-selective
vasoconstriction.  In view of the relevance that this animal model has had in the
development and pharmacological characterisation of antimigraine drugs[161, 162,
167, 177, 269], the present results may suggest that the clinical efficacy of
isometheptene in migraine may be due to its vasoconstrictor properties, as previously
suggested[212, 272-274, 276].  The fact that reserpine markedly attenuated
isometheptene-induced vasoconstrictor responses strongly suggests that a part of the
carotid vasoconstrictor effect is due to an indirect sympathomimetic action[201].  The
dose of reserpine (5 mg kg-1, i.p.) is sufficient to abolish the external carotid
vasoconstriction produced by tyramine, in the same experimental set-up (Villalón,
unpublished observations).
Involvement of a1/2-adrenoceptors
Recently, we have shown that both a1- and a2-adrenoceptors are operative in vivo and
can mediate carotid vasoconstriction in anaesthetised pigs and dogs[219, 246].
Subsequent investigations revealed that the pharmacological profile of a1- and
a2-adrenoceptor subtypes mediating canine external carotid vasoconstriction
resembles that of a1A/D- and a2A/C-adrenoceptors, respectively[270].  In the present
experiments, we observed that isometheptene-induced carotid vasoconstrictor
responses remained unchanged after prazosin (100 µg kg-1), but were clearly
diminished by rauwolscine (300 µg kg-1) in both untreated and reserpine-treated dogs.
The doses of prazosin and rauwolscine used by us are sufficient to selectively abolish
carotid vasoconstrictor effects of phenylephrine[219] and BHT933 (6-ethyl-
 5,6,7,8- tetrahydro- 4H- oxazolo [4,5-d] azepin-2-amine dihydrochloride[219]),
respectively.  It may also be noted that rauwolscine, which only partly affected
isometheptene responses in untreated dogs, was able to completely eliminate its
reserpine-resistant part (see Figure 8.2).  These results demonstrate that, like
amphetamine and ephedrine [201], isometheptene behaves as a dual-acting
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sympathomimetic agent.  Unlike these two compounds that seem to act on both a1-
and a2-adrenoceptors[201], isometheptene only stimulated a2-adrenoceptors in this
vascular bed.  Furthermore, it is interesting to recall that amphetamine, ephedrine and
isometheptene all have chiral centres and, therefore, it could well be that one of the
stereoisomers releases noradrenaline, while the other interacts with the postsynaptic
receptors.
Having established the role of a2-adrenoceptors, we subsequently investigated the
subtype-specificity of isometheptene using relatively selective antagonists at a2A-
(BRL44408), a2B- (imiloxan) and a2C- (MK912) adrenoceptors (for affinity constants,
see Table 1).  While imiloxan was ineffective, both BRL44408 and MK912 markedly
attenuated the vascular effects of isometheptene (see Figure 8.3).  These observations
suggest that carotid vasoconstriction by isometheptene, as is the case with
BHT933[270], is mediated mainly by a2A- and a2C-adrenoceptors.
Involvement of 5-HT1B/1D receptors
Several studies have shown that the vasoconstrictor effect of triptans is mediated
predominantly by the 5-HT1B receptor[168, 215, 216, 250, 270].  Recently,
SB224289[277] and BRL15572[278] have been shown to possess high degree of
selectivity for the human 5-HT1B and 5-HT1D receptors, respectively.  Since
SB224289  (300 µg kg-1), which effectively blocks the carotid vascular effect of
sumatriptan in the dog[217], was ineffective against isometheptene, the role of
5-HT1B receptors can be ruled out.  In view of the ineffectiveness of BRL15572, the
same can probably be said about the involvement of the 5-HT1D receptor.  However,
we must point out to a caveat that we do not know the affinity constant of BRL15572
for the canine 5-HT1D receptor; our recent data show that this compound,
unexpectedly, has little affinity at the cloned porcine 5-HT1D receptor[279].
Based on the present results, we conclude that intracarotid infusion of
isometheptene produces a cranio-selective vasoconstriction in the canine external
carotid vascular bed, via both direct and indirect sympathomimetic mechanisms.  The
direct mechanism seems to involve a2A- and a2C-adrenoceptors.
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Chapter 9
Summary, general discussion, and implications for future research
Summary of the thesis
Belonging to the academic thesis: “Characterisation of a-adrenoceptor subtypes in
the carotid vasculature: possible implications to migraine therapy”
This thesis mainly focusses on the possible role of a-adrenoceptor mediating
vasoconstriction in the carotid vasculature of anaesthetised pigs and dogs.  For this
purpose we investigated the possible involvement of a1- and a2-adrenoceptors and
their respective subtypes (a1A, a1B, a1D and a2A, a2B, a2C), using selective agonists
and antagonists.  Since vasoconstriction in these models seems predictive for
antimigraine activity, we made a correlation between the outcome of the present
studies and their possible relevance to migraine therapy.  However, these implications
(see below) need further validation in humans.
Chapter 1 summarises the current pharmacological aspects of a–adrenoceptors in
general, that of a1- and a2-adrenoceptors and their respective subtypes.  Furthermore,
the potential therapeutic application of drugs interacting with a-adrenoceptors, with
special emphasis of their possible role in migraine therapy, has been discussed briefly.
a1-Adrenoceptors are mainly located postsynaptically on smooth muscles and
stimulation of these receptors causes vasoconstriction of vascular and non-vascular
tissues, a response mainly produced by an increase in inositol triphosphate (IP3)
turnover and cellular Ca2+-levels.  Even though the a1-adrenoceptor subtypes are
regarded pharmacologically different, comparable pharmacological characteristics
have been reported for these receptors (Table 1.1).  The distribution of specific
a1-adrenoceptor subtypes in the peripheral and central vasculature and their possible
role in the regulation of physiological responses, such as blood pressure, has been a
matter of great interest.  However, this has been hampered due to a controversy in the
relationship between the pharmacologically defined (native) subtypes and the cDNA
(recombinant) clones.  Following cloning of human a1-adrenoceptor subtypes and the
development of subtype-selective ligands (see Table 1.2), it is now generally agreed
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that the three subtypes (a1A, a1B and a1D) can be distinguished pharmacologically in
various tissues.  Because of the fact that specific a1-adrenoceptor subtypes play an
important role in the regulation of blood pressure and prostate tone, several
pharmaceutical companies have developed selective ligands as putative therapeutic
agents (e.g. treatment of hypertension or benigh prostatic hypertrophy).  Several lines
of evidence suggest the existence of some other a1-adrenoceptor subtypes (e.g. a1L),
however, these putative receptors lack full characterisation based on structural
(structure of receptor), operational (functional responses of ligands/receptor) and
transductional information (signal transductional pathways).
Already since the 1970’s, it is known that a2-adrenoceptors are located both pre-
and postsynaptically (see Table 1.3). Presynaptic a2-adrenoceptors can regulate
neurotransmitter (e.g. noradrenaline) release, which is mediated by a2A- and/or
a2C-adrenoceptor subtypes, depending on species and tissue.  Even though stimulation
of postsynaptic a2-adrenoceptors has been known to produce vasopressor responses,
little is known about the individual contribution of the three known a2-adrenoceptors
subtypes (a2A, a2B and a2C).  Nevertheless, it has been reported that
a2B-adrenoceptors mediate vasopressor responses in anaesthetised mice, whereas
a2C-adrenoceptors mediate noradrenaline-induced contraction of human isolated
saphenous vein.  Common difficulties experienced in distinguishing specific
a2-adrenoceptor subtype(s) mediating a physiological response include diversity in
signal-transduction mechanisms, co-expression of these subtypes and the lack of
highly subtype-selective ligands (especially antagonists). Recently, several
moderately selective antagonists have been developed (see Table 1.2), which may
help resolve these matters.  Eventually, this information may lead to the development
of novel and/or better (fewer side effects) therapeutic agents acting directly at specific
a2-adrenoceptor subtypes.
Since it has been shown that vasoconstriction in the carotid vasculature seems
predictive for antimigraine activity, the possibility of a-adrenoceptors as a new
avenue for migraine therapy has been discussed.  The following chapters are designed
to elucidate this matter in greater detail.
Chapter 2 addresses the question whether a-adrenoceptors mediate porcine carotid
vasoconstriction, with special emphasis on carotid arteriovenous anastomoses.  To
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elucidate this matter in more detail, we selectively stimulated a1- and
a2-adrenoceptors by, respectively, phenylephrine (a1-adrenoceptor agonist) and
BHT933 (a2-adrenoceptor agonist), which were administered via the common carotid
artery.  Without causing major systemic haemodynamic changes, both agonists
produced dose-dependent vasoconstriction of carotid arteriovenous anastomoses
without affecting the distribution of carotid blood flow to the different cranial tissues.
Prior treatment of the animals with prazosin (a1-adrenoceptor antagonist) and
rauwolscine (a2-adrenoceptor antagonist) selectively abolished the vascular effects of
phenylephrine and BHT933, respectively.
These results clearly show that both a1- and a2-adrenoceptors can mediate
vasoconstriction of carotid arteriovenous anastomoses in anaesthetised pigs.  This
knowledge could be helpful in developing future therapy for migraine.
Chapter 3 sets out to further characterise a1-adrenoceptor subtypes that mediate
vasoconstriction in the carotid arterial bed of anaesthetised pigs.  We analysed the
effects of selective antagonists (5-methylurapidil, L-765,314 and BMY7378,
respectively) at a1A-, a1B- and a1D-adrenoceptors on the carotid arteriovenous
anastomotic vasoconstriction produced by intracarotid infusions of phenylephrine in
anaesthetised pigs. 5-Methylurapidil and BMY7378 (both partially) and L-765,314
(completely) attenuated this response, in doses (300 and 1000 µg kg-1) sufficient to
block their respective receptors.  It must be noted that the effect produced by the
highest dose of BMY7378 is likely to be due to a1B-adrenoceptor blockade.
These results suggest the involvement of both a1A- and a1B-adrenoceptors in the
phenylephrine-induced carotid vasoconstriction, while that of a1D-adrenoceptors is
limited (if any).  The a1B-adrenoceptor may turn out to be an interesting target for
future antimigraine drugs, especially when considering that these receptors, in
contrast to the a1A-adrenoceptor subtype, do not seem to be involved much in the
vasoconstriction of the peripheral blood vessels.  Indeed, our results show that the
vasopressor effect caused by intravenous bolus injections of phenylephrine is
mediated by a1A-adrenoceptors, but is not affected by a1B-adrenoceptor blockade,
which is in agreement with results obtained in other species, including man.
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Chapter 4 addresses the receptors involved in the total carotid and arteriovenous
anastomotic vasoconstriction produced by intracarotid infusions of the
a1A-adrenoceptor agonist A61603, using the same experimental set up as the
described in the previous two chapters.  Except for A61603 (a1A), selective agonists
at the different a1-adrenoceptor subtypes are currently unavailable.  As described in
the previous chapter, a1A-adrenoceptors mediate phenylephrine-induced
vasoconstriction in the systemic and carotid circulation of anaesthetised pigs.  In order
to verify this hypothesis, we decided to investigate the vascular effects of A61603 in
this model.  A61603 produced a dose-dependent vasopressor response, either by an
intracarotid or an intravenous route of administration, accompanied by a
dose-dependent carotid vasoconstriction.  Unexpectedly, 5-methylurapidil
(a1A-antagonist) did not attenuate the carotid vascular effects to A61603, whereas it
slightly attenuated the observed vasopressor response after intravenous bolus
injections of A61603.  Furthermore, other antagonists at known vasoconstrictor
receptors, i.e. prazosin (a1), a combination of prazosin and rauwolscine (a2),
phentolamine (a), GR127935 (5-HT1B/1D) or ketanserin (5-HT2) alone or in
combination, also did not produce major changes in above-mentioned responses.
Exclusion of these receptors in these responses is important when considering that
methiothepin, a 5-HT1/2 antagonist, partially attenuated the carotid vasoconstriction
and abolished the vasopressor responses produced by A61603.
Taken together, the present results show that A61603 does not behave as a potent
and selective a1A-adrenoceptor agonist in the pig and that the vasoconstriction of
porcine carotid arteriovenous anastomoses by A61603 is primarily mediated by a
novel methiothepin-sensitive receptor/mechanism.  A selective agonist at this novel
receptor, without causing major systemic haemodynamic changes (e.g. hypertension),
could be successful in the therapy of migraine.
Chapter 5 assesses the antimigraine potential of the newly developed a-adrenoceptor
agonist S19014 by analysing its systemic and carotid haemodynamic effects in
anaesthetised pigs.  S19014 displays high (nanomolar) affinity for a1- and
a2-adrenoceptors and produces an a-adrenoceptor-mediated vasoconstriction of
several isolated blood vessels.  Intravenous administration of S19014 produced a
small, short-lasting hypertension accompanied by a long-lasting, dose-dependent
- 5 -
vasoconstriction of carotid arteriovenous anastomoses in anaesthetised pigs.  Whereas
treatment of the animals with prazosin was ineffective, rauwolscine markedly
attenuated the carotid vasoconstrictor response and produced a rightward shift of the
S19014-induced vasopressor response curve.  Subsequent studies showed that S19014
produced only minor changes in the distribution of cardiac output in anaesthetised
pigs, which suggests few vascular side-effects when tested in humans.
These results show that mainly a2-adrenoceptors mediate the S19014-induced
vasoconstriction of porcine carotid arteriovenous anastomoses and the short-lasting
hypertension.  For this reason, S19014 could be effective in aborting migraine attacks,
however, further studies have to be conducted to evaluate the clinical relevance of
potential side-effects (hypertension) in humans.  In this context, the development and
evaluation of other, more subtype-selective, potent and efficacious (full agonists)
a2-adrenoceptor agonists are awaited with great interest.
Chapter 6 investigates the possible external carotid effects of adrenaline and
noradrenaline and the receptors involved in anaesthetised dogs.  It has been known for
several decades that the endogenous catecholamines, adrenaline and noradrenaline
produce their vascular effects via a- (vasoconstriction) and b-adrenoceptors
(vasodilatation).  Whereas the effects of serotonin (5-HT) and its receptors in the
canine external carotid vasculature has been well characterised pharmacologically,
little is known about the effects of these catecholamines in this vascular bed.
Consecutive 1-min intracarotid infusions of either adrenaline or noradrenaline
produced equipotent, dose-dependent external carotid vasoconstriction, without
affecting heart rate or blood pressure.  These responses, being mimicked by
phenylephrine (a1-adrenoceptor agonist) and BHT933 (a2-adrenoceptor agonist),
remained unaffected by administration of saline. Treatment of the animals with
phentolamine (non-selective a-adrenoceptor antagonist) revealed a vasodilator
component to adrenaline and noradrenaline, which was subsequently abolished by
propranolol (non-selective b-adrenoceptor antagonist).  Similarly, rauwolscine partly
attenuated the external carotid vascular effects of both adrenaline and noradrenaline,
whereas subsequently administration of prazosin abolished these effects and revealed
vasodilator responses to these sympathomimetic agents.  In line with these findings,
rauwolscine markedly attenuated the responses to BHT933 without affecting those to
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phenylephrine; likewise, prazosin abolished the responses to phenylephrine without
affecting those to BHT933.
These data show that (i) both adrenaline and noradrenaline produce effects in the
external carotid vasculature of anaesthetised dogs; (ii) the doses of prazosin
(100 µg kg-1) and rauwolscine (300 µg kg-1) are sufficient to block a1- and
a2-adrenoceptors, respectively; and (iii) adrenaline and noradrenaline exert their
external carotid vascular effects via a1-, a2- and b-adrenoceptors, mediating
vasoconstriction and vasodilatation, respectively.
Chapter 7 describes the pharmacological characterisation of a1- and a2-adrenoceptor
subtypes mediating external carotid vasoconstriction in anaesthetised dogs.  As shown
in the previous chapter, both a1- and a2-adrenoceptor are operative in mediating
external carotid vasoconstriction in anaesthetised dogs.  For this purpose, we analysed
the effects of several selective antagonists at the different a1- (5-methylurapidil,
L-765,314 and BMY7378) and a2-adrenoceptor subtypes (BRL44408, imiloxan and
MK912) on the external carotid vasoconstrictor effects produced by consecutive
intracarotid infusions of phenylephrine and BHT933 in anaesthetised dogs.  Whereas
L-765,314 (a1B) was ineffective, 5-methylurapidil (a1A) and BMY7378 (a1D), alone
or in combination, attenuated the effects to phenylephrine; the antagonists did not
affect the external carotid vascular effects to BHT933.  Similarly, whereas imiloxan
(a2B) was ineffective, BRL44408 (a2A) and MK912 (a2C), alone or in combination,
attenuated the effects to BHT933; the vasoconstrictor effects of phenylephrine
remained unaffected.
These results suggest that both a1A- and a1D-adrenoceptors mediate the external
carotid effects of phenylephrine, whereas the involvement of a1B-adrenoceptors is
limited (if any), while those to BHT933 are mediated by a2A- and a2C-adrenoceptors;
the involvement of a2B-adrenoceptors seems also limited.  Moreover, a selective
agonist at any of these specific receptor subtypes, which is currently unavailable,
could be efficacious in the treatment of migraine.  It must be noted that even though
A61603 is regarded to be a selective a1A-adrenoceptor agonist, it also displays
moderate affinity at a2-adrenoceptors and other, yet unknown, receptors (see
Chapter 4).
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Chapter 8 investigates the external carotid vascular effects of the known antimigraine
agent isometheptene and the possible mechanisms of action, using the same
experimental set-up as described in Chapters 6 and 7.  Intracarotid infusions of
isometheptene produced a dose-dependent vasoconstriction in the external carotid
vascular bed on anaesthetised dogs, devoid of any systemic haemodynamic changes.
Treatment of these animals with the monoamine depletor reserpine markedly
attenuated the decrease in external carotid blood flow produced by isometheptene.
Whereas prazosin (a1-adrenoceptor antagonist) was ineffective in control and
reserpine-treated dogs, treatment with rauwolscine (a2-adrenoceptor antagonist)
produced a marked attenuation in control animals and complete blockade of this
response in rauwolscine-treated, reserpinised dogs.  Further investigation into the
specific a2-adrenoceptor subtypes, using selective antagonists, showed that
BRL44408 (a2A) and MK912 (a2C) markedly attenuated this response, while imiloxan
(a2B) was ineffective; SB224289 (5-HT1B) and BRL15572 (5-HT1D), in doses
sufficient to block their respective receptors, were also ineffective against this
response.  Taken together, from the present results we can conclude that intracarotid
infusion of isometheptene produces a cranio-selective vasoconstriction in the canine
external carotid vascular bed, via both direct (a2-adrenoceptor-mediated) and indirect
(tyramine-like) mechanisms.  Furthermore, the carotid vasoconstrictor effect produced
by isometheptene is mainly mediated by a2A- and a2C-adrenoceptors, while the
involvement of a1-, a2B-adrenoceptors or 5-HT1B/1D receptors seem unlikely.
General discussion
Introduction of sumatriptan and the second generation triptans in migraine therapy
Even though the underlying mechanisms for the pathophysiology of migraine attacks
are (still) not completely understood, many studies have shown that serotonin and its
receptors play an important role in the therapy of this disorder.  Ever since the success
of sumatriptan (GR43175) in the treatment of acute migraine attacks[see 215, 280,
281, 282], it became clear that 5-HT1 receptors might serve as a prospective target for
the development of antimigraine agents.  Several lines of evidence suggest that
sumatriptan owes its antimigraine action to vasoconstriction of dilated extracerebral,
intracranial blood vessels and inhibition of neuropeptide (e.g. CGRP and substance P)
release from trigeminal nerve endings by activation of 5-HT1 receptors[216].  Based
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on different in vitro and in vivo studies, using the potent and selective 5-HT1B/1D
receptor antagonist GR127935[see 215, 216], it has been established that mainly
5-HT1B/1D receptors mediate these responses.
Despite its great utility in migraine management, sumatriptan has several
limitations, i.e. low oral bioavailability, high headache recurrence and
contra-indication in patients with coronary artery disease[216, 228].  Over the years,
many pharmaceutical companies have developed derivatives of sumatriptan, known as
second generation triptans, for example eletriptan (Pfizer), zolmitriptan (Zeneca),
naratriptan (GlaxoWelcome Ltd.), frovatriptan (SmithKline Beecham
Pharmaceuticals/Vanguard Medica), almotriptan (Almirall Prodesfarma), rizatriptan
(Merck Sharp & Dohme Laboratories) and donitriptan (Centre de Recherche Pierre
Fabre).   Even though these compounds display different pharmacodynamic or
pharmacokinetic properties with respect to the affinity at 5-HT1B/1D receptors,
bioavailability or lipophilicity (i.e. central penetration), their therapeutic efficacy in
migraine are comparable[215].  Pharmacological, molecular and
immunocytochemical investigations[see 168, 178, 217, 283] suggest that mainly the
5-HT1B receptor is involved in the sumatriptan-induced vasoconstriction of several
cranial and extracranial blood vessels, while 5-HT1D and/or 5-HT1F receptors mediate
the pre-synaptic inhibition of the trigemino-vascular inflammatory response.
Recently, it has been shown that the selective 5-HT1D receptor agonist PNU109791
was devoid of any carotid vasoconstrictor effects in anaesthetised cats[284], pigs
(De Vries et al., unpublished observations) or dogs (Villalon et al., unpublished
observations).  Therefore, the introduction of potent and selective 5-HT1B receptor
agonists for the treatment of migraine is awaited with great interest.
Animal model based on shunt hypothesis
As described in Chapter 1, several studies[see 169, 170, 175] show that vasodilatation
of cranial blood vessels may play an important role in the pathophysiology of
migraine.  Based on this, the animal model used in the present studies has proved
predictive for antimigraine activity[161].  This animal model, together with the
microsphere method[197], enables us to determine the distribution of porcine carotid
blood flow into different cranial tissues (such as skin, fat, muscles, etc.) and carotid
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arteriovenous anastomoses.  As described by Saxena [161], arteriovenous anastomoses
are large precapillary communications between arteries and veins and are present in
most structures (see Chapter 1).  Under normal physiological conditions, these shunt
vessels are under a sympathetic vasoconstrictor tone, shunting less than 3% of the
total carotid blood flow[174].  Opening of carotid arteriovenous anastomoses will
result that a large portion of carotid blood flow is shunted back to the venous side,
thereby bypassing the cephalic tissues, which may explain the facial pallor of patients
during a migraine attack.  Based on the work of Heyck (1969), it has been proposed
that carotid arteriovenous anastomoses are dilated during the headache phase of a
migraine attack and that compounds that constrict these shunt vessels may have
antimigraine activity[161, 285].  To date, all acutely acting antimigraine agents, such
as the triptans (e.g. sumatriptan) or ergots (ergotamine or dihydroergotamine) produce
a potent reduction in the porcine carotid blood flow, exclusively by constricting
arteriovenous anastomoses[see 167, 215, 216].
Besides the role of specific 5-HT receptors in migraine treatment, also other
mechanisms that may play an important role in the pathogenesis of a migraine attack
have been investigated using this in vivo shunt model.  For example, Van Gelderen
et al. have shown that nitric oxide plays an important role in the shunting of arterial
blood through carotid arteriovenous anastomoses[286, 287].  These results may
suggest that a selective nitric oxide synthase inhibitor could be successful as
prophylactic antimigraine agent, preventing the proposed vasodilatation of
extracerebral, intracranial blood vessels in a migraine attack.
Résumé of the results and conclusions
The present investigation was conducted to investigate whether a-adrenoceptors can
mediate vasoconstriction in the carotid circulation of both anaesthetised pigs and dogs
and, if so, which subtypes are involved.  For this reason, we explored the possibility
of a-adrenoceptors as a novel avenue for the development of acutely acting
antimigraine agents, with fewer side-effects than those current available (e.g. the
triptans or ergots).  We investigated the possible vasoconstrictor role of a1- and
a2-adrenoceptors in the porcine (arteriovenous anastomoses) and canine (external)
carotid circulation.  For this purpose, we tested the carotid vascular effects of
selective agonists (i.e. phenylephrine and BHT933, respectively) and antagonists
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(prazosin and rauwolscine, respectively), at these receptors in the carotid circulation
of these species.  In order to avoid any systemic haemodynamic changes, for example
an increase in blood pressure, we administered the agonists by slow and local,
intracarotid infusions. As described in Chapters 2 (pigs) and 6 (dogs), it turned out
that both a1- and a2-adrenoceptors mediate vasoconstriction in this vascular bed in
both species.  Further investigation described in Chapter 3 revealed that both a1A- and
a1B-adrenoceptors mediate carotid arteriovenous anastomotic vasoconstriction in
anaesthetised pigs.  Interestingly, in anaesthetised dogs, the phenylephrine-induced
carotid vasoconstriction was mediated by a1A- and a1D-adrenoceptors; the
a1B-adrenoceptor antagonist L-765,314 was ineffective.  Taking into consideration
that both in vivo models are predictive for antimigraine activity[see 161, 162, 167,
177, 215], this discrepancy in the involvement of a1B-adrenoceptors in porcine and
canine carotid vasoconstriction may be explained by a species difference.  Since these
results have been obtained from animal models, the possible usefulness of a selective
a1B-adrenoceptor agonist (currently unavailable) in the treatment of migraine
obviously needs to be validated by clinical studies in humans.  The potential
unwanted side effects mediated by a1A-adrenoceptors (e.g. blood pressure changes)
limits the possible use of a1A-adrenoceptor agonists in migraine therapy.  In order to
verify this hypothesis, we investigated the effects of intravenous (possible side-
effects) and intracarotid (therapeutic efficacy) administration of the selective
a1A-adrenoceptor agonist A61603 (see Chapter 4).  Even though, A61603 potently
constricted porcine carotid arteriovenous anastomoses, it also produced a pressor
response after both routes of administration.  It was found that the A61603-induced
vasoconstriction of these shunt vessels was mediated by novel methiothepin-sensitive
receptors, unrelated to a-adrenoceptors or 5-HT receptors.  In Chapter 5, we assessed
the antimigraine potential of the newly developed a-adrenoceptor agonist S19014,
using the porcine in vivo model.  It has been shown that S19014 produced a moderate
vasoconstriction of porcine carotid arteriovenous anastomoses, accompanied by a
short-lasting hypertension; a2-adrenoceptors mediated both responses.  These results
suggest that S19014 could be effective in migraine therapy, however, the clinical
relevance of observed hypertension requires further study, and that a potent and
selective agonist at a2-adrenoceptors or its subtypes, which are also currently
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unavailable, could be effective in migraine therapy.  For example, clonidine
(a2-adrenoceptor agonist) is one of such compounds that has been used for many
decades in the treatment of migraine[288-290].  The latter has been substantiated by
the fact that a2-adrenoceptors can mediate carotid vasoconstriction in anaesthetised
pigs (see Chapter 2) and dogs (Chapter 6).  For this reason, it would be very
interesting to know which specific subtype (a2A, a2B and a2C) can mediate
vasoconstriction of porcine carotid arteriovenous anastomoses; this was, however, not
investigated in the present investigation.  On the other hand, both a2A- (slightly) and
a2C-adrenoceptors (predominantly) mediate the external carotid vasoconstriction in
anaesthetised dogs, produced by intracarotid infusions of BHT933 (see Chapter 7).
Moreover, the external carotid vascular effects of the acutely acting antimigraine
agent isometheptene were also mediated by these receptors, whereas the involvement
of a1-adrenergic or 5-HT1B/1D receptors seemd unlikely, if any (see Chapter 8).
The results described in this thesis clearly show that: (i) both a1- and
a2-adrenoceptors can mediate vasoconstriction in the carotid circulation of
anaesthetised pigs and dogs; (ii) a1A- and a1B-adrenoceptors mediate the
phenylephrine-induced porcine carotid vasoconstriction, while a1A- and
a1D-adrenoceptors mediate this response in anaesthetised dogs; (iii) the carotid
haemodynamic effect of the a1A-adrenoceptor agonist A61603 involves unknown,
methiothepin-sensitive receptors in anaesthetised pigs, unrelated to a-adrenoceptors
or 5-HT receptors; (iv) the newly developed a-adrenoceptor agonist S19014 could be
effective in the treatment of acute migraine attacks; (v) a2A- and a2C-adrenoceptors
mediate carotid vasoconstriction induced by BHT933 in anaesthetised dogs; (vi) the
antimigraine agent isometheptene produces external carotid vasoconstriction via
a2A/C-adrenoceptors.  Based on these results, it seems of interest to develop potent and
selective agonists at the different a1- and a2-adrenoceptor subtypes in order to verify
the present results (which are mainly based on antagonists) and for their possible
clinical implication in migraine therapy.  Potential side-effects (e.g. hypertension) of
these specific subtype-selective agonists requires extensive investigation before they
could be useful in migraine therapy.  Additionally, in vitro experiments assessing their
contractile properties in isolated blood vessels of importance in migraine therapy (e.g.
middle meningeal or temporal artery) may also be very useful.
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Implications for future research
Although the present studies offer a better insight in the existence of a1- and
a2-adrenoceptors subtypes eliciting vasoconstriction within the carotid arterial bed,
several questions still remain.
1. Which specific a2-adrenoceptor subtype mediates vasoconstriction of porcine
carotid arteriovenous anastomoses?  As shown in Chapter 2, both a1- and
a2-adrenoceptors mediate vasoconstriction in this vascular bed.  Only the
involvement of a1-adrenoceptor subtype has been investigated in the pigs.
2. Are a1- and/or a2-adrenoceptor subtypes involved in the porcine carotid
vasoconstriction elicited by ergotamine and dihydroergotamine?  The
vasoconstriction of porcine carotid arteriovenous anastomoses by these ergot
alkaloids was attenuated, but not completely blocked by the 5-HT1B/1D receptor
antagonist GR127935[181], thereby revealing a GR127935-insensitive
vasoconstrictor component.  Since the ergots show high affinity for both a1- and
a2-adrenoceptors, it could be that these receptors play a role in the carotid
vasoconstrictor effects to these antimigraine agents.  Indeed, in anaesthetised
dogs, it has been shown that besides 5-HT1B/1D receptors, also a2-adrenoceptors
mediate the external carotid vasoconstrictor effects produced by ergotamine as
well as dihydroergotamine[177].
3. Are a2-adrenoceptors a better target for future migraine therapy over
a1-adrenoceptors?  Based on the involvement of a2-adrenoceptors in the carotid
vasoconstriction produced by ergotamine (in dogs), dihydroergotamine (in dogs),
S19014 (in pigs, Chapter 4) and isometheptene (in dogs, Chapter 8), it is likely
that an a2-adrenoceptor subtype-selective agonist may be more useful in the
treatment of migraine than an a1-adrenoceptor subtype agonist.  Additionally,
since a2-adrenoceptors distribution is less widespread as compared to
a1-adrenoceptors, an antimigraine agent acting at specific a2-adrenoceptor
subtypes may cause fewer side effects than an a1-adrenoceptor agonist.  This
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question should be investigated in more detail by developing and evaluating
potent and selective (subtype-selective) a2-adrenoceptor agonists.
4. Is there a difference in receptors mediating carotid vasoconstriction in
anaesthetised dogs and pigs?  It has been known that intracarotid infusions of
either buspirone[200] or isometheptene (see Chapter 8) elicits vasoconstriction in
the canine external carotid vasculature, while buspirone (Villalón et al.,
unpublished observations) and isometheptene (Willems et al., unpublished
observations) are ineffective in the porcine carotid circulation to produce these
carotid vasoconstrictor effects.  This feature can well be explained by the
involvement of different mechanisms (e.g. receptors), probably due to a species
variation, and requires further investigation.
5. Are there other possibilities for novel migraine therapy?
· Calcitonin gene-related peptide (CGRP) antagonists.  The innervation of the
cranial vessels by the trigeminal nerve, the trigeminovascular system, has been
the subject of major studies in view of its possible role in the mediation of some
aspects of migraine[see 214]. Since stimulation of the trigeminal ganglion in
humans leads to facial pain and flushing and associated release of powerful
neuropeptide vasodilator substances (e.g. SP, CGRP, VIP, NPY; for full names,
see list of abbreviations), their release has been investigated in humans[291].  It
has been shown that during a migraine attack, jugular venous blood levels of
CGRP were elevated, while that of the others remained unaltered[292].
Moreover, treatment of these patients with acute antimigraine agents like
dihydroergotamine or sumatriptan reduced this elevated CGRP plasma
level[292, 293].  In addition, a selective CGRP antagonist, h-CGRP(8-37),
markedly reduced trigeminal-evoked cerebral vasodilatory responses[291],
showing the possible importance of CGRP antagonists as potential prophylactic
antimigraine agents.  In this context, a potent and chemically stable CGRP
receptor antagonist, BIBN4096BS has been developed[294].  It would be very
interesting to evaluate the effects of BIBN4096BS against vasodilator effects of
endogenous CGRP, released either by capsaicin[see 295] or trigeminal nerve
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stimulation, on porcine arteriovenous anastomotic blood flow.  The effects of
BIBN4096B may also be investigated in vitro models, relevant for migraine.
· 5-HT7 receptor antagonists. Indirect evidence has demonstrated that the
5-HT7 receptor mediates cranial vessel vasodilatation in dogs [296-298] and,
possibly, pigs as well[181].  It would be very interesting to investigate the
blocking effects of the recent developed potent and selective 5-HT7 receptor
antagonist (SB258719) on the 5-HT-induced vasodilatation (after 5-HT1/2
receptor blockade) within the carotid circulation of anaesthetised dogs and pigs.
· In vitro experiments.  Besides in vivo experiments, it would be interesting to
know whether potent and selective agonist at specific a1- and a2-adrenoceptor
subtypes produce contraction of human isolated blood vessels and to correlate
this with the experiments gathered from in vivo animal experiments and clinical
data.
6. Which receptors mediate the ‘uroselectivity of a1A-adrenoceptor antagonists?
Several lines of evidence have shown that a1A-adrenoceptor agonists and
antagonists are useful in the treatment of urinary incontinence[72] and benign
prostatic hypertrophy[see 79, 129, 299], respectively.  Since the a1A is the main
a1-adrenoceptor subtype regulating systemic resistance and blood pressure
changes[44], uroselective a1A-adrenoceptor antagonists that do not cause
hypotension may be more useful in the treatment of the benign prostatic
hypertrophy. Several animal models have been developed where the effects of
a1-adrenoceptor antagonists on blood pressure and urethral pressure have been
measured simultaneously.  Using these animal models, diverse compounds have
been developed (e.g. RWJ-38063[79]) that show high selectivity at cloned human
a1A-adrenoceptors and markedly attenuate phenylephrine-induced urethral
pressure, without causing any blood pressure changes.  One likely explanation for
this discrepancy could be the involvement of another a1(A)-adrenoceptor subtype,
sensitive to these a1A-adrenoceptor antagonists, but which is not involved in the
regulation of blood pressure.  A possible candidate for these receptors could be
one of the novel human a1A-adrenoceptor isoforms[40], since Daniels et al.[41]
have shown that these isoforms display a1L-adrenoceptor pharmacology in
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functional studies.  Further investigation into the existence of other
a1-adrenoceptors, in particular that of the contentious a1L-adrenoceptors, may turn
out to be of importance for the treatment of a variety of disorders, including
benign prostatic hypertrophy.
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Chapter 10
Samenvatting in het Nederlands; Summary in Dutch
Behorende bij het proefschrift: “Karakterisering van a-adrenoceptoren in het
halsslagader vaatbed: mogelijk implicaties voor migraine therapie”
Dit proefschrift behandelt voornamelijk de mogelijk rol van a-adrenoceptoren in de
vasoconstrictie in het halsslagader (carotid) vaatbed van zowel genarcotiseerde
varkens als honden.  Met dit in ogenschouw hebben we de mogelijke betrokkenheid
van zowel a1- en a2-adrenoceptoren, maar ook van de respectieve lijke subtypen (a1A,
a1B, a1D en/of a2A, a2B, a2C), onderzocht in dit vaatbed, gebruikmakend van
verschillende selectieve agonisten en antagonisten.  Omdat vasoconstrictie in deze
experimentele modellen voorspelbaar is voor antimigraine activiteit, hebben we de
resultaten van de beschreven studies proberen te correleren met eventuele
therapeutische mogelijkheden in de behandeling van migraine.  Echter, deze
mogelijke implicaties moeten worden gevalideerd in mensen.
Hoofdstuk 1 probeert de huidige farmacologische aspecten van a-adrenoceptoren in
het algemeen, van a1- en a2-adrenoceptoren en de respectievelijke subtypen samen te
vatten.  Bovendien worden de therapeutische toepassingen van geneesmiddelen die
interacties aangaan met a-adrenoceptoren in het kort behandeld, met speciale
aandacht voor de behandeling van migraine.
a1-Adrenoceptoren zijn voornamelijk post-synaptisch gelokaliseerd, bijvoorbeeld
op glad spier weefsel.  Activatie van deze receptoren geeft aanleiding tot
vasoconstrictie van vasculaire en niet-vasculaire weefsel, een effect dat voornamelijk
wordt veroorzaakt door een verhoogde inositol trifosfaat (IP3) productie en cellulaire
calcium concentratie.  Alhoewel de a1-adrenoceptor subtypen als farmacologisch
verschillende receptoren worden beschouwd, zijn er echter vergelijkbare
farmacologische karakteristieken gerapporteerd, zoals weergegeven in Tabel 1.1.  De
distributie van specifieke a1-adrenoceptor subtypen in zowel perifeer als centraal
vasculatuur en de eventuele betrokkenheid van deze receptoren in de regulatie van
verschillend fysiologische effecten, bijvoorbeeld bloeddrukregulatie, heeft de
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afgelopen jaren veel aandacht gekregen.  Het in kaart brengen hiervan was echter voor
vele jaren bemoeilijkt door een discrepantie in de relatie tussen de farmacologisch
bepaalde receptoren en de gekloneerde subtypen.  Sinds 1995 wordt het algemeen
aangenomen dat de drie oorspronkelijke subtypen (a1A, a1B en a1D) farmacologisch
kunnen worden gescheiden en vertonen gelijkwaardigheid met de gekloneerde en de
functionele subtypen in de verschillende weefsels.  Deze consensus was voornamelijk
bereikt door het kloneren van de humane a1-adrenoceptor subtypen en het testen van
meer subtype-selectieve liganden (zie Tabel 1.2).  Doordat specifieke a1-adrenoceptor
subtypen een belangrijke rol spelen in de tonus regulatie van vasculaire en
niet-vasculaire weefsels, zijn verscheidene farmaceutische bedrijven al jaren bezig om
meer selectieve agonisten/antagonisten van deze subtypen te ontwikkelen, met als
doel deze op de markt te brengen als geneesmiddel.  Verschillende studies hebben het
mogelijke bestaan van additionele a1-adrenoceptor subtypen aangetoond,
bijvoorbeeld a1L-adrenoceptoren.  Daar deze receptoren nog niet volledig zijn
gekarakteriseerd, zoals dit tegenwoordig is gebaseerd op zowel structurele,
operationele en transductionele informatie, kunnen ze nog niet als apart worden
beschouwd.
Sinds het begin van de jaren zeventig is het al bekend dat a2-adrenoceptoren zowel
pre- als post-synaptisch zijn gelokaliseerd.  Pre-synaptische a2-adrenoceptoren
kunnen de afgifte van verschillende transmitters, bijvoorbeeld noradrenaline,
reguleren.  Zeer recentelijk is het aangetoond dat dit effect voornamelijk wordt
gemedieerd door a2A- en/of a2C-adrenoceptors, afhankelijk van de te onderzoeken
species en/of weefsel.  Alhoewel het bekend is dat stimulatie van post-synaptische
a2-adrenoceptoren een verhoging van de bloeddruk veroorzaakt, is de informatie over
de specifieke distributie van de verschillende a2-adrenoceptor (a2A, a2B en a2C)
subtypen schaars.  Desalniettemin is het bekend dat a2B-adrenoceptoren een
belangrijke rol spelen in de bloeddrukregulatie van genarcotiseerde muizen, terwijl
contractie van de humaan geïsoleerde saphena vein wordt gemedieerd door
voornamelijk a2C-adrenoceptoren.  Verscheidene problemen voor het ontrafelen van
welke specifieke a2-adrenoceptor subtypen een bepaald fysiologische effect mediëren
zijn de overeenkomstig signaal transductie mechanismen, de aanwezigheid van
verschillende subtypen en het gebrek aan zeer selectieve antagonisten.  Recentelijk
zijn er selectieve antagonisten van de verschillende a2-adrenoceptor subtypen
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ontwikkeld (zie Tabel 1.3), waardoor dit hopelijk mogelijk wordt gemaakt.
Uiteindelijk zal deze informatie kunnen leiden tot de ontwikkeling van andere,
mogelijkerwijs betere, antimigraine middelen.  De studies, beschreven in de volgende
hoofdstukken, zijn uitgevoerd om deze mogelijkheid nauwkeurig te onderzoeken.
Hoofdstuk 2 onderzoekt of a-adrenoceptoren inderdaad vasoconstrictie kunnen
mediëren in de halsslagader (carotid) vasculatuur van het genarcotiseerde varken, met
de nadruk op de carotid arteriovenous anastomoses.  Verscheidene aanwijzingen
bewogen ons om dit onderzoeken, gebaseerd op zowel in vitro als in vivo studies.
Een belangrijke reden waardoor deze studie gehinderd werd, was de ongevoeligheid
van carotid arteriovenous anastomoses voor sympathisch zenuwstimulatie of
exgogeen toegevoegde (intracarotid infusie) van noradrenaline in genarcotiseerde
varkens.  Om dit nader te onderzoeken diende we phenylephrine (a1-adrenoceptor
agonist) en BHT933 (a2-adrenoceptor agonist) via de halsslagader (lokale
toevoeging) toe om de respectievelijke receptoren selectief te stimuleren.  Beide
agonisten veroorzaakten een dosis-afhankelijke vasoconstrictie van carotid
arteriovenous anastomoses.  Terwijl de bloeddruk niet veranderde tijdens of na de
toediening van deze agonisten, veroorzaakte phenylephrine echter een b-adrenoceptor
gemedieerde tachycardia; BHT933 veroorzaakte geen hartritme veranderingen.
Bovendien bleef de distributie van de totale halsslagader bloeddoorstroming naar de
verschillende craniële weefsels onveranderd door beide agonisten.  De vasculaire
effecten van phenylephrine en BHT933 waren afwezig na behandeling van de dieren
met, respectievelijk, prazosin (a1-adrenoceptor antagonist; 100 µg kg-1) en
rauwolscine (a2-adrenoceptor antagonist; 300 µg kg-1).
Deze resultaten geven op een duidelijke manier weer dat zowel a1- als
a2-adrenoceptoren vasoconstrictie in de halsslagader vasculaire circulatie kunnen
mediëren, wat nuttige informatie kan zijn voor de ontwikkeling van toekomstige
antimigraine middelen.
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Hoofdstuk 3 beschrijft de farmacologische karakterisering van a1-adrenoceptor
subtypen die zijn betrokken bij de phenylephrine-geïnduceerde halsslagader
vasoconstrictie van het genarcotiseerde varken, gebaseerd op het vorige hoofdstuk.
Gebruikmakend van hetzelfde experimentele model, hebben we de effecten
onderzocht van selectieve antagonisten van a1A-, a1B- en a1D-adrenoceptor subtypen
op de carotid arteriovenous anastomotic vasoconstrictie veroorzaakt door
phenylephrine.  Zowel 5-methylurapidil (a1A), L-765,314 (a1B) als een hoge dosering
van BMY7378 (a1D) veroorzaakte een verminderde vasoconstrictie door
phenylephrine, in doseringen voldoende om de respectievelijke a1-adrenoceptor
subtypen te blokkeren.  Belangrijk om op te merken is dat het verminderde effect na
BMY7378 waarschijnlijk wordt veroorzaakt door blokkade van a1A- en/of
a1B-adrenoceptoren; de betrokkenheid van a1D-adrenoceptoren is onwaarschijnlijk.
De resultaten van deze studie suggereren de betrokkenheid van zowel a1A- als
a1B-adrenoceptoren in de phenylephrine-geïnduceerde halsslagader vasoconstrictie,
terwijl dat van a1D-adrenoceptoren onwaarschijnlijk is.  De a1B-adrenoceptor zou een
interessante kandidaat kunnen zijn als mogelijk doel voor toekomstige antimigraine
middelen, daar de betrokkenheid van deze receptoren in de vasoconstrictie van
perifere bloedvaten miniem is.  De resultaten laten zien dat de dosis-afhankelijke
hypertensie, geproduceerd door intraveneus toegediende phenylephrine, is
gemedieerd door a1A-adrenoceptoren en niet door a1B- of a1D-adrenoceptoren, wat
overeen komt met studies uitgevoerd in andere species, alsmede in de mens.
Hoofdstuk 4 onderzoekt welke receptoren betrokken zijn bij de halsslagader
vasoconstrictie, geproduceerd door intracarotid infusie van de a1A-adrenoceptor
agonist A-61603 in genarcotiseerde varkens, gebruikmakend van hetzelfde model als
beschreven in afgelopen twee hoofdstukken.  Behalve A61603 (a1A), zijn selectieve
agonisten voor de verschillende a1-adrenoceptoren momenteel niet beschikbaar.
Zoals beschreven in het vorige hoofdstuk, wordt de halsslagader vasoconstrictie door
phenylephrine mede gemedieerd door a1A-adrenoceptors.  Om deze hypothese te
testen, besloten we om de vasculaire effecten van A61603 in dit model te testen.
A61603 produceerde een verhoging van de bloeddruk, zowel na intracarotid als
intraveneuze toediening, gepaard gaand met dosis-afhankelijke halsslagader
vasoconstrictie na intracarotid toediening.   De halsslagader vasculaire effecten van
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A61603 werden niet verminderd door de selectieve a1A-adrenoceptor antagonist
5-methylurapidil (1000 µg kg-1), terwijl het de verhoogde bloeddruk door intraveneus
toegediende A61603 in mindere mate verzwakte.  Bovendien, andere antagonisten
voor bekende vasoconstrictieve receptoren, namelijk prazosin (a1), rauwolscine (a2),
phentolamine (a), GR127935 (5-HT1B/1D) of ketanserin (5-HT2), individueel of in
combinatie, waren ook ineffectief om deze vasculaire effecten te verminderen.
Uitsluiting van al deze receptoren is belangrijk wanneer men beseft dat
methiothepine, een 5-HT1/2 antagonist, deze halsslagader (partieel) en systemisch
(volledig) haemodynamische effecten verminderde.
Samengevat laten deze resultaten zien dat de carotid arteriovenous anastomotic
vasconstrictie door intracarotid infusies van A61603 in genarcotiseerde varkens is
gemedieerd door onbekende en methiothepin-gevoelige receptoren, niet gerelateerd
aan a-adrenerge of 5-HT receptoren. Overeenstemmend, a1A-adrenoceptoren en nog
onbekend, methiothepin-gevoelige receptoren mediëren de A61603-geïnduceerde
hypertensie.  Een selectieve agonist voor deze receptor, zonder systemisch
haemodynamische effecten, zou effectief kunnen zijn voor de behandeling van
migraine.
Hoofdstuk 5 stelt de antimigraine effectiviteit van de a-adrenoceptor agonist S19014
vast door de potentiëel systemische en halsslagader haemodynamische effecten van
intraveneuze administratie van S19014 in genarcotiseerde varkens te onderzoeken.
S19014 heeft hoge affiniteit voor zowel a1- als a2-adrenoceptoren en functionele
studies hebben aangetoond dat S19014 contractie veroorzaakt van humaan en dierlijk
geïsoleerde bloedvaten (Verbeuren et al., niet gepubliceerde observaties).
Intraveneuze toediening van S19104 veroorzaakte een kleine en kortstondige
bloeddrukverhoging, vergezeld gaand met een langdurige en dosis-afhankelijke
vasoconstrictie van carotid arteriovenous anastomoses in genarcotiseerde varkens.
Terwijl behandeling van de dieren met prazosin (100 µg kg-1) ineffectief was,
veroorzaakte voorbehandeling met rauwolscine (300 µg kg-1) een aanzienlijke
vermindering van de halsslagader vasoconstrictoire effecten en veroorzaakte een
rechtsverschuiving van de bloeddrukverhoging respons-curve geproduceerd door
S19014.
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Deze resultaten tonen aan dat voornamelijk a2-adrenoceptoren de
S19014-geïnduceerde halsslagader vasoconstrictie en de hypertensie mediëren.
S19014 zou een effectief antimigraine medicijn kunnen zijn, daar dit model
predicatief is voor antimigraine activiteit.  Echter, additionele studies moeten worden
uitgevoerd om de klinische relevantie van eventueel ongewenste bijwerkingen,
bijvoorbeeld op de bloeddruk, in mensen te bepalen.  Om deze redenen wordt de
ontwikkeling en evaluatie van meer subtype-selectieve a2-adrenoceptor agonisten met
veel interesse tegemoet gezien.
Hoofdstuk 6 onderzoekt de potentiële external (externe) halsslagader effecten van
adrenaline en noradrenaline en de mogelijk betrokken receptoren in genarcotiseerde
honden.  Het is al lang bekend dat de endogene catecholamines (adrenaline en
noradrenaline), die worden vrijgegeven na stimulatie van het sympathische
zenuwstelsel, vele vasculaire effecten veroorzaken via zowel a- (voornamelijk
vasoconstrictie) als b-adrenoceptoren (voornamelijk vasodilatatie).  Terwijl de
vasculaire effecten van serotonine (5-HT) en de betrokken receptoren in het external
halsslagader vaatbed in genarcotiseerd honden farmacologisch grotendeels zijn
gekaraktiseerd, is er echter weinig bekend over de effecten van deze catecholamines
in dit vaatbed.  Achtereenvolgende één minuut infusies van adrenaline en
noradrenaline in de external carotid arterie produceerde een equipotent en
dosis-afhankelijke external halsslagader vasoconstrictie, zonder enig effect op
hartritme of bloeddruk.  Deze cranio-selectieve vasoconstrictoire effecten, die werden
gesimuleerd door phenylephrine (a1-adrenoceptor agonist) en BHT933
(a2-adrenoceptor agonist), werden niet beïnvloed door intraveneuze toediening van
fysiologische saline.  Behandeling van de honden met de niet-selectieve
a-adrenoceptor antagonist phentolamine openbaarde een vasodilatoire component, die
was verdwenen na voorbehandeling met de niet-selectieve b-adrenoceptor antagonist
propranolol.  Voorbehandeling met rauwolscine verminderde de external halsslagader
vasoconstrictoire effecten van zowel adrenaline en noradrenaline gedeeltelijk, die
volkomen waren verdwenen na achtereenvolgende toediening van prazosin.  Na
blokkade van a1- en a2-adrenoceptoren, door toediening van rauwolscine en prazosin,
werd er wederom een external halsslagader vasodilatatie waargenomen.  In
overeenstemming met deze resultaten, waren de external halsslagader
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vasoconstrictoire effecten van BHT933 afwezig na voorbehandeling met rauwolscine,
zonder die van phenylephrine te beïnvloeden; de vasculaire effecten van
phenylephrine waren afwezig na voorbehandeling met prazosin; prazsoin had geen
effect op de vasoconstrictieve effecten van BHT933.
Deze resultaten tonen aan dat: (i) zowel adrenaline als noradrenaline vasculaire
effecten in de external halsslagader vasculatuur in genarcotiseerde honden
produceren; (ii) de dosis van prazosin (100 µg kg-1) en rauwolscine (300 µg kg-1)
voldoende zijn voor de blokkade van, respectievelijk, a1- en a2-adrenoceptoren; en
(iii) adrenaline en noradrenaline produceren vasoconstrictie via zowel a1- als
a2-adrenoceptoren en vasodilatatie via b-adrenoceptoren in dit vaatbed.
Hoofdstuk 7 Beschrijft de farmacologische karakterisering van de verschillende a1-
en a2-adrenoceptor subtypen die vasoconstrictie in het external halsslagader vaatbed
van genarcotiseerde honden mogelijkerwijs kunnen mediëren.  Zoals beschreven in
het vorige hoofdstuk, zijn zowel a1- als a2-adrenoceptoren operatief in vivo door
vasoconstrictie te mediëren in dit vaatbed.  Met dit doel voor ogen, analyseerde we de
effecten van verschillende selectieve antagonisten van de verschillende a1-
(5-methylurapidil, L-765,314 en BMY7378) en a2-adrenoceptor subtypen
(BRL44408, imiloxan en MK912) op de vasoconstrictoire effecten van phenylephrine
(a1) en BHT933 (a2) in dit model.  Terwijl L-765,314 (a1B) ineffectief was,
verminderden 5-methylurapidil (a1A) en BMY 7378 (a1D), alleen of in combinatie, de
effecten van phenylephrine zonder die van BHT933 te beïnvloeden.  Terwijl imiloxan
(a2B) ineffectief was, verminderde BRL44408 (a2A) en MK912 (a2C), alleen of in
combinatie, de effecten van BHT933 zonder enige effecten op die geproduceerd door
phenylephrine.
Deze resultaten suggereren dat: (i) zowel a1A- als a1D-adrenoceptoren de external
halsslagader vasoconstrictoire effecten van phenylephrine mediëren, terwijl de
betrokkenheid van a1B-adrenoceptoren miniem is; (ii) de BHT933-geïnduceerde
external halsslagader vasoconstrictoire effecten zijn gemedieerd door zowel a2A- als
a2C-adrenoceptoren, terwijl de betrokkenheid van a2B-adrenoceptoren miniem is; en
(iii) een selectieve agonist van een specifieke a1A/D- of a2A/C-adrenoceptor subtype zal
effectief zijn in de behandeling van migraine.  Desalniettemin zullen eventuele
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mogelijke ongewenste bijwerkingen van een dergelijke a-adrenoceptor
subtype-selectieve agonist, met name bloeddrukverhoging, alvorens in ogenschouw
moeten worden genomen.  Belangrijk om te vermelden is dat ondanks A61603 wordt
beschouwd als een potent en selectieve a1A-adrenoceptor agonist, het ook
middelmatige affiniteit (en activiteit) vertoont voor a2-adrenoceptoren en andere, nog
onbekende, receptoren (zie Hoofdstuk 4).
Hoofdstuk 8 onderzoekt de mogelijke external halsslagader vasoconstrictoire effecten
van het bekende antimigraine middel isometheptene en de mogelijke betrokkenheid
van a1- en/of a2-adrenoceptoren, gebruikmakend van hetzelfde experimentele model
als beschreven in Hoofdstukken 6 en 7.  Achtereenvolgende intracarotid toediening
van isometheptene produceerde een dosis-afhankelijke vasoconstrictie in dit vaatbed,
zonder enige effecten op hartritme of bloeddruk.  Dit vasoconstrictieve effect was
aanzienlijk verminderd in honden die waren voorbehandeld met de monoamine
depletor reserpine. Terwijl prazosin (100 µg kg-1) ineffectief was in zowel
onbehandelde als reserpine-behandelde dieren, was het effect van isometheptene
aanzienlijk verminderd in rauwolscine (300 µg kg-1) dieren en afwezig in dieren
behandeld met reserpine en rauwolscine.  Bovendien, SB224289 (5-HT1D) en
BRL15572 (5-HT1D) waren ineffectief om het vasoconstrictieve effect van
isometheptene te verminderen.  Deze resultaten laten duidelijk zien dat isometheptene
halsslagader vasoconstrictie in genarcotiseerde honden kan veroorzaken, die wordt
gemedieerd door zowel indirekte (zogenaamde tyramine-like effect ) als directe
(a2-adrenoceptor-gemedieerd) mechanismen, terwijl a1-adrenerge en 5-HT1B/1D
receptoren niet betrokken zijn bij dit effect.  Vervolgens werd er door middel van het
testen van verschillende subtype-selectieve antagonisten (BRL44408, imiloxan en
MK912) onderzocht door welke specifieke a2-adrenoceptor subtypen de external
halsslagader vasculaire effecten van isometheptene worden gemedieerd.  Daar
BRL44408 en MK912, alleen of in combinatie, de effecten van isometheptene
verminderde, terwijl imiloxan ineffectief was, suggereert dat a2A- en
a2C-adrenoceptors de external halsslagader vasculaire effecten van isometheptene
mediëren, terwijl de betrokkenheid van het a2B-adrenoceptor subtype
onwaarschijnlijk is.
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List of abbreviations
oC : Degrees Celsius.
g : Gamma (radiation).
3H : Tritium-radiolabelled hydrogen.
µg : Microgra m (10-6 g).
5-HT : 5-Hydroxytryptamine (serotonin).
5-methylurapidil : 5-Methyl-6[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]
amino]-1,3-dimethyluracil.
A61603 : N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy -5,6,7,8-
tetrahydronaphthalen-1-yl]methanesulphonamide.
A131701 : 3-[2-((3aR,9bR)-cis -6-methoxy -2,3,3a,4,5,9b-hexahydroxy-1H-benisoindol-
2-yl)ethyl]pyrido-[3’,4’:4,5]thieno[3,2-d] pyrimidine-2,4(1H,3H)-dione.
ANOVA : Analysis of variance.
ARC239 : 2-[2[4-(O-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethyl-1,3-(2 H,4H)-
isoquinolimedione.
AVA : Arteriovenous anastomotic (arteriovenous anastomoses).
AVSO2 : Difference between arterial and jugular-venous oxygen saturation.
BHT920 : 5-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]azepine
dihydrochloride.
BHT933 : 6-Ethyl- 5,6,7,8- tetrahydro- 4H- oxazolo[4,5-d] azepin-2-amine
dihydrochloride.
BMY7378 : 8-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]-ethyl]-8-azaspiro[4,5
decane-7,9- dione dihydrochloride.
BPH : Benigh prostatic hyperplasia (hypertrophy).
BRL 41992 : 1,2-Dimethyl-2,3,9,13b-tetrahydro-1H-ibenzo[c,f]imidazol[1,5-a]azepine.
BRL44408 : 2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-
dihydroimidazole.
CA : Chicago (USA).
Ca2+ : Calcium(II).
cAMP : Cyclic adenosine monophosphate.
cDNA : Complementary deoxyribonucleic acid.
Ce : Cerium.
CEC : Chloroethylclonidine.
CGRP : Calcitonin gene-related peptide.
CHO : Chinese Hamster Ovary.
CINVESTAV (IPN) : Center of Research and Advanced Studies (Instituto Politecnico Nacional).
CRW : Centraal Research Werkplaats.
D : Dopamine (of Dosis in pD2 of ED50).
DAP : Diastolic blood pressure.
ECG : Electrocardiography.
e.g. : For example.
et al. : and colleagues.
F12640 : 4-(4-(2-[3-(2-aminoethyl)-1H-indol-5-yloxyl]-acethyl)-piperazin-1-yl)-
benzonitril mesylate.
G : G-protein.
GR127935 : N-[methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-
1,2,4-oxadiazol-3-yl)[1,1-biphenyl]-4-carboxamide hydrochloride.
GTP : Guanosine triphosphate.
H : Histamine.
H+ : Hydrogen(I).
HBr : Hydrobromide.
HCl : Hydrochloride.
HEK 293 : Human embryonic kidney cells.
HV 723 : a-Ethyl-3,4,5-trimethoxy-a-(3-((2-(2-methoxyphenoxy)ethyl)-amino)-
propyl)-benzene acetonitrile fumarate.
I : Imidazoline.
i.a. : Intrinsic activity.
i.c. : Intracarotid.
i.e. : Namely.
IL : Illinois (USA).
i.m. : Intramuscular.
Imiloxan : RS-21361-193.
IP3 : Inositol triphosphate.
IUPHAR : International Union of Pharmacology Committee on Receptor Nomenclature
and Drug Classification.
i.v. : Intravenous.
K+ : Potassium(I)
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KB : The equilibrium dissociation constant (mol litre
-1) for a competitive
antagonist.
KeV : Kilo electro-volt (radioactive g-radiation).
kg : Kilogram (103 g).
L-765,314 : 4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)-[[(1,1- dimethylethyl) amino]
carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline.
M : Molar concentration (mol litre -1).
MA : Massachusetts (USA).
MAP : Mean arterial blood pressure.
mg : Milligram (10-3 g).
min : minutes.
ml : millilitre.
MK912 : (2S,12bS)-1’3’-dimethylspiro(1,3,4,5’,6,6’,7,12b-octahydro-
2H-benzo[b]furo[2,3-a]quinazoline)-2,4’-pyrimidin-2’-one (L-657743).
mmHg : Millimetre mercury (pressure).
MO : Montana (USA).
mRNA : Messenger RNA.
n : Number of animals used.
Na+ : Sodium(I).
Nb : Niobium.
NEN : New English Nuclear.
ng : Nanogram (10-9 g).
NPY : Neuropeptide Y.
NY : New York.
P : Probability.
pCO2 : Negative logarithm to base 10 of the carbon-dioxide (CO2) concentration.
pEC50 : Negative logarithm to base 10 of an agonist concentration eliciting half the
maximum effect.
pH : Negative logarithm of base 10 of the hydrogen (H) concentration.
PI : Phosphoinositol.
pKi : Negative logarithm of a concentration of a competing ligand in a
competition assay that would occupy 50% of the receptors if no radioligand
would be present.
pO2 : Negative logarithm of oxygen (O2) concentration.
RBI : Research Biochemicals International (SIGMA-Aldrich).
Rec 15/2739 : 8-3-[4-(2-Methoxyphenyl)-1-piperazinyl]propylcarbamoyl)-3-methyl-4oxo-
22-phenyl-4H-1-benzopyran dihydrochloride.
RS 10753 : N-[2-(2-cyclopropyl methoxy phenoxy)ethyl]5-chloro-a,a-dimethyl-1H-
indole-3-ethanamine hydrochloride.
Ru : Ruthenium.
RWJ-38063 : N-(2-{4-[2-methylethoxy)phenyl]piperazinyl}ethyl)-2-(2-
oxopiperidyl)acetamide.
S19014 : Servier compound.
SAP : Systolic blood pressure.
Sc : Scandium.
s.d. : Standard deviation.
SDZ NVI 085 : (-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-
methylthio-2H-naphth[2,3b]-1,4-oxazine.
SEM : Standard error of the mean.
SKF 104078 : 6-Chloro-9—[(methyl-2-butenyl)oxyl]-3-methyl-1H-2,3,4,5-tetrahydro-3-
bezazepine.
SKF 104856 : 2-Vinyl-7-chloro-3,4,5,6-tetrahydro-4-methylthienol[4,3,2
ef][3]benzazepine.
Sn : Stannum.
SNAP 5089 : 2,6-Dimethyl-4-(4-nitrophenyl)1,4-dihydropyridine-3,5-dicarboxylic acid-
N[3-(4,4-diphenylpiperidine-1-yl)propyl]amide-methyl ester.
SP : Substance P.
UK : United Kingdom.
UK 14304 : 6-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline tartrate.
USA : United Stated of America.
VIP : Vasoactive intestinal polypeptide.
vs. : Versus.
WB 4101 : 2-(2’,5’-Dimethoxyphenoxyethyl) aminoethyl-1,4-benzodioxan.
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General terms and definitions in quantitative pharmacology
Table. General terms and definitions in quantitative pharmacology, according to the IUPHAR[12, 300].
Term Suggested usage
Agonist A ligand that binds to receptors and thereby alters the proportion of them that are in an active form, resulting in a biological response.
Conventional agonists increase this proportion, while inverse agonists reduce it.
Agonist potency
ratios
Quantitative agonist data are preferably gives as equi-effective molar ratios where the standard agonist = 1, defined in terms of a
functional response in a particular tissue or cell type.
Antagonist A drug that reduces the action of another drug, generally an agonist.  Many act at the same active site as the agonist.  Antagonists of
this kind may be surmountable or insurmountable depending on the experimental conditions (see below).
Antagonist potency Expressed as pKB or pA2 values from functional studies, or as IC50 values.
Competitive
antagonism
If the agonist and antagonist form only short-lasting combinations with the receptor active site, so that equilibrium between agonist,
antagonist and receptors is reached during the presence of the agonist, the antagonism will be surmountable over a wide range of
concentrations (reversible competitive antagonism).  In contrast, some antagonists when in close enough proximity to their binding
site may form a covalent bond with it (irreversible competitive antagonism), and the antagonism becomes insurmountable when no
spare receptors remain.
Concentration It is recommended that the concentration of a drug is referred to the molar concentration, denoted by either [X] or cX, with the formed
preferred.  Decimal multipliers should be indicated using either SI prefixes (e.g. mM, nM) or by powers of ten (e.g. 3x10-8 M), with
the former preferred.
Desensitisation,
fade, tachyphylaxis
Overlapping terms that refer to a spontaneous decline in the response to a continuous application of agonist, or to repeated
applications or doses.
Dose In some cases (e.g. in therapeutics and clinical pharmacology, in in vivo experiments and when tissues are perfused in vitro, and
exposed to a bolus application of a drug), absolute drug concentrations are uncertain.  It becomes more appropriate to specify the
quantity of drug administration, either in mass or mol quantity.  In the case of in vivo experiments, the quantity of the drug should be
expressed per unit of animal mass (e.g. mol kg-1 , µg kg-1).
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Table continued…
EC50 The molar concentration of an agonist that produces 50% of the maximal possible effect of that agonist.  Other percentage values
(EC20, EC40, etc.) can be specified.
ED50 Either the dose of a drug that produces (on average) a specified all-or-none response in 50% of a test population or the dose of a drug
that produces 50% of the maximal response to that drug if the response is graded.
Efficacy (e) The concept and numerical term that expresses the way in which different agonists vary in their ability to produce a response, even
though they may occupy the same proportion of receptors.
Full agonists When a tissue has spare receptors, several agonists may be able to elicit the same maximal response, albeit at different receptor
occupancies.  They are said to be full agonists in that experimental situation.  A full agonist in one tissue may be a partial agonist in
another.
Functional assay Pharmacological test systems in which a response can be firmly attributed to the function of a defined receptor type or subtype.
Hill equation
(Concentration-
Effect relation)
E/Emax = [L]
nH / (EC50 + [L]
nH),
Where E=effect, Emax=maximal effect, EC50=concentration that produces 50% of maximal effect, [L]=concentration of ligand (L),
nH=Hill coefficient.
IC50 Either the molar concentration of an antagonist that reduces a specified response to 50% of its former value (see EC50) or the molar
concentration of an agent/ligand (agonist or antagonist) that causes a 50% reduction in the specific binding of a radioligand (also
referred to as pK i).
Intrinsic efficacy See efficacy.
Inverse agonist A ligand which by binding to receptors reduces the fraction of them in an active conformation (see agonist).  This can occur if some of
the receptors are in the active form even in the absence of a conventional agonist.
Ligand A compound that acts on a receptor, either an agonist or antagonist.
Ligand affinity Binding affinity for key ligands are given as pIC50 (or IC50) values or expressed as pKd (or Kd) values unless otherwise stated.
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Table continued…
Maximal agonist
effect (a)
The maximal effect that an agonist, whether conventional or inverse, can elicit in a given tissue under particular experimental
conditions, expressed as a fraction of that produced by a full agonist acting through the same receptors under the same conditions; also
referred to as intrinsic activity (though the maximal agonist effect is preferable) or efficacy.-
Modulator A ligand that increases or decreases the action or an agonist by combining with the distinct (allosteric) site(s) on the receptor.
Non-competitive
antagonism
Agonist and antagonist can be bound simultaneously; antagonist binding reduces or prevents the action of the agonist.  This usage
covers situations as diverse as channel block of the nicotinic acethylcholine receptor and inhibition by adrenoceptor antagonists of the
response to tyramine (so-called indirect antagonism).
pA2 The negative logarithm to base 10 of the molar concentration of an antagonist that makes it necessary to double the concentration of
an agonist needed to elicit the original submaximal response[302].
Partial agonist An agonist which in a given tissue, under specified experimental conditions, cannot elicit as large an effect (even when applied at
higher concentration, so that all the receptors should be occupied) as can a full agonist acting through the same receptors.  See full
agonist, maximal agonist effect, and efficacy.
pEC50 Negative logarithm to the base 10 of the EC50 of an agonist (also called pD2).
Potency An expression of the activity of a drug, either in terms of the concentration or amount needed to produce a defined effect, or, less
acceptably, with regard to the maximal effect attainable.  An imprecise term that should always be defined (see EC50, IC50, maximal
effect. etc.)
Previous name(s) Outdated names that exists in the literature, but which are no longer the recommended nomenclature.
Radioligands Available radioactive-labelled ligands (agonists or antagonists, selective or non-selective).
Radioligand assays Cell lines expressing cloned receptors, or any tissue or cell lines expressing endogenous receptors in which the radioligand is used.
Receptor Cellular macromolecules that are concerned directly and specifically in chemical signalling between and within cells.  The region of
the receptor macromolecule to which endogenous ligands bind are referred to as the recognition or active site(s) of the receptor.
Receptor
distribution
Central and peripheral distribution of the receptor.
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Table continued…
Receptor reserve /
Spare receptors
In some tissues, agonists of higher efficacy can produce a maximal effects even when a small fraction of the receptors are occupied.  It
is therefor possible to inactivate some of the receptors (e.g. by applying an irreversible competitive antagonist) without reducing the
maximal response (although the curve relating the effect to the concentration of agonist will be shifted to the right).  The tissue is said
to posses spare receptors, and for a given level of response, there is a larger receptor reserve for the action of that agonist.  Receptor
reserve is both tissue and agonist dependent.  An agent that is a partial agonist in one tissue may act as a full agonist in a second tissue
with a greater receptor reserve.
Receptor type Nomenclature for a structurally and operationally distinct receptor in a given family.
Receptor subtype Nomenclature for a receptor with strong structural homology to other types, but with distinct operational characteristics.
Receptor code A preliminary receptor code (RC), without the species abbreviation.
Schild plot A graph of (r-1) against log[antagonist], where r is the concentration ratio.  This should yield a straight line of unity slope if the Schild
equation is obeyed[303].
Selective agonists Agonists that are selective for the receptor type (e.g. phenylephrine at a1-adrenoceptors); specific agonists, which are not selective
between receptor types in the family, are included if useful (e.g. noradrenaline at adrenoceptors).
Selective antagonist Antagonists that are selective for the receptor type (e.g. prazosin at a1-adrenoceptors); specific antagonists, which are not selective
between receptor types in the family, are included if useful (e.g. phentolamine at a-adrenoceptors).
Structural
information
The number of transmembrane domains (TM) and amino acids (aa).
Transduction
mechanism(s)
The preferred receptor signalling pathways of mechanism, when established; any identified alternative mechanism.
Tissue function(s) The physiological response mediated by the receptor if established in whole tissue, preferably in vivo.
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STELLINGEN / STATEMENTS
1. Selective agonists at a1- and a2-adrenoceptor subtypes could provide a
novel avenue for antimigraine drug development
2. The limited number of potential therapeutic applications probably does
not stimulate pharmaceutical companies to develop selective a1- and
a2-adrenoceptor subtype ligands
3. A theory is right until proven otherwise!  However, if you cannot prove
that something is right, try to prove it wrong and, if you fail, it is
probably right (Jim Andrews)
4. Tidy desk – inactive mind, messy desk – busy mind (Jim Andrews)
5. Stress is a reflection of your incompetence to organise your professional
and social life
6. Hoe zou het zijn om een vulkaan te zijn, de hele dag liggen roken en
iedereen zegt dat je werkt!  (Arthur Brouns)
7. Sportklimmen is de beste remedie voor nagelbijten!
8. The only lessons we learn are from the things we regret (Ed Stasium,
Biohazard, 1994)
9. Het is makkelijker om iets nieuws te leren dan iets af te leren
10. Waar karate is gebasseerd op natuurlijk ronde bewegingen, het zijn de
directe bewegingen die vaak effectief zijn in het dagelijks leven
11. Het waarnemen van het probleem, is meestal het probleem niet
12. We don’t plan to fail, we just fail to plan (L. Verspui)
13. Patience is the art of concealing your impatience (History & Heraldry)
E.W. Willems
Rotterdam, The Netherlands, 2001
